NZ309945A - Abundant extracellular products and their use as vaccines - Google Patents

Abstract

Vaccines based on one or more combinations of majorly abundant extracellular products of pathogens and methods for their use and production. The most prevalent or majorly abundant extracellular products of a target pathogen are selected irrespective of their absolute molecular immunogenicity and used as vaccines to stimulate a protective immune response in mammalian hosts against subsequent infection by the target pathogen. The majorly abundant extracellular products may be characterized and distinguished by their respective N-terminal amino acid, amino acid, or DNA sequences. As the vaccines may comprise different combinations of the extracellular products, subunits thereof, or encoding nucleic acids, a broad range of effective immunotherapeutic compositions are provided. In addition to other infectious agents, the vaccines so produced can be used to stimulate an effective immune response against intracellular pathogens and in particular Mycobacterium tuberculosis.

Description

WO 96/37219 PCT/US96/07781 Description ABUNDANT EXTRACELLULAR PRODUCTS AND METHODS FOR THEIR PRODUCTION AND USE Reference to Government This invention was made with Government support under Grant Nos. AI-35275 and AI-31338 awarded by the Department of Health and Human Services. The Government has certain rights in this invention.

Field of the Invention The present invention generally relates to immunotherapeutic agents and vaccines against pathogenic organisms such as bacteria, protozoa, viruses and fungus. More specifically, unlike prior art vaccines and immunotherapeutic agents based upon 15 pathogenic subunits or products which exhibit the greatest or most specific molecular immunogenicity, the present invention uses the most prevalent or majorly abundant immunogenic determinants released by a selected pathogen such as Mycobacterium tuberculosis to stimulate an effective immune response in mammalian hosts. Accordingly, the acquired immunity and immunotherapeutic activity produced through 20 the present invention is directed to those antigenic markers which are displayed most often on infected host cells during the course of a pathogenic infection without particular regard to the relative or absolute immunogenicity of the administered compound.

Background of the Invention It has long been recognized that parasitic microorganisms possess the ability to infect animals thereby causing disease and often the death of the host. Pathogenic agents have been a leading cause of death throughout history and continue to inflict immense suffering. Though the last hundred years have seen dramatic 30 advances in the prevention and treatment of many infectious diseases, complicated host-parasite interactions still limit the universal effectiveness of therapeutic measures. Difficulties in countering the sophisticated invasive mechanisms displayed by many pathogenic vectors is evidenced by the resurgence of various diseases such as tuberculosis, as well as the appearance of numerous drug resistant strains of bacteria 35 and viruses.

' WO 96/37219 PCT/US96/07781 Among those pathogenic agents of major epidemiological concern, intracellular bacteria have proven to be particularly intractable in the face of therapeutic or prophylactic measures. Intracellular bacteria, including the genus Mycobacterium and the genus Legionella, complete all or part of their life cycle within the cells of the 5 infected host organism rather than extracellularly. Around the world, intracellular bacteria are responsible for millions of deaths each year and untold suffering. Tuberculosis, caused by Mycobacterium tuberculosis, is the leading cause of death from infectious disease worldwide, with 10 million new cases and 2.9 million deaths every year. In addition, intracellular bacteria are responsible for millions of cases of leprosy. 10 Other debilitating diseases transmitted by intracellular agents include cutaneous and visceral leishmaniasis, American trypanosomiasis (Chagas disease), listeriosis, toxoplasmosis, histoplasmosis, trachoma, psittacosis, Q-fever, and Legionellosis including Legionnaires' disease. At this time, relatively little can be done to prevent debilitating infections in susceptible individuals exposed to these organisms. 15 Due to this inability to effectively protect populations from tuberculosis and the inherent human morbidity and mortality caused by tuberculosis, this is one of the most important diseases confronting mankind. More specifically, human pulmonary tuberculosis primarily caused by M. tuberculosis is a major cause of death in developing countries. Capable of surviving inside macrophages and monocytes, M. tuberculosis 20 may produce a chronic intracellular infection. By concealing itself within the cells primarily responsible for the detection of foreign elements and subsequent activation of the immune system, M. tuberculosis is relatively successful in evading the normal defenses of the host organism. These same pathogenic characteristics have heretofore prevented the development of an effective immunotherapeutic agent or vaccine against 25 tubercular infections. At the same time tubercle bacilli are relatively easy to culture and observe under laboratory conditions. Accordingly, M. tuberculosis is particularly well suited for demonstrating the principles and advantages of the present invention.

Those skilled in the art will appreciate that the following exemplary discussion of M. tuberculosis is in no way intended to limit the scope of the present 30 invention to the treatment of M. tuberculosis. Similarly, the teachings herein are not limited in any way to the treatment of tubercular infections. On the contrary, this invention may be used to advantageously provide safe and effective vaccines and immunotherapeutic agents against the immunogenic determinants of any pathogenic agent expressing extracellular products and thereby inhibit the infectious transmission 35 of those organisms.

^ WO 96/37219 PCT/US96/07781 Currently it is believed that approximately half of the world's population is infected by M. tuberculosis resulting in millions of cases of pulmonary tuberculosis annually. While this disease is a particularly acute health problem in the developing countries of Latin America, Africa, and Asia, it is also becoming more prevalent in the 5 first world. In the United States specific populations are at increased risk, especially urban poor, immunocompromised individuals and immigrants from areas of high disease prevalence. Largely due to the AIDS epidemic the incidence of tuberculosis is presently increasing in developed countries, often in the form of multi-drug resistant M. tuberculosis.

Recently, tuberculosis resistance to one or more drugs was reported in 36 of the 50 United States. In New York City, one-third of all cases tested in 1991 were resistant to one or more major drugs. Though non-resistant tuberculosis can be cured with a long course of antibiotics, the outlook regarding drug resistant strains is bleak. Patients infected with strains resistant to two or more major antibiotics have a fatality 15 rate of around 50%. Accordingly, a safe and effective vaccine against such varieties of M. tuberculosis is sorely needed.

Initial infections of M. tuberculosis almost always occur through the inhalation of aerosolized particles as the pathogen can remain viable for weeks or months in moist or dry sputum. Although the primary site of the infection is in the 20 lungs, the organism can also cause infection of the bones, spleen, meninges and skin. Depending on the virulence of the particular strain and the resistance of the host, the infection and corresponding damage to the tissue may be minor or extensive. In the case of humans, the initial infection is controlled in the majority of individuals exposed to virulent strains of the bacteria. The development of acquired immunity following the 25 initial challenge reduces bacterial proliferation thereby allowing lesions to heal and leaving the subject largely asymptomatic but possibly contagious.

When M. tuberculosis is not controlled by the infected subject, it often results in the extensive degradation of lung tissue. In susceptible individuals lesions are usually formed in the lung as the tubercle bacilli reproduce within alveolar or 30 pulmonary macrophages. As the organisms multiply, they may spread through the lymphatic system to distal lymph nodes and through the blood stream to the lung apices, bone marrow, kidney and meninges surrounding the brain. Primarily as the result of cell-mediated hypersensitivity responses, characteristic granulomatous lesions or tubercles are produced in proportion to the severity of the infection. These lesions 35 consist of epithelioid cells bordered by monocytes, lymphocytes and fibroblasts. In ^ WO 96/37219 4 most instances a lesion or tubercle eventually becomes necrotic and undergoes caseation.

While M. tuberculosis is a significant pathogen, other species of the genus Mycobacterium also cause disease in animals including man and are clearly 5 within the scope of the present invention. For example, M. bovis is closely related to M. tuberculosis and is responsible for tubercular infections in domestic animals such as cattle, pigs, sheep, horses, dogs and cats. Further, M. bovis may infect humans via the intestinal tract, typically from the ingestion of raw milk. The localized intestinal infection eventually spreads to the respiratory tract and is followed shortly by the 10 classic symptoms of tuberculosis. Another important pathogenic vector of the genus Mycobacterium is M. leprae which causes millions of cases of the ancient disease leprosy. Other species of this genus which cause disease in animals and man include M. kansasii, M. avium intracellulare, M. fortuitum, M. marinum, M. chelonei, M. africanum, M. ulcerans, M. microti and M. scrofulaceum. The pathogenic 15 mycobacterial species frequently exhibit a high degree of homology in their respective DNA and corresponding protein sequences and some species, such as M. tuberculosis and M. bovis are highly related.

For obvious practical and moral reasons, initial work in humans to determine the efficacy of experimental compositions with regard to such afflictions is 20 infeasible. Accordingly, in the early development of any drug or vaccine it is standard procedure to employ appropriate animal models for reasons of safety and expense. The success of implementing laboratory animal models is predicated on the understanding that immunodominant epitopes are frequently active in different host species. Thus, an immunogenic determinant in one species, for example a rodent or guinea pig, will 25 generally be immunoreactive in a different species such as in humans. Only after the appropriate animal models are sufficiently developed will clinical trials in humans be carried out to further demonstrate the safety and efficacy of a vaccine in man.

With regard to alveolar or pulmonary infections by M. tuberculosis, the guinea pig model closely resembles the human pathology of the disease in many 30 respects. Accordingly, it is well understood by those skilled in the art that it is appropriate to extrapolate the guinea pig model of this disease to humans and other mammals. As with humans, guinea pigs are susceptible to tubercular infection with low doses of the aerosolized human pathogen M. tuberculosis. Unlike humans where the initial infection is usually controlled, guinea pigs consistently develop disseminated 35 disease upon exposure to the aerosolized pathogen, facilitating subsequent analysis. Further, both guinea pigs and humans display cutaneous delayed-type hypersensitivity WO 96/37219 PCT/US96/07781 reactions characterized by the development of a dense mononuclear cell induration or rigid area at the skin test site. Finally, the characteristic tubercular lesions of humans and guinea pigs exhibit similar morphology including the presence of Langhans giant cells. As guinea pigs are more susceptible to initial infection and progression of the 5 disease than humans, any protection conferred in experiments using this animal model provides a strong indication that the same protective immunity may be generated in man or other less susceptible mammals. Accordingly, for purposes of explanation only and not for purposes of limitation, the present invention will be primarily demonstrated in the exemplary context of guinea pigs as the mammalian host. Those skilled in the art 10 will appreciate that the present invention may be practiced with other mammalian hosts including humans and domesticated animals.

Any animal or human infected with a pathogenic vector and, in particular, an intracellular organism presents a difficult challenge to the host immune system. While many infectious agents may be effectively controlled by the humoral 15 response and corresponding production of protective antibodies, these mechanisms are primarily effective only against those pathogens located in the body's extracellular fluid. In particular, opsonizing antibodies bind to extracellular foreign agents thereby rendering them susceptible to phagocytosis and subsequent intracellular killing. Yet this is not the case for other pathogens. For example, previous studies have indicated 20 that the humoral immune response does not appear to play a significant protective role against infections by intracellular bacteria such as M. tuberculosis. However, the present invention may generate a beneficial humoral response to the target pathogen and, as such, its effectiveness is not limited to any specific component of the stimulated immune response.

More specifically, antibody mediated defenses seemingly do not prevent the initial infection of intracellular pathogens and are ineffectual once the bacteria are sequestered within the cells of the host. As water soluble proteins, antibodies can permeate the extracellular fluid and blood, but have difficulty migrating across the lipid membranes of cells. Further, the production of opsonizing antibodies against bacterial 30 surface structures may actually assist intracellular pathogens in entering the host cell. Accordingly, any effective prophylactic measure against intracellular agents, such as Mycobacterium, should incorporate an aggressive cell-mediated immune response component leading to the rapid proliferation of antigen specific lymphocytes which activate the compromised phagocytes or cytotoxically eliminate them. However, as will 35 be discussed in detail below, inducing a cell-mediated immune response does not equal the induction of protective immunity. Though cell-mediated immunity may be a WO 96/37219 PCT/US96/07781 prerequisite to protective immunity, the production of vaccines in accordance with the teachings of the present invention requires animal based challenge studies.

This cell-mediated immune response generally involves two steps. The initial step, signaling that the cell is infected, is accomplished by special molecules 5 (major histocompatibility or MHC molecules) which deliver pieces of the pathogen to the surface of the cell. These MHC molecules bind to small fragments of bacterial proteins which have been degraded within the infected cell and present them at the surface of the cell. Their presentation to T-cells stimulates the immune system of the host to eliminate the infected host cell or induces the host cell to eradicate any bacteria 10 residing within.

Unlike most infectious bacteria, Mycobacterium, including M. tuberculosis, tend to proliferate in vacuoles which are substantially sealed off from the rest of the cell by a membrane. Phagocytes naturally form these protective vacuoles making them particularly susceptible to infection by this class of pathogen. In such 15 vacuoles the bacteria are effectively protected from degradation, making it difficult for the immune system to present integral bacterial components on the surface of infected cells. However, the infected cell's MHC molecules will move to the vacuole and collect any free (released) bacterial products or move to other sites in the host cell to which the foreign extracellular bacterial products have been transported for normal presentation of 20 the products at the cell surface. As previously indicated, the presentation of the foreign bacterial products will provoke the proper response by the host immune system.

The problems intracellular pathogens pose for the immune system also constitute a special challenge to vaccine development. Thus far, the production of an effective vaccine against Mycobacterium infections and, in particular, against 25 M. tuberculosis has eluded most researchers. At the present time the only widely available vaccine against intracellular pathogens is the live attenuated vaccine BCG, an avirulent strain of M. bovis, which is used as a prophylactic measure against the tubercle bacillus. Yet in 1988, extensive World Health Organization studies from India determined that the efficacy of the best BCG vaccines was so slight as to be 30 immeasurable. Despite this questionable efficacy, BCG vaccine has been extensively employed in high incidence areas of tuberculosis throughout the world. Complicating the matter even further individuals who have been vaccinated with BCG will often develop sensitivity to tuberculin which negates the usefulness of the most common skin test for tuberculosis screening and control.

Another serious problem involving the use of a live, attenuated vaccine such as BCG is the possibility of initiating a life-threatening disease in PCT/U S96/07781 7 immunocompromised patients. These vaccines pose a particular risk for persons with depressed cell-mediated immunity because of their diminished capacity to fight a rapidly proliferating induced infection. Such individuals include those weakened by malnourishment and inferior living conditions, organ transplant recipients, and persons 5 infected with HIV. In the case of BCG vaccine, high risk individuals also include those suffering from lung disorders such as emphysema, chronic bronchitis, pneumoconiosis, silicosis or previous tuberculosis. Accordingly, the use of attenuated vaccines is limited in the very population where they have the greatest potential benefit.

The use of live attenuated vaccines may also produce other undesirable 10 side effects. Because live vaccines reproduce in the recipient, they provoke a broader range of antibodies and a less directed cell-mediated immune response than noninfectious vaccines. Often this shotgun approach tends to occlude the immune response directed at the molecular structures most involved in cellular prophylaxis. Moreover, the use of live vaccines with an intact membrane may induce opsonizing 15 antibodies which prepare a foreign body for effective phagocytosis. Thus, upon host exposure to virulent strains of the target organism, the presence of such antibodies could actually enhance the uptake of non-attenuated pathogens into host cells where they can survive and multiply. Further, an attenuated vaccine contains thousands of different molecular species and consequently is more likely to contain a molecular species that is 20 toxic or able to provoke an adverse immune response in the patient. Other problems with live vaccines include virulence reversion, natural spread to contacts, contaminating viruses and viral interference, and difficulty with standardization.

Similarly, noninfectious vaccines, such as killed organisms or conventional second generation subunit vaccines directed at strongly antigenic 25 membrane bound structures, are limited with respect to the inhibition of intracellular bacteria. Like attenuated vaccines, killed bacteria provoke an indiscriminate response which may inhibit the most effective prophylactic determinants. Further, killed vaccines still present large numbers of potentially antigenic structures to the immune system thereby increasing the likelihood of toxic reactions or opsonization by the 30 immune system. Traditional subunit vaccines incorporating membrane bound structures, whether synthesized or purified, can also induce a strong opsonic effect facilitating the entry of the intracellular pathogen into phagocytes in which they multiply. By increasing the rate of bacterial inclusion, killed vaccines directed to intracellular surface antigens may increase the relative virulence of the pathogenic 35 agent. Thus, conventional attenuated or killed vaccines directed against strongly WO 96/37219 PCT/US96/07781 8 309945 antigenic bacterial surface components may be contraindicated in the case of intracellular pathogens.

In order to circumvent the problems associated with the use of traditional vaccines, developments have been made using extracellular proteins or their immunogenic analogs to stimulate protective immunity against specific intracellular pathogens. For example, this inventor's U.S. Patent No. 5,108,745. issued April 28, 1992 discloses vaccines and methods of producing protective immunity against Legionella pneumophila and M. tuberculosis as well as other intracellular pathogens.

These prior art vaccines are broadly based on extracellular products originally derived from proteinaceojis compounds released extracellularlv by the pathogenic bacteria into broth culture in vitro and released extracellularlv by bacteria within infected host cells in vivo. As disclosed therein, these vaccines are selectively based on the identification of extracellular products or their analogs which stimulate a strong immune response against the target pathogen in a mammalian host. Horwitz et al. (Proc. Nat 7 Acad. Sci. 92: 1520, 1995) refers 15 to protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis.

More specifically, these prior art candidate extracellular proteins were screened by determining their ability to provoke either a strong lymphocyte proliferative response or a cutaneous delayed-type hypersensitivity response in mammals which were immune to the pathogen of interest. Though this disclosed method and associated vaccines avoid many of the drawbacks inherent in the use of 20 traditional vaccines, conflicting immunoresponsive results due to cross-reactivity and host variation may complicate the selection of effective immunizing agents. Thus, while molecular immunogenicity is one indication of an effective vaccine, other factors may complicate its use in eliciting an effective immune response in vivo.

More importantly, it surprisingly was discovered that, particularly with 25 respect to M. tuberculosis, conventional prior art methods for identifying effective protective immunity inducing vaccines were cumbersome and potentially ineffective. For example, SDS-PAGE analysis of bulk M. tuberculosis extracellular protein followed by conventional Western blot techniques aimed at identifying the most immunogenic of these extracellular components produced inconsistent results. 30 Repeated testing failed to identify which extracellular product would produce the strongest immunogenic response and, consistent with prior art thinking, thereby function as the most effective vaccine. Many of the extracellular products of M. tuberculosis are well known in the art, having been identified and, in some cases, sequenced. Further, like any foreign protein, it can be shown that these known compounds induce an immune response (Horwitz et al. Proc. Nat'I Acad. Sci. 92. 151-. v v v intellectual property office of n.z. 1995). However, nothing in the art directly indicates 2 0 FEB 2001 RECEIVED 9 that any of these known compounds will induce protective immunity as traditionally identified. vaccines or immunotherapeutic agents and methods for their production and use in 5 mounting an effective immune response against infectious bacterial pathogens which do not rely upon traditional vaccine considerations and selection techniques based upon highly specific, strongly immunogenic operability; and/or immunotherapeutic agents and methods for their use to impart acquired immunity in a 10 mammalian host against intracellular pathogens including M. tuberculosis, M. bovis, M. kansasii, M. avium-intracellulare, M. fortuitum, M. chelonei, M. marinum, M. scrofulaceum, M. leprae, M. africanum, M. ulcerans and M. microti; and/or produced vaccines and immunotherapeutic agents exhibiting reduced toxicity relative to 15 killed or attenuated vaccines; and/or to provide the public with a useful choice.

Summary of the Invention objects by providing compounds for use as vaccines and/or immunotherapeutic agents 20 and methods for their production and use to generate protective or therapeutic immune responses in mammalian hosts against infection by pathogens. In a broad aspect, the invention provides the means to induce a protective or therapeutic immune response against infectious vectors producing extracellular compounds. While the compounds of the present invention are particularly effective against pathogenic bacteria, they may be 25 used to generate a protective or therapeutic immune response to any pathogen producing majorly abundant extracellular products.

Accordingly, it is a principal object of the present invention to provide to provide vaccines or to provide easily The present invention accomplishes the above-described and other intellectual property office of n.z. 2 0 FEB 2001 RECEIVED 9a Specifically, the present invention provides a DNA molecule containing a coding sequence comprising the amino acid sequence of M. tuberculosis 58 KD protein and fragments and derivatives thereof, wherein said coding sequence includes the sequence: 1 31 gtg ACG GAA AAG ACG CCC GAC GAC GTC TTC AAA CTT GCC AAG GAC GAG AAG GTC GAA TAT 61 91 GTC GAC GTC CGG TTC TGT GAC CTG CCT GGC ATC ATG CAG CAC TTC ACG ATT CCG GCT TCG 121 151 GCC I I i GAC AAG AGC GTG TTT GAC GAC GGC TTG GCC TTT GAC GGC TCG TCG ATT CGC GGG iai 2ii TTC CAG TCG ATC CAC GAA TCC GAC ATG TTG CTT CTT CCC GAT CCC GAG ACG GCG CGC ATC 241 271 GAC CCG TTC CGC GCG GCC AAG ACG CTG AAT ATC AAC TTC TTT GTG CAC GAC CCG TTC ACC 301 331 CTG GAG CCG TAC TCC CGC GAC CCG CGC AAC ATC GCC CGC AAG GCC GAG AAC TAC CTG ATC 361 391 AGC ACT GGC ATC GCC GAC ACC GCA TAC TTC GGC GCC GAG GCC GAG TTC TAC ATT TTC GAT 421 451 TCG GTG AGC TTC GAC TCG CGC GCC AAC GGC TCC TTC TAC GAG GTG GAC GCC ATC TCG GGG 481 511 TGG TGG AAC ACC GGC GCG GCG ACC GAG GCC GAC GGC AGT CCC AAC CGG GGC TAC AAG GTC 541 571 CGC CAC AAG GGC GGG TAT TTC CCA GTG GCC CCC AAC GAC CAA TAC GTC GAC CTG CGC GAC 601 631 AAG ATG CTG ACC AAC CTG ATC AAC TCC GGC TTC ATC CTG GAG AAG GGC CAC CAC GAG GTG 661 691 GGC AGC GGC GGA CAG GCC GAG ATC AAC TAC CAG TTC AAT TCG CTG CTG CAC GCC GCC GAC 721 751 GAC ATG CAG TTG TAC AAG TAC ATC ATC AAG AAC ACC GCC TGG CAG AAC GGC AAA ACG GTC 781 811 ACG TTC ATG CCC AAG CCG CTG TTC GGC GAC AAC GGG TCC GGC ATG CAC TGT CAT CAG TCG 841 871 CTG TGG AAG GAC GGG GCC CCG CTG ATG TAC GAC GAG ACG GGT TAT GCC GGT CTG TCG GAC 901 931 ACG GCC CGT CAT TAC ATC GGC GGC CTG TTA CAC CAC GCG CCG TCG CTG CTG GCC TTC ACC 961 . 991 AAC CCG ACG GTG AAC TCC TAC AAG CGG CTG GTT CCC GGT TAC GAG GCC CCG ATC AA.C CTG 1021 1051 GTC TAT AGC CAG CGC AA.C CGG TCG GCA TGC GTG CGC ATC CCG ATC ACC GGC AGC AAC CCG 1081 1111 AAG GCC AAG CGG CTG GAG TTC CGA AGC CCC GAC TCG TCG GGC AAC CCG TAT CTG GCG TTC 1141 1171 TCG GCC ATG CTG ATG GCA GGC CTG GAC GGT ATC AAG AAC AAG ATC GAG CCG CAG GCG CCC 1201 1231 GTC GAC AAG GAT CTC TAC GAG CTG CCG CCG GAA GAG GCC GCG AGT ATC CCG CAG ACT CCG 1261 1291 ACC CAG CTG TCA GAT GTG ATC GAC CGT CTC GAG GCC GAC CAC GAA TAC CTC ACC GAA GGA 1321 1351 GGG GTG TTC ACA AAC GAC CTG ATC GAG ACG TGG ATC AGT TTC AAG CGC GAA AAC GAG ATC 1381 1411 GAG CCG GTC AAC ATC CGG CCG CAT CCC TAC GAA TTC GCG CTG TAC TAC GAC GTT taa, and respective analogs, homologs and subunits thereof wherein said fragments, derivatives, analogs, homologs and subunits thereof comprise at least 70% homology to said DNA molecule. intellectual property office of n.z. 9b The present invention also provides vaccinating agents comprising the DNA molecule of the invention; use of the DNA molecule of the invention in the manufacture of a medicament for immunizing a mammalian host against infectious pathogen of the genus Mycobacterium.

According to a further aspect the invention provides an immunodiagnostic agent for use in promoting a detectable immune response in a mammalian host identifying an infectious pathogen from the genus Mycobacterium, said immunodiagnostic agent comprising: at least one immunodominant epitope selected from the group consisting of M. tuberculosis 30 KD protein subunits having the amino acid sequences FSRPGLPVEYLQVPS (Seq ID No:37), LPVEYLQVPSPSMGR (Seq ID No:38), LQVPSPSMGRDIKVQ (Seq ID No:39), DIKVQFQS GGNNSP A (Seq ID No:41), F'QSGGNNSPAV Y L L D (Seq ID No:42), YYQSGLSIV MP VGGQ (Seq ID No:49), L T S E L P Q WLSANRAV (Seq ID No:57). S M A G S S A MI L A A Y H P (Seq ID No:62). SAM ILAAYHPQQFIY (Seq ID No:63), ALLDPSQGMGPSLIG (Seq ID No:67), PSLIGLAMGDAGGYK (Seq ID No:69). AADMWGPSSDPAWER (Seq ID No:72), GPS SDP AWE RNDPTQ (Seq ID No:73), VANNTRL WVYCGN G T (Seq ID No:77), GANIP AEFLENF VRS (Seq ID No:81), QDAYNAAGG H N A V F N (Seq ID No:85), THSWEYWGAQLNAMK (Seq ID No:89), and respective analogs, homologs. and subunits thereof including single or multiple amino acid substitutions, deletions, insertions, and inversions having at least 70% homology to said / amino acid sequence. intellectual property office of n.z. ' 1 MAR 2001 RECEIVED According to a further aspect the invention provides a method for detecting the presence of an immune response in a mammal against a pathogen of the genus Mycobacterium, said method comprising the steps of: providing at least one immunodominant epitope selected from the group consisting of M. tuberculosis 30 KD protein subunits having the amino acid sequences FSRPGLPVEYLQVPS (Seq ID No:37), L P V E Y LQVPSPSMGR (Seq ID No:38). LQVPSPSMGRDIKVQ (Seq ID No:39), D I KVQFQSGGNNSPA (Seq ID No:41), FQSGGNNSPAV YLLD (Seq ID No:42), YYQSGLSIVMPVGGQ (Seq ID No:49), LTSELPQWLSANRAV (Seq ID No:57), SM AGSS AMILAAYHP (Seq ID No:62), S A M I L A A Y H P Q Q F I Y (Seq ID No:63), ALLDPSQGMGPSLIG (Seq ID No:67), P S L I G L A M G D A G G Y K (Seq ID No:69), AADMWGPSSDP AWER (Seq ID No:72), GPS SDPAWERNDPTQ (Seq ID No:73), V ANNTRL WV YCGNGT (Seq ID No: 77), GANIPAEFLENFVRS (Seq ID No:81), QDAYNAAGGHNAVFN (Seq ID No:85), THSWEYWGAQLNAMK (Seq ID No:89), and respective analogs, homologs, and subunits thereof including single or multiple amino acid substitutions, deletions, insertions, and inversions having at least 70% homology to said amino acid sequence; administering said at least one immunodominant epitope to said mammal; and measuring the resultant immune response.

For purposes of the present invention, the term "majorlv abundant" should be understood as a relative term identifying those extracellular products released in the greatest quantity by the pathogen of interest. For example, with respect to M. tuberculosis grown under various conditions of culture to an optical density of approximately 0.5, one skilled in the art should expect to obtain on the order of 10 ug/L or more of a majorlv abundant extracellular product. Thus, out of the total exemplary 4 mg/L total output of extracellular product for M. tuberculosis grown under normal or heat shock conditions, approximately fifteen to twenty (alone or in combination) of the one hundred or so known extracellular products will constitute approximately ninety percent of the total quantity. These are the majorlv abundant extracellular products intellectual property office of n.z. " 1 MAR 2001 P Fn Fivrn W- WO 96/37219 contemplated as being within the scope of the present invention and are readily identifiable as the broad bands appearing in SDS/PAGE gels. In addition, the extracellular products of interest may further be characterized and differentiated by amino acid sequencing. The remaining extracellular products are minor. Those skilled 5 in the art will also appreciate that the relative quantitative abundance of specific major extracellular products may vary depending upon conditions of culture. However, in most cases, the identification of an individual majorly abundant extracellular product will not change.

Accordingly, the present invention may be used to protect a mammalian 10 host against infection by viral, bacterial, fungal or protozoan pathogens. It should be noted that in some cases, such as in viral infections, the majorly abundant extracellular products may be generated by the infected host cell. While active against all microorganisms releasing majorly abundant extracellular products, the vaccines and methods of the present invention are particularly effective in generating protective 15 immunity against intracellular pathogens, including various species and serogroups of the genus Mycobacterium. The vaccines of the present invention are also effective as immunotherapeutic agents for the treatment of existing disease conditions.

Surprisingly, it has been found by this inventor that immunization with the most or majorly abundant products released extracellularly by bacterial pathogens or 20 their immunogenic analogs can provoke an effective immune response irrespective of the absolute immunogenicity of the administered compound. Due to their release from the organism and hence their availability to host molecules involved in antigen processing and presentation and due to their naturally high concentration in tissue during infection, the majorly abundant extracellular products of a pathogenic agent are 25 processed and presented to the host immune system more often than other bacterial components. In the case of intracellular pathogens, the majorly abundant extracellular products are the principal immunogenic determinants presented on the surface of the infected host cells and therefore exhibit a greater presence in the surrounding environment. Accordingly, acquired immunity against the majorly abundant 30 extracellular products of a pathogenic organism allows the host defense system to swiftly detect pathogens sequestered inside host cells and effectively inhibit them.

More particularly, the principal or majorly abundant products released by pathogenic bacteria appear to be processed by phagocytes and other host immune system mechanisms at a greater rate than less prevalent or membrane bound pathogenic 35 components regardless of their respective immunogenic activity or specificity. This immunoprocessing disparity is particularly significant when the pathogenic agent is an 11 intracellular bacteria sequestered from normal immune activity. By virtue of their profuse and continual presentation to the infected host's immune system, the most prevalent bacterial extracellular products or their immunogenic analogs provoke a vigorous immune response largely irrespective of their individual molecular 5 immunogenic characteristics.

Majorly abundant extracellular products are the principal constituents of proteins and other molecular entities which are released by the target pathogen into the surrounding environment. Current research indicates that in some instances a single majorly abundant extracellular product may comprise up to 40% by weight of the 10 products released by a microorganism. More often, individual majorly abundant extracellular products account for between from about 0.5% to about 25% of the total products released by the infectious pathogen. Moreover, the top five or six majorly abundant extracellular products may be found to comprise between 60% to 70% of the total mass released by a microorganism. Of course those skilled in the art will 15 appreciate that the relative levels of extracellular products may fluctuate over time as can the absolute or relative quantity of products released. For example, pH, oxidants, osmolality, heat and other conditions of stress on the organism, stage of life cycle, reproduction status and the composition of the surrounding environment may alter the composition and quantity of products released. Further, the absolute and relative levels 20 of extracellular products may differ greatly from species to species and even between strains within a species.

In the case of intracellular pathogens, extracellular products appear to expand the population of specifically immune lymphocytes capable of detecting and exerting an antimicrobial effect against macrophages containing live bacteria. Further, 25 by virtue of their repeated display on the surface of infected cells, the majorly abundant or principal extracellular products function as effective antigenic markers. Accordingly, pursuant to the teachings of the present invention, vaccination and the inducement of protective immunity directed to the majorly abundant extracellular products of a pathogenic bacteria or their immunogenically equivalent determinants, prompts the host 30 immune system to mount a rapid and efficient immune response with a strong cell-mediated component when subsequently infected by the target pathogen.

In direct contrast to prior art immunization activities which have primarily been focused on the production of vaccines and the stimulation of immune responses based upon the highly specific molecular antigenicity of individual screened 35 pathogen components, the present invention advantageously exploits the relative abundance of bacterial extracellular products or their immunogenic analogs (rather than 12 their immunogenic specificities) to establish or induce protective immunity with compounds which may actually exhibit lower immunogenic specificity than less prevalent extracellular products. For the purposes of this disclosure an immunogenic analog is any molecule or compound sufficiently analogous to at least one majorly 5 abundant extracellular product expressed by the target pathogen, or any fraction thereof, to have the capacity to stimulate a protective immune response in a vaccinated mammalian host upon subsequent infection by the target pathogen. In short, the vaccines of the present invention are identified or produced by selecting the majorly abundant product or products released extracellularly by a specific pathogen (or 10 molecular analogs capable of stimulating a substantially equivalent immune response) and isolating them in a relatively pure form or subsequently sequencing the DNA or RNA responsible for their production to enable their synthetic or endogenous production. The desired prophylactic immune response to the target pathogen may then be elicited by formulating one or more of the isolated immunoreactive products or the 15 encoding genetic material using techniques well known in the art and immunizing a mammalian host prior to infection by the target pathogen.

It is anticipated that the present invention will consist of at least one, two or, possibly even several well defined immunogenic determinants. As a result, the present invention produces consistent, standardized vaccines which may be developed, 20 tested and administered with relative ease and speed. Further, the use of a few well defined molecules corresponding to the majorly abundant secretory or extracellular products greatly reduces the risk of adverse side effects associated with conventional vaccines and eliminates the possible occlusion of effective immunogenic markers. Similarly, because the present invention is not an attenuated or a killed vaccine the risk 25 of infection during production, purification or upon administration is effectively eliminated. As such, the vaccines of the present invention may be administered safely to immunocompromised individuals, including asymptomatic tuberculosis patients and those infected with HIV. Moreover, as the humoral immune response is directed exclusively to products released by the target pathogen, there is little chance of 30 generating a detrimental opsonic immune component. Accordingly, the present invention allows the stimulated humoral response to assist in the elimination of the target pathogen from antibody susceptible areas.

Another beneficial aspect of the present invention is the ease by which the vaccines may be harvested or produced and subsequently purified and sequenced. 35 For example, the predominantly abundant extracellular products may be obtained from cultures of the target pathogen, including M. tuberculosis or M. bovis, with little effort.

WO 96/37219 PCT/US96/07781 13 As the desired compounds are released into the media during growth, they can readily be separated from the intrabacterial and membrane-bound components of the target pathogen utilizing conventional techniques. More preferably, the desired immunoreactive constituents of the vaccines of the present invention may be produced 5 and purified from genetically engineered organisms into which the genes expressing the specific extracellular products of M. tuberculosis, M. bovis, M. leprae or any other pathogen of interest have been cloned. As known in the art, such engineered organisms can be modified to produce higher levels of the selected extracellular products or modified immunogenic analogs. Alternatively, the immunoprotective products, 10 portions thereof or analogs thereof, can be chemically synthesized using techniques well known in the art or directly expressed in host cells injected with naked genes encoding therefor. Whatever production source is employed, the immunogenic components of the predominant or majorly abundant extracellular products may be separated and subsequently formulated into deliverable vaccines using common biochemical 15 procedures such as fractionation, chromatography or other purification methodology and conventional formulation techniques or directly expressed in host cells containing directly introduced genetic constructs encoding therefor.

For example, in an exemplary embodiment of the present invention the target pathogen is M. tuberculosis and the majorly abundant products released 20 extracellularly by M. tuberculosis into broth culture are separated from other bacterial components and used to elicit an immune response in mammalian hosts. Individual proteins or groups of proteins are then utilized in animal based challenge experiments to identify those which induce protective immunity making them suitable for use as vaccines in accordance with the teachings of the present invention. More specifically, 25 following the growth and harvesting of the bacteria, by virtue of their physical abundance the principal extracellular products are separated from intrabacterial and other components through centrifugation and filtration. If desired, the resultant bulk filtrate is then subjected to fractionation using ammonium sulfate precipitation with subsequent dialysis to give a mixture of extracellular products, commonly termed EP. 30 Solubilized extracellular products in the dialyzed fractions are then purified to substantial homogeneity using suitable chromatographic techniques as known in the art and as described more fully below.

These exemplary procedures result in the production of fourteen individual proteinaceous major extracellular products of M. tuberculosis having 35 molecular weights ranging from 110 kilo Daltons (KD) to 12 KD. Following purification each individual majorly abundant extracellular product exhibits one band WO 96/37219 PCT/US96/07781 14 corresponding to its respective molecular weight when subjected to polyacrylamide gel electrophoresis thereby allowing individual products or groups of products corresponding to the majorly abundant extracellular products to be identified and prepared for use as vaccines in accordance with the teachings of the present invention. 5 The purified majorly abundant extracellular products may further be characterized and distinguished by determining all or part of their respective amino acid sequences using techniques common in the art. Sequencing may also provide information regarding possible structural relationships between the majorly abundant extracellular products.

Subsequently, immunization and the stimulation of acquired immunity in 10 a mammalian host system may be accomplished through the teachings of the present invention utilizing a series of subcutaneous or intradermal injections of these purified extracellular products over a course of time. For example, injection with a purified majorly abundant bacterial extracellular product or products in incomplete Freund's adjuvant followed by a second injection in the same adjuvant approximately three 15 weeks later can be used to elicit a protective response upon subsequent challenge with the virulent pathogen. Other exemplary immunization protocols within the scope and teachings of the present invention may include a series of three or four injections of purified extracellular product or products or their analogs in Syntex Adjuvant Formulation (SAF) over a period of time. While a series of injections may generally 20 prove more efficacious, the single administration of a selected majorly abundant extracellular product or its immunogenic subunits or analogs can impart the desired immune response and is contemplated as being within the scope of the present invention as well.

Such exemplary protocols can be demonstrated using art accepted 25 laboratory models such as guinea pigs. For example, as will be discussed in detail, immunization of several guinea pigs with a combination of five majorly abundant extracellular products (purified from M. tuberculosis as previously discussed) was accomplished with an immunization series of three injections of the bacterial products in SAF adjuvant with corresponding sham-immunization of control animals. 30 Exemplary dosages of each protein ranged from 100 \xg to 2 ng. Following the last vaccination all of the animals were simultaneously exposed to an infectious and potentially lethal dose of aerosolized M. tuberculosis and monitored for an extended period of time. The control animals showed a significant loss in weight when compared with the animals immunized with the combination of the majorly abundant extracellular 35 products of M. tuberculosis. Moreover, half of the control animals died during the observation period while none of the immunized animals succumbed to tuberculosis.

Autopsies conducted after this experiment revealed that the non-immunized control animals had significantly more colony forming units (CFU) and corresponding damage in their lungs and spleens than the protected animals. Seventeen additional combinations of purified majorly abundant extracellular products provided 5 immunoprophylaxis when tested, thereby demonstrating the scope of the present invention and broad range of vaccines which may be formulated in accordance with the teachings thereof.

However, it should be emphasized that the present invention is not restricted to combinations of secretory or extracellular products. For example, several 10 alternative experimental protocols demonstrate the capacity of a single abundant extracellular product to induce mammalian protective immunity in accordance with the teachings of the present invention. In each experiment guinea pigs were immunized with a single majorly abundant extracellular product purified from M. tuberculosis EP using the chromatography protocols detailed herein. In one example the animals were 15 vaccinated in multiple experiments with an adjuvant composition containing a purified abundant secretory product having a molecular weight corresponding to 30 KD. In another example of the present invention, different guinea pigs were vaccinated with an adjuvant composition containing an abundant extracellular product isolated from M. tuberculosis having a molecular weight corresponding to 71 KD. Following their 20 respective immunizations both sets of animals and the appropriate controls were exposed to lethal doses of aerosolized M. tuberculosis to determine vaccine effectiveness.

More particularly, in one experiment six guinea pigs were immunized with 100 fig of 30 KD protein in SAF on three occasions spread over a period of six 25 weeks. Control animals were simultaneously vaccinated with corresponding amounts of a bulk preparation of extracellular proteins (EP) or buffer. Three weeks after the final vaccination, the animals were challenged with an aerosolized lethal dose of M. tuberculosis and monitored for a period of 14 weeks. The 30 KD immunized guinea pigs and those immunized with the bulk extracellular preparation had survival rates o r 30 67% and 50% respectively (illustrating the unexpectedly superior performance of the majorly abundant extracellular product versus EP), while the sham-immunized animals had a survival rate of only 17%. Upon termination of the experiment the animals were sacrificed and examined for viable tubercle bacilli. Unsurprisingly, the non-immunized animal showed markedly higher concentrations of M. tuberculosis in the lungs and 35 spleen. 16 Similar experiments were performed on those animals vaccinated with 71 KD protein. In one experiment six guinea pigs were vaccinated with an SAF adjuvant composition containing 100 |ag purified 71 KD protein two times over a period of three weeks. Other animals were similarly immunized with a bulk preparation of 5 unpurified extracellular proteins or EP for use as a positive control and with buffer for use as a negative control. Following exposure to lethal doses of aerosolized tubercle bacilli the weight of the guinea pigs was monitored for a period of 6 months. Once again the animals immunized with the purified form of the abundant extracellular product developed protective immunity with respect to the virulent M. tuberculosis. By 10 the end of that period the buffer immunized animals showed a significant loss in weight when compared with the immunized animals. Further, while the positive controls and 71 KD immunized animals had survival rates of 63% and 50% respectively, the non-immunized animals all died before the end of the observation period.

It is important to note that the formulation of the vaccine is not critical to 15 the present invention and may be optimized to facilitate administration. Solutions of the purified immunogenic determinants derived from the majorly abundant pathogenic extracellular products may be administered alone or in combination in any manner designed to generate a protective immune response. The purified protein solutions may be delivered alone, or formulated with an adjuvant before being administered. Specific 20 exemplary adjuvants used in the instant invention to enhance the activity of the selected immunogenic determinants are SAF, adjuvants containing Monophosphoryl Lipid A (MPL), Freund's incomplete adjuvant, Freund's complete adjuvant containing killed bacteria, gamma interferons (Radford et al., American Society of Hepatology 2008-2015, 1991; Watanabe et al., PNAS 86:9456-9460, 1989; Gansbacher et al., Cancer 25 Research 50:7820-7825, 1990; Maio et al., Can. Immunol. Immunother. 50:34-42, 1989; U.S. Patent Nos. 4,762,791 and 4,727,138), MF59, MF59 plus MTP, MF59 plus IL-12, MPL plus TDM (Trehalose (Dimycolate), QS-21, QS-21 plus IL-12, IL-2 (American Type Culture Collection Nos. 39405, 39452 and 39516; see also U.S. Patent No. 4,518,584), IL-12, IL-15 (Grabstein et al., Science 264:965-968, 1994), 30 dimethyldioctadecyl ammonium (ddA), ddA plus dextran, alum, Quil A, ISCOMS, (Immunostimulatory Complexes), Liposomes, Lipid Carriers, Protein Carriers, and Microencapsulation techniques. Additional adjuvants that may be useful in the present invention are water-in-oil emulsions, mineral salts (for example, alum), nucleic acids, block polymer surfactants, and microbial cell walls (peptido glycolipids). While not 35 limiting the scope of the invention it is believed that adjuvants may magnify immune responses due to the slow release of antigens from the site of injection. 17 Alternatively, genetic material encoding the genes for one or more of the immunogenic determinants derived from the majorly abundant pathogenic extracellular products may be coupled with eucaryotic promoter and/or secretion sequences and injected directly into a mammalian host to induce and endogenous expression of the 5 immunogenic determinants and subsequent protective immunity.

Other objects, features and advantages of the present invention will be apparent to those skilled in the art from a consideration of the following detailed description of preferred exemplary embodiments thereof taken in conjunction with the figures which will first be described briefly.

Brief Description of the Drawings Figure 1 is a representation of 4 Coomassie blue stained gels, labeled la to Id, illustrating the purification of exemplary majorly abundant extracellular products of M. tuberculosis as identified by sodium dodecyl sulfate polyacrylamide gel 15 electrophoresis (SDS-PAGE).

Figure 2 is a tabular representation identifying the five N-terminal amino acids of fourteen exemplary majorly abundant extracellular products of M. tuberculosis (Sequence ID Nos. 1-14) and the apparent molecular weight for such products.

Figure 3 is a tabular representation of the extended N-terminal amino 20 acid sequence of three exemplary majorly abundant secretory products of M. tuberculosis (Sequence ID Nos. 15-17) which were not distinguished by the five N-terminal amino acids shown in Figure 2.

Figure 4 is a graphical comparison of the survival rate of guinea pigs immunized with exemplary purified majorly abundant 30 KD secretory product of 25 M. tuberculosis versus positive controls immunized with a prior art bulk preparation of extracellular proteins and non-immunized negative controls following exposure to an aerosolized lethal dose of M. tuberculosis.

Figure 5 is a graphical comparison of mean guinea pig body weight of animals immunized with purified majorly abundant 71 KD extracellular product versus 30 positive controls immunized with a prior art bulk preparation of extracellular proteins from M. tuberculosis and non-immunized negative controls following exposure to an aerosolized lethal dose of M. tuberculosis.

Figure 6 is a graphical comparison of the survival rate of guinea pigs immunized in Figure 5 with exemplary majorly abundant purified 71 KD extracellular 35 product of M. tuberculosis versus positive controls immunized with a prior art bulk 18 preparation of extracellular proteins from M. tuberculosis and non-immunized negative controls following exposure to an aerosolized lethal dose of M. tuberculosis.

Figure 7 is a graphical comparison of mean guinea pig body weight of animals immunized with exemplary purified majorly abundant 71 KD extracellular 5 product and non-immunized negative controls following exposure to an aerosolized lethal dose of M. tuberculosis in a second, separate experiment.

Figures 8a and 8b are graphical comparisons of lymphocyte proliferative responses to exemplary purified majorly abundant 71 KD extracellular product in PPD+ (indicative of infection with M. tuberculosis) and PPD- human subjects. Figure 8a is a 10 graph of the values measured at 2 days after incubation of lymphocytes with this antigen while Figure 8b is a graph of the values measured at 4 days after incubation.

Figure 9 is a graphical comparison of mean guinea pig body weight of animals immunized with vaccine comprising a combination of extracellular products produced according to the teachings of the present invention and non-immunized 15 controls following exposure to an aerosolized lethal dose of M. tuberculosis.

Figure 10 is a graphical comparison of mean guinea pig body weight of animals immunized with three different dosages of a vaccine comprising a combination of extracellular products produced according to the teachings of the present invention and non-immunized controls following exposure to an aerosolized lethal dose of 20 M. tuberculosis.

Figure 11 is a, graphical comparison of mean guinea pig body weight of animals immunized with vaccines comprising six different combinations of extracellular products produced according to the teachings of the present invention and non-immunized controls following exposure to an aerosolized lethal dose of 25 M. tuberculosis.

Figures 12a and b are graphical illustrations of the mapping of the immunodominant epitopes of the 30 KD protein of M. tuberculosis. Figure 12a illustrates the percentage of 24 guinea pigs immunized with the 30 KD protein responding to overlapping peptides (15-mer) covering the entire 30 KD protein 30 sequence. Figure 12b illustrates a corresponding set of data for a group of 19 sham immunized guinea pigs. The response of each group of animals to native 30 KD protein, purified protein derivative (PPD) and concanavalin A (con A) appears at the right of each graph.

Figure 13 provides a diagrammatic representation of the constructs used 35 for the expression of recombinant 30 kDa protein. The diagram depicts the pET22b vectors used for the expression of recombinant 30 kDa protein. The vectors express the 19 mature 30 kDa protein fused to its own leader (30W-pET22b) or the plasmid encoded pelB leader (30M-pET22b). Abbreviations used: Ori, ColEl type origin of replication; F1 ori, phage F1 origin of replication; Amp, ampicillin resistance gene; 30W/M, full-length (30W)) or mature (30M) 30 kDa protein; lacl, lac repressor gene; P^, phage T7 5 RNA polymerase specific promoter; Ndel and Ncol, restriction enzyme sites at vector/insert junctions.

Figure 14 shows electrophoresis test results and a Western blot analysis which confirm the expression of full-length and mature 30 kDa protein in E. coli BL21(DE3)pLysS.

Figure 15 is a diagrammatic representation of an alternate construct system used to express the 30 kDa protein.

Figure 16 shows electrophoresis test results which confirm the expression of the M. tuberculosis 30 kDa protein in M. smegmatis.

Figure 17 depicts the results of a Western blot analysis, confirming the 15 expression of the M. tuberculosis 30 kDa protein in M. smegmatis.

Detailed Description The present invention is directed to compounds and methods for their production and use against pathogenic organisms as vaccines and immunotherapeutic 20 agents. More specifically, the present invention is directed to the production and use of majorly abundant extracellular products released by pathogenic organisms, their immunogenic analogs or the associated genetic material encoding therefor as vaccines or immunotherapeutic agents and to associated methods for generating protective immunity in mammalian hosts against infection. These compounds will be referred to 25 as vaccines throughout this application for purposes of simplicity.

In exemplary embodiments, illustrative of the teachings of the present invention, the majorly abundant extracellular products of M. tuberculosis were distinguished and subsequently purified. Guinea pigs were immunized with purified forms of these majorly prevalent extracellular products with no determination of the 30 individual product's specific molecular immunogenicity. Further, the exemplary immunizations were carried out using the purified extracellular products alone or in combination and with various dosages and routes of administration. Those skilled in the art will recognize that the foregoing strategy can be utilized with any pathogenic organism or bacteria to practice the method of the present invention and, accordingly, 35 the present invention is not specifically limited to vaccines and methods directed against M. tuberculosis.

In these exemplary embodiments, the majorly abundant extracellular products of M. tuberculosis were separated and purified using column chromatography. Determination of the relative abundance and purification of the extracellular products was accomplished using polyacrylamide gel electrophoresis. Following purification of 5 the vaccine components, guinea pigs were vaccinated with the majorly abundant extracellular products alone or in combination and subsequently challenged with M. tuberculosis. As will be discussed in detail, in addition to developing the expected measurable responses to these extracellular products following immunization, the vaccines of the present invention unexpectedly conferred an effective immunity in these 10 laboratory animals against subsequent lethal doses of aerosolized M. tuberculosis.

While these exemplary embodiments used purified forms of the extracellular products, those skilled in the art will appreciate that the present invention may easily be practiced using immunogenic analogs which are produced through recombinant means or other forms of chemical synthesis using techniques well known 15 in the art. Further, immunogenic analogs, homologs or selected segments of the majorly abundant extracellular products may be employed in lieu of the naturally occurring products within the scope and teaching of the present invention.

A further understanding of the present invention will be provided to those skilled in the art from the following non-limiting examples which illustrate 20 exemplary protocols for the identification, isolation, production and use of majorly abundant extracellular products (alone and in combination) as vaccines.

EXAMPLES EXAMPLE 1 Isolation and Production of Bulk Extracellular Proteins (EP) from Mycobacterium tuberculosis M. tuberculosis Erdman strain (ATCC 35801) was obtained from the American Tissue Culture Collection (Rockville, Md.). The lyophilized bacteria were 30 reconstituted in Middlebrook 7H9 culture medium (Difco Laboratories, Detroit, Mich.) and maintained on Middlebrook 7H11 agar. 7H11 agar was prepared using Bacto Middlebrook 7H10 agar (Difco), OADC Enrichment Medium (Difco), 0.1% casein enzymatic hydrolysate (Sigma), and glycerol as previously described by Cohn (Cohn, M.I., Am. Rev. Respir. Dis. 98:295-296) and incorporated herein by reference. 35 Following sterilization by autoclaving, the agar was dispensed into bacteriologic Petri dishes (100 by 15 mm) and allowed to cool.

PCT/U S96/07781 21 M. tuberculosis was then plated using sterile techniques and grown at 37°C in 5% C02-95% air, 100% humidity. After culture on 7H11 for 7 days, the colonies were scraped from the plates, suspended in 7H9 broth to 108 CFU/ml and aliquoted into 1.8-ml Nunc cryotubes (Roskilde, Denmark). Each liter of the broth was 5 prepared by rehydrating 4.7 g of Bacto Middlebrook 7H9 powder with 998 ml of distilled water, and 2 ml of glycerol (Sigma Chemical Co., St. Louis, Mo.) before adjusting the mixture to a pH value of 6.75 and autoclaving the broth for 15 min at 121 °C. The aliquoted cells were then slowly frozen and stored at -70°C. Cells stored under these conditions remained viable indefinitely and were used as needed. 10 Bulk extracellular protein (EP) preparations were obtained from cultures of M. tuberculosis grown in the Middlebrook 7H9 broth made as above. Following reconstitution, 150 ml aliquots of the broth were autoclaved for 15 min at 121 °C and dispensed into vented Co-star 225 cm2 tissue culture flasks. M. tuberculosis cells stored at -70°C as described in the previous paragraph were thawed and used to inoculate 15 7H11 agar plates. After culture for 7 days, the colonies were scraped from the plates, suspended in a few ml of 7H9 broth, and sonicated in a water bath to form a single cell suspension. The M. tuberculosis cells were suspended in the sterile 150 ml aliquots at an initial optical density of 0.05, as determined by a Perkin-Elmer Junior model 35 spectrophotometer (Norwalk, Conn). The cells were then incubated at 37°C in 5% 20 C02-95% air for 3 weeks until the suspension showed an optical density of 0.4 to 0.5. These cultures were used as stock bottles for subsequent cultures also in 7H9 broth. The stock bottles were sonicated in a water bath to form a single cell suspension. The M. tuberculosis cells were then diluted in 7H9 broth to an initial optical density of 0.05 and incubated at 37°C in 5% C02-95% air for 2 Vi to 3 weeks until the suspension 25 showed an optical density of 0.4 to 0.5. Culture supernatant was then decanted and filter sterilized sequentially through 0.8 |im and 0.2 p.m low-protein-binding filters (Gelman Sciences Inc., Ann Arbor, Mich.). The filtrate was then concentrated approximately 35 fold in a Filtron Minisette with an Omega membrane having a 10 KD cutoff and stored at 4°C. Analysis of the bulk extracellular protein preparation by 30 sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) revealed a protein composition with multiple bands. Bulk extracellular protein mixture (EP) was prepared by obtaining a 40%-95% ammonium sulfate cut of the culture filtrate. 309945 EXAMPLE 2 Purification of Principal Majorly Abundant Extracellular Products of Mycobacterium tuberculosis Ammonium sulfate (grade I, Sigma) was added to the sterile culture filtrate of Example 1 in concentrations ranging from 10% to 95% at 0°C and gently stirred to fractionate the proteins. The suspension was then transferred to plastic bottles and centrifuged in a swinging bucket rotor at 3,000 rpm on a RC3B Sorvall Centrifuge to pellet the resulting precipitate. The supernatant fluid was decanted and, depending 10 on the product of interest, the supernatant fluid or pellet was subjected to further purification. When the product of interest was contained in the supernatant fluid a second ammonium sulfate cut was executed by increasing the salt concentration above that of the first cut. After a period of gentle stirring the solution was then centrifuged as previously described to precipitate the desired product and the second supernatant fluid 15 was subjected to further purification.

Following centrifugation. the precipitated proteins were resolubilized in the appropriate cold buffer and dialyzed extensively in a Spectrapor dialysis membrane (Spectrum Medical Industries, Los Angeles, California) with a 6,000 to 8,000 molecular weight cut-off to remove the salt. Extracellular protein concentration was determined 20 by a bicinchoninic acid protein assay (Pierce Chemical Co., Rockford, Illinois) and fraction components were determined using SDS-PAGE. The fractions were then applied to chromatography columns for further purification.

Using the general scheme outlined immediately above fourteen extracellular products were purified from the bulk extracellular protein filtrate obtained 25 by the process detailed in Example 1. The exact ammonium sulfate precipitation procedure and chromatography protocol is detailed below for each extracellular product isolated.

A. 110 KD Extracellular Product 30 1. A 50%-100% ammonium sulfate precipitate was obtained as discussed above. 2. The resolubilized precipitate was dialyzed and applied to a DEAE Sepharose®CL-6B or QAE Sepharose® ion exchange column in column buffer consisting of 10% sorbitol, 10 mM potassium phosphate, pH 7, 5 mM 2-mercaptoethanol, and 0.2 mM EDTA and eluted with a SQflirr" rhloritjt* intellectual property office of n.z. 2 0 FEB 2001 RECEIVED WO 96/37219 PCT/US96/07781 • 23 30 9945 gradient. Fractions containing 110 KD protein elute at approximately 550 mM salt and were collected. 3. Collected fractions were applied to S200 Sepharose® size fractionation column in PBS (phosphate buffered saline) buffer. The protein eluted as a 5 homogeneous 110 KD protein.

B. 80 KD Extracellular Product 1. The 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded and the 25%-60% ammonium sulfate cut (overnight at 0°C) was retained as discussed above. 2. A DEAE CL-6B column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1M NaCl and equilibrated with 25 mM Tris, pH 8.7, 10 mM NaCl and the protein sample was dialyzed against 25 mM Tris, pH 8.7, 10 mM NaCl and applied to the column. The column was washed overnight with the same buffer. A first salt gradient of 10 mM to 200 mM NaCl in 25 mM Tris, pH 8.7 was run through the column to elute other proteins. A second salt gradient (200 to 300 mM NaCl) was run through the column and the 80 KD protein eluted at approximately 275 mM NaCl. 3. A Q-Sepharose®HP column was charged with 25 mM Tris, pH 8.7, 1M NaCl and re-equilibrated to 25 mM Tris, pH 8.7, 10 mM NaCl. The protein sample was dialyzed against 25 mM Tris, pH 8.7, 10 mM NaCl and applied to the column. Tne column was washed in the same buffer and then eluted with 200-300 mM NaCl in 25 mM Tris, pH 8.7. 4. Fractions containing the 80 KD protein were collected and dialyzed against 25 mM Tris, pH 8.7, 10 mM NaCl, and then concentrated in a Speed- Vac®concentrator to 1-2 ml. The protein sample was applied to aSuperdex®75 column and eluted with 25 mM Tris. pH 8.7, 150 mM NaCl. The 80 KD protein eluted as a homogenous protein.

C. 71 KD Extracellular Product 1. A 40%-95% ammonium sulfate precipitate was obtained as discussed above with the exception that the 71 KD product was cultured in 7H9 broth at pH 7.4 and at 0% C02 and heat-shocked at 42°C for 3h once per week. The precipitate was dialyzed against Initial Buffer (20 mM HEPES, 2 mM MgAc. 25 mM KC1, 10 mM (NH4)2S04, 0.8 mM DL-Dithiothreitol, pH 7.0). intellectual property office of n.z. 2 0 FEB 2001 RECEIVED 24 2. The resolubilized precipitate was applied to an ATP Agarose column equilibrated with Initial Buffer. Effluent was collected and reapplied to the ATP Agarose column. The 71 KD protein bound to the column. 3. Subsequently the ATP Agarose column was washed, first with 5 Initial Buffer, then 1 M KC1, then Initial Buffer. 4. Homogeneous 71 KD protein was eluted from the column with 10 mM ATP and dialyzed against phosphate buffer.

D. 58 KD Extracellular Product k A 25%-50% ammonium sulfate precipitate was obtained as discussed above. 2. The resolubilized precipitate was dialyzed and applied to a DEAE-Sepharose®CL-6B or QAE-Sepharose®column and eluted with NaCl. Collected fractions containing the 58 KD Protein eluted at approximately 400 mM NaCl. 15 3. Collected fractions were then applied to a Sepharose®CL-6B size fractionation column. The protein eluted at approximately 670-700,000 Daltons. 4. The eluted protein was applied to a thiopropyl-sepharose column. The homogeneous 58 KD protein eluted at approximately 250-350 mM 2-mercaptoethanol. The eluted protein was monitored using SDS-PAGE and exhibited 20 the single band shown in Figure 1A, col. 2.

E. 45 KD Extracellular Product 1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded. b. The 25%-60% ammonium sulfate cut (overnight at 0°C) was retained. 2. a. A DEAE CL-6B column (Pharmacia) was charged with 2.5 mM Tris, pH 8.7 containing 1 M NaCl and equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7. b. The protein sample was dialyzed against 25 mM Tris, mM NaCl, pH 8.7 and applied to column. The column was then washed overnight with the same buffer. c. The column was eluted with a salt gradient (10 mM to 200 mM) in 25 mM Tris, pH 8.7 buffer. The 45 KD protein eluted at approximately 35 40 mM NaCl. ___ intellectual property office of n.z. 2 0 FEB 2001 RECEIVED wo 96/37219 PCT/US96/07781 3. a. A Q-Sepharose®HP (Pharmacia) column was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl and re-equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7. b. The protein sample was dialyzed against 25 mM Tris, 5 10 mM NaCl, pH 8.7 and applied to column with subsequent washing using the same buffer. c. The column was eluted with 10-150 mM NaCl in 25 mM Tris, pH 8.7. 4. a. Fractions containing the 45 KD product were collected, 10 pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentration to 1 ml in a Speed Vac® concentrator. b. Concentrate was Applied to Superdex®75 column equilibrated with 25 mM Tris 150 mM NaCl, pH 8.7. The product eluted as a homogeneous protein. The eluted protein was monitored using SDS-PAGE and 15 resulted in the single band shown in Figure IB, col. 2.

F. 32 KD Extracellular Product (A*) 1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded. b. The 25%-60% ammonium sulfate cut (overnight at 0°C) was retained. 2. a. A DEAE CL-6B column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl and then equilibrated with 25 mM Tris. 10 mM NaCl, pH 8.7. b. The protein sample was dialyzed against 25 mM Tris, mM NaCl, pH 8.7 and applied to the column with subsequent washing overnight with same buffer. c. The column was eluted with a salt gradient (10 mM to 200 mM) in 25 mM Tris, pH 8.7 buffer. The 32 KD protein eluted at approximately 30 70 mM NaCl. 3. a. Fractions containing the 32 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentrating the protein sample to 1 ml in aSpeed-Vac®Concentrator. b. The concentrate was then Applied to aSuperdex®75 column equilibrated with 25 mM Tris, 150 mM NaCl. pH 8.7-and-eluted—wqth-th&s- intellectual property buffer. The 32 KD product eluted as homogeneous protem.

OFFICE OF N.Z. 2 0 FEB 2001 RECEIVED WO 96/37219 PCT/US96/07781 26 9 9 A 5 4. a. A Q-Sepharose HP column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl, and re-equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7. b. The protein sample was dialyzed against 25 mM Tris, 5 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing in the same buffer. c. The column was eluted with a 100-300 mM NaCl gradient. Labeled 32A, the homogeneous protein eiutes at approximately 120 mM NaCl and is shown as a single band in Figure IB, col. 4.

G. 32 KD Extracellular Product (B) 1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded. b. The 25%-60% ammonium sulfate cut (overnight at 0°C) was retained. 2. a. A DEAE CL-6B column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl and then equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7. b. The protein sample was dialyzed against 25 mM Tris, 20 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing overnight with same buffer. c. A preliminary salt gradient of 10 mM to 200 mM NaCl in 25 mM Tris, pH 8.7 was run, eluting various proteins. Following column equilibration, a second salt gradient (200 to 300 mM NaCl) was run. The 32 KD protein eluted at approximately 225 mM NaCl. 3. a. AQ-Sepharose®HP column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl, and re-equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7. b. The protein sample was dialyzed against 25 mM Tris, 30 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing in the same buffer. c. The column was eluted with a 200-300 mM NaCl gradient in the same buffer. 4. a. Fractions containing the 32 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, befdr^<^<^^ii^c$f RTY" protein sample to 1 ml in aSpeed-Vac®Concentrator. office of n.z. 2 0 FEB 2001 RECEIVED WO 96/37219 PCT/US96/07781 27 m b. The concentrate was then applied to a Superdex®75 column equilibrated writh 25 mM Tris, 150 mM NaCl, pH 8.7 and eluted with the same buffer. The 32 KD product, labeled 32B to distinguish it from the protein of 32 KD separated using protocol H, eluted as homogeneous protein and is shown as a single band on Figure IB, col. 3.

H. 30 KD Extracellular Product 1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded. - b. The 25%-60% ammonium sulfate cut (overnight at 0°C) was retained. 2. a. A DEAE CL-6B column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl and then equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7. b. The protein sample was dialyzed against 25 mM Tris, lOmM NaCl, pH 8.7 and applied to the column with subsequent washing overnight with same buffer. c. The column was eluted with a salt gradient (10 mM to 200 mM) in 25 mM Tris, pH 8.7 buffer. The 30 KD protein eluted at approximately 140 mM NaCl. 3. a. Fractions containing the 30 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentrating the protein sample to 1 ml in aSpeed-Vac®Concentrator. b. The concentrate was then Applied to a Superdex®75 25 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7 and eluted with this buffer. The 30 KD product eluted as homogeneous protein and is shown as a single band on Figure IB, col. 5.

I. 24 KD Extracellular Product 1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded. b. The 25%-60% ammonium sulfate cut (overnight at 0°C) was retained. 2. a. A DEAE CL-6B column (Pharmacia) was charged with 35 25 mM Tris, pH 8.7 containing 1 M NaCl and then equilibrated with 25 mM Tris, mM NaCl, pH 8.7. intellectual property office of n.z. 2 0 FEB 2001 RECEIVED b. The protein sample was dialyzed against 25 mM Tris, lOmM NaCl, pH 8.7 and applied to the column with subsequent washing overnight with same buffer. c. A preliminary salt gradient of 10 mM to 200 mM NaCl in 5 25 mM Tris, pH 8.7 was run, eluting various proteins. Following column equilibration a second salt gradient (200 to 300 mM NaCl) was run. The 24 KD elutes at approximately 250 mM NaCl. 3. a. A Q-Sepharose®HP column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl, and re-equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7. . b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing in the same buffer. c. The column was eluted with a 200-300 mM NaCl 15 gradient in the same buffer. 4. a. Fractions containing the 24 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentrating the protein sample to 1 ml in aSpeed-Vac®Concentrator. b. The concentrate was then applied to a Superdex® 75 20 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7 and eluted with the same buffer. The 24 KD product eluted as homogeneous protein and is shown as a single band on Figure IB, column 7.

J. 23.5 KD Extracellular Product 25 1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded. b. The 25%-60% ammonium sulfate cut (overnight at 0°C) was retained. 2. a. A DEAE CL-6B column (Pharmacia) was charged with 30 25 mM Tris, pH 8.7 containing 1 M NaCl and then equilibrated with 25 mM Tris. 10 mM NaCl, pH 8.7. b. The protein sample was dialyzed against 25 mM Tris. 10 mM NaCl, pH 8.7 and applied to the column prior to subsequent washing overnight with same buffer. intellectual property office of n.z. 2 0 FEB 2001 RECEIVED 29 c. The column was eluted with a salt gradient (10 mM to 200 mM) in 25 mM Tris, pH 8.7 buffer. The 23.5 KD protein eluted at approximately 80 mM NaCl. 3. a. A Q-Sepharose® HP column was charged with 25 mM 5 Tris, pH 8.7 containing 1 M NaCl, and re-equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7. b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing in the same buffer. " c. The column was eluted with 100-300 mM NaCl in mM Tris, pH 8.7. d. Steps 3a to 3c were repeated. 4. a. Fractions containing 23.5 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentrating the protein sample to 1 ml in aSpeed-Vac®Concentrator. b. The concentrate was then applied to a Superdex®75 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7 and eluted with the same buffer. The 23.5 KD product eluted as homogeneous protein. The eluted protein was monitored using SDS-PAGE and resulted in the single band shown in Figure IB, 20 column 6.

K. 23 KD Extracellular Product 1. a. Ammonium sulfate cuts of 0-25% (lh at 0°C) and 25%-60% (overnight at 0°C) were discarded. b. A 60%-95% ammonium sulfate cut was retained. 2. a. A DEAE CL-6B column (Pharmacia) was charged with 50 mM Bis-Tris pH 7.0 containing 1 M NaCl and equilibrated with 50 mM Bis-Tris, 100 mM NaCl, pH 7.0. b. The protein sample was dialyzed against 50 mM Bis-Tris, 30 pH 7.0, 100 mM NaCl buffer and applied to the column before washing the column overnight with the same buffer. c. The column was eluted with a 100 to 300 mM NaCl linear gradient in 50 mM Bis-Tris pH 7.0. d. Fractions were collected containing the 23 KD protein which eluted at approximately 100-150 mM NaCl. intellectual property office of n.z. 2 0 FEB 2001 RECEIVED WO 96/37219 PCT/US96/07781 3. a. The protein fractions were dialyzed against 25 mM Tris, pH 8.7, 10 mM NaCl and concentrated to 1-2 ml on a Savant Speed Vac®Concentrator. b. The concentrate was applied to a Superdex®75 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7. The product elutes as a 5 homogeneous protein as is shown in Figure IB col. 8.

L. 16 KD Extracellular Product 1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded. b. The 25-60% ammonium sulfate cut (overnight at 0°C) was retained. 2. a. A DEAE CL-6B column (Pharmacia) was charged with 2.5 mM Tris, pH 8.7 containing 1 M NaCl and then equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7. b. The protein sample was dialyzed against 25 mM Tris, mM NaCl, pH 8.7 and applied to the column with subsequent washing overnight in the same buffer. c. The column was eluted with a salt gradient (10 mM to 200 mM) in 25 mM Tris, pH 8.7 buffer. The 16 KD protein eluted at approximately 20 50 mM NaCl. 3. a. Fractions containing 16KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentrating the protein sample to 1 ml in aSpeed-Vac®Concentrator. b. The concentrate was then applied to a Superdex® 75 25 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7 and eluted with the same buffer. A 16 KD product eluted as homogeneous protein. The eluted protein was monitored using SDS-PAGE and resulted in the single band shown in Figure IB, col. 9.

M. 14 KD Extracellular Product 1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded. b. The 25-60% ammonium sulfate cut (overnight at 0°C) was retained. intellectual property office of n.z. 2 0 FEB 2001 RECEIVED WO 96/37219 PCT/US96/07781 2. a. A DEAE CL-6B column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl and then equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7. b. The protein sample was dialyzed against 25 mM Tris, 5 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing overnight in the same buffer. c. The column was eluted with a salt gradient (10 mM to 200 mM) in 25 mM Tris, pH 8.7 buffer. The 14 KD protein eluted at approximately 60 mM NaCl. 3. a. A Q-Sepharose® HP column was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl, and re-equilibrated with 25 mM NaCl, pH 8.7. b. The protein sample was dialyzed against 25 mM Tris. 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing in the same buffer. c. The column was eluted with 10-150 mM NaCl in 25 mM Tris, pH 8.7. d. Steps 3 a through 3 c were repeated. 4. a. Fractions containing 14 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentrating the 20 protein sample to 1 ml in aSpeed-Vac®Concentrator. b. The concentrate was then applied to a Superdex® 75 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7 and eluted with this buffer. The 14KD product eluted as homogeneous protein. The eluted protein was monitored using SDS-PAGE and resulted in the single band shown in Figure 1C, 25 column 2.

N. 12 KD Extracellular Products 1. A 0-10% ammonium sulfate precipitate was obtained (overnight at 4°C). 2. The resolubilized precipitate was applied to a S200 Sephacryf size fractionation column eluting the protein as a 12 KD molecule. 3. The protein fractions were applied to a DEAE-Sepharose®CL-6B or QAE-Sepharose® ion exchange column and eluted with an NaCl gradient as previously described. Fractions containing two homogeneous proteins having 35 molecular weights of approximately 12 KD eluted at approximately 300-350 mM NaCl intellectual property office of n.z. 2 0 FEB 2001 RECEIVED 32 and were collected. The proteins were labeled 12A and 12B and purified as a doublet shown in Figure ID, col. 2.

As illustrated in the SDS-PAGE profile of Figure 1, the principal or 5 majorly abundant extracellular proteins of M. tuberculosis were purified to homogeneity through the use of the protocols detailed in Examples 2A - 2N above. More particularly, Figure 1 illustrates four exemplary 12.5% acrylamide gels developed using SDS-PAGE and labeled 1A, IB, 1C, and ID. The standard in lane 1 of gels 1A-1C has proteins with molecular weights of 66,45, 36, 29, 24, 20, and 14 KD. In gel ID 10 the standard in lane 1 contains proteins with molecular weights of 68, 45, 31, 29, 20, and 14 KD. The lanes containing the respective purified extracellular products show essentially one band at the reported molecular weight of the individual protein. It should be noted that in gel 1 D the 12 KD protein runs as a doublet visible in lane 2. Sequence analysis shows that the lower 12 KD (or 12B KD band) is equivalent to the 15 upper 12 KD (or 12A KD) band except that it lacks the first 3 N-terminal amino acids.

Further analysis of these individual exemplary majorly abundant extracellular products is provided in Figure 2. More particularly Figure 2 is a tabular compilation of N-terminal sequence data obtained from these purified extracellular products showing that the majority of the isolated products are indeed distinct 20 (Sequence ID Nos. 1-14). Proteins 32A, 32B and 30 all had the same 5 N-terminal amino acids therefore further sequencing was necessary to fully characterize and differentiate them. Figure 3 shows the extended N-terminal amino acid sequences for these three purified secretory products (Sequence ID Nos. 15-17). Different amino acids at positions 16 (Sequence ID No. 17), 31 (Sequence ID No. 16) and 36 (Sequence 25 ID No. 16) demonstrate that these isolated proteins are distinct from one another despite their similarity in molecular weight.

In addition to proteins 30, 32A and 32B, extended N-terminal amino acid sequences of other majorly abundant extracellular products were determined to provide primary structural data and to uncover possible relationships between the proteins. 30 Sequencing was performed on the extracellular products purified according to Example 2 using techniques well known in the art. Varying lengths of the N-terminal amino acid sequence, determined for each individual extracellular product, are shown below identified by the apparent molecular weight of the intact protein, and represented using standard one letter abbreviations for the naturally occurring amino acids. In keeping 35 with established rules of notation, the N-terminal sequences are written left to right in the direction of the amino terminus to the carboxy terminus. Those positions where the 33 identity of the determined amino acid is less than certain are underlined. Where the amino acid at a particular position is unknown or ambiguous, the position in the sequence is represented by a dash. Finally, where two amino acids are separated by a slash, the correct constituent has not been explicitly identified and either one may 5 occupy the position in that sequence.

PROTEIN N-TERMINAL AMINO ACID SEQUENCE 10 15 20 25 30 35 12 KD FDTRL MRLED EMKEG RYEVR AELPG VDPDK DVDIM 40 45 VRDGQ LTIKA ERT (Sequence ID No. 18) 10 14 KD ADPRL QFTAT (Sequence ID Nos. 19 and 20) 20 25 30 TLSGA PFDGA S/NLQGK PAVLW 10 15 20 25 30 16 KD AYPIT GKLGS ELTMT DTVGQ VVLGW KVSDL 40 45 30 F/YKSTA VIPGY JV-EQ QI (Sequence ID Nos. 21 and 22) 10 15 20 23 KD AETYL PDLDW DYGAL EPHIS GQ (Sequence ID No. 23) 40 10 23.5 KD APKTY -EELK GTD 45 (Sequence ID No. 24) PCT/U S96/07781 34 10 30 24 KD APYEN LMVPS PSMGR DIPVA FLAGG PHAVY LLDAF 40 45 50 55 60 NAGPD VSNWV TAGNA MMTLA -KGIC/S (Sequence ID Nos. 25 and 26) 10 15 20 25 30 35 30 KD FSRPG LPVEY LQVPS PSMGR DIKVQ FQSGG NNSPA 40 VYLLD (Sequence ID No. 27) 10 15 20 25 30 35 40 32A KD FSRPG LPVEY LQVPS PSMGR DIKVQ FQSGG ANSP- LYLLD (Sequence ID No. 28) 10 15 20 32B KD FSRPG LPVEY LQVPS A-MGR DI (Sequence ID No. 29) 5 10 15 20 25 30 45 KD DPEPA PPVPD DAASP PDDAA APPA£ ADPP- (Sequence ID No. 30) 40 10 15 20 58 KD TEKTP DDVFK LAKDE KVLYL 45 (Sequence ID No. 31) 50 71 KD ARAVG I (Sequence ID No. 32) 80 KD TDRVS VGN 5 (Sequence ID No. 33) 10 15 20 10 110 KD NSKSV NSFGA HDTLK V-ERK RQ (Sequence ID No. 34) DNA sequencing was performed on the 30, 32A, 16, 58, 23.5, and 24 KD proteins using techniques well known in the art. These DNA sequences, and the corresponding amino acids, including upstream and downstream sequences, are shown below identified by the apparent molecular weight of the intact protein and represented 20 using standard abbreviations and rules of notation.

KD DNA SEQUENCE 1/1 31/11 ATG ACA GAC GTG AGC CGA AAG ATT CGA GCT TGG GGA CGC CGA met thr asp val ser arg lys ile arg ala trp gly arg arg 61/21 TTG ATG ATC GGC ACG GCA GCG GCT GTA GTC CTT CCG GGC CTG leu met ile gly thr ala ala ala val val leu pro gly leu 91/31 GTG GGG CTT GCC GGC GGA GCG GCA ACC GCG GGC GCG val gly leu ala gly gly ala ala thr ala gly ala 121/41 151/51 TTC TCC CGG CCG GGG CTG CCG GTC GAG TAC CTG CAG GTG CCG phe ser arg pro gly leu pro val glu tyr leu gin val pro 181/61 TCG CCG TCG ATG GGC CGC GAC ATC AAG GTT CAG TTC CAG AGC ser pro ser 211/71 met gly arg asp ile lys val gin phe gin ser 241/81 GGT GGG AAC AAC TCA CCT GCG GTT TAT CTG CTC GAC GGC CTG 40 gly gly asn asn ser pro ala val tyr leu leu asp gly leu 271/91 CGC GCC CAA GAC GAC TAC AAC GGC TGG GAT ATC AAC ACC CCG arg ala gin asp asp tyr asn gly trp asp ile asn thr pro 301/101 45 GCG TTC GAG TGG TAC TAC CAG TCG GGA CTG TCG ATA GTC ATG ala phe glu trp tyr tyr gin ser gly leu ser ile val met 331/111 361/121 CCG GTC GGC GGG CAG TCC AGC TTC TAC AGC GAC TGG TAC AGC pro val gly gly gin ser ser phe tyr ser asp trp tyr ser 36 391/131 CCG GCC TGC GGT AAG GCT GGC TGC CAG ACT TAC AAG TGG GAA pro ala cys gly lys ala gly cys gin thr tyr lys trp glu 421/141 451/151 ACC nC CTG ACC AGC GAG CTG CCG CAA TGG TTG TCC GCC AAC thr phe leu thr ser glu leu pro gin trp leu ser ala asn 481/161 AGG GCC GTG AAG CCC ACC GGC AGC GCT GCA ATC GGC TTG TCG arg ala val lys pro thr gly ser ala ala ile gly leu ser 10 511/171 ATG GCC GGC TCG TCG GCA ATG ATC TTG GCC GCC TAC CAC CCC met ala gly ser ser ala met ile leu ala ala tyr his pro 541/181 571/191 CAG CAG TTC ATC TAC GCC GGC TCG CTG TCG GCC CTG CTG GAC 15 gin gin phe ile tyr ala gly ser leu ser ala leu leu asp 601/201 CCC TCT CAG GGG ATG GGG CCT AGC CTG ATC GGC CTC GCG ATG pro ser gin gly met gly pro ser leu ile gly leu ala met 631/211 661/221 GGT GAC GCC GGC GGT TAC AAG GCC GCA GAC ATG TGG GGT CCC gly asp ala gly gly tyr lys ala ala asp met trp gly pro 691/231 TCG AGT GAC CCG GCA TGG GAG CGC AAC GAC CCT ACG CAG CAG ser ser asp pro ala trp glu arg asn asp pro thr gin gin 25 721/241 ATC CCC AAG CTG GTC GCA AAC AAC ACC CGG CTA TGG GTT TAT ile pro lys leu val ala asn asn thr arg leu trp val tyr 751/251 781/261 TGC GGG AAC GGC ACC CCG AAC GAG TTG GGC GGT GCC AAC ATA 30 cys gly asn gly thr pro asn glu leu gly gly ala asn ile 811/271 CCC GCC GAG TTC TTG GAG AAC TTC GTT CGT AGC AGC AAC CTG pro ala glu phe leu glu asn phe val arg ser ser asn leu 841/281 871/291 AAG TTC CAG GAT GCG TZC AAC GCC GCG GGC GGG CAC AAC GCC lys phe gin asp ala tyr asn ala ala gly gly his asn ala 901/301 GTG TTC AAC TTC CCG CCC AAC GGC ACG CAC AGC TGG GAG TAC val phe asn phe pro pro asn gly thr his ser trp glu tyr 40 931/311 TGG GGC GCT CAG CTC AAC GCC ATG AAG GGT GAC CTG CAG AGT trp gly ala gin leu asn ala met lys gly asp leu gin ser 961/321 TCG TTA GGC GCC GGC TGA 45 ser leu gly ala gly 0PA (Sequence ID No. 35) 32A KD DNA SEQUENCE 1/1 31/11 50 ATG CAG CTT GTT GAC AGG GTT CGT GGC GCC GTC ACG GGT ATG met gin leu val asp arg val arg gly ala val thr gly met 61/21 TCG CGT CGA CTC GTG GTC GGG CCC CTC CCC CCG GCC CTA CTG ser arg arg leu val val gly ala val gly ala ala leu val 37 91/31 121/41 TCC GGT CTG GTC GGC GCC GTC GGT GGC ACG GCG ACC GCG GGG ser gly leu val gly ala val gly gly thr ala thr ala gly 151/51 GCA TTT TCC CGG CCG GGC TTG CCG GTG GAG TAC CTG CAG GTG ala phe ser arg pro gly leu pro val glu tyr leu gin val 181/61 CCG TCG CCG TCG ATG GGC CGT GAC ATC AAG GTC CAA TTC CAA pro ser pro ser met gly arg asp ile lys val gin phe gin 10 211/71 241/81 AGT GGT GGT GCC AAC TCG CCC GCC CTG TAC CTG CTC GAC GGC ser gly gly ala asn ser pro ala leu tyr leu leu asp gly 271/91 CTG CGC GCG CAG GAC GAC TTC AGC GGC TGG GAC ATC AAC ACC 15 leu arg ala gin asp asp phe ser gly trp asp ile asn thr 301/101 331/111 CCG GCG TTC GAG TCC TAC GAC CAG TCG GGC CTG TCG GTG GTC pro ala phe glu trp tyr asp gin ser gly leu ser val val 361/121 ATG CCG GTG GGT GGC CAG TCA AGC TTC TAC TCC GAC TGG TAC met pro val gly gly gin ser ser phe tyr ser asp trp tyr 391/131 CAG CCC GCC TGC GGC AAG GCC GGT TGC CAG ACT TAC AAG TGG gin pro ala cys gly lys ala gly cys gin thr tyr lys trp 25 421/141 451/151 GAG ACC TTC CTG ACC ACC CAC CTC CCC GGG TGG CTC CAC CCC glu thr phe leu thr ser glu leu pro gly trp leu gin ala 481/161 AAC AGG CAC GTC AAG CCC ACC GGA AGC GCC GTC TGC GGT CTT 30 asn arg his val lys pro thr gly ser ala val val gly leu 511/171 " 541/181 TCG ATG GCT GCT TCT TCG GCG CTG ACG CTG GCG ATC TAT CAC ser met ala ala ser ser ala leu thr leu ala ile tyr his 571/191 CCC CAG CAG TTC GTC TAC GCG GGA GCG ATG TCG GGC CTG TTG pro gin..gin phe val tyr ala gly ala met ser gly leu leu 601/201 GAC CCC TCC CAG GCG ATG GGT CCC ACC CTG ATC GGC CTG GCG asp pro ser gin ala met gly pro thr leu ile gly leu ala 40 631/211 661/221 ATG GGT GAC GCT GGC GGC TAC AAG GCC TCC GAC ATG TGG GGC met gly asp ala gly gly tyr lys ala ser asp met trp gly 691/231 CCG AAG GAG GAC CCG GCG TGG CAG CGC AAC GAC CCG CTG TTG 45 pro lys glu asp pro ala trp gin arg asn asp pro leu leu 721/241 751/251 AAC GTC GGG AAG CTG ATC GCC AAC AAC ACC CGC GTC TGG GTG asn val gly lys leu ile ala asn asn thr arg val trp val 781/261 50 TAC TGC GGC AAC GGC AAG CCG TCG GAT CTG GGT GGC AAC AAC tyr cys gly asn gly lys pro ser asp leu gly gly asn asn 811/271 CTG CCG GCC AAG TTC CTC GAG GGC TTC GTG CGG ACC AGC AAC leu pro ala lys phe leu glu gly phe val arg thr ser asn 38 841/281 871/291 ATC AAG TTC CAA GAC GCC TAC AAC GCC GGT GGC GGC CAC AAC ile lys phe gin asp ala tyr asn ala gly gly gly his asn 901/301 GGC GTG TTC GAC TTC CCG GAC AGC GGT ACG CAC AGC TGG GAG gly val phe asp phe pro asp ser gly thr his ser trp glu 931/311 961/321 TAC TGG GGC GCG CAG CTC AAC GCT ATG AAG CCC GAC CTG CAA tyr trp gly ala gin leu asn ala met lys pro asp leu gin 991/331 CGG GCA CTG GGT GCC ACG CCC AAC ACC GGG CCC GCG CCC CAG arg ala leu gly ala thr pro asn thr gly pro ala pro gin GGC GCC TAG gly ala AMB (Sequence ID No. 36) 16 KD DNA SEQUENCE 40 1/1 31/11 atg AAG CTC ACC ACA ATG ATC AAG ACG GCA GTA GCG GTC GTG GCC atg GCG GCC ATC GCG Met lys leu thr thr met ile lys thr ala val ala val val ala met ala ala ile ala 61/21 91/31 ACC TTT GCG GCA CCG GTC GCG TTG GCT GCC TAT CCC ATC ACC GGA AAA CTT GGC AGT GAG thr phe ala ala pro val ala leu ala ala tyr pro ile thr giy lys leu giy ser glu 121/41 151/51 CTA ACG ATG ACC GAC ACC GTT GGC CAA GTC GTG CTC GGC TGG AAG GTC AGT GAT CTC AAA leu thr met thr asp thr val gly gin val val leu giy trp lys val ser asp leu lys 181/61 211/71 TCC AGC ACG GCA GTC ATC CCC GGC TAT CCG GTG GCC GGC CAG GTC TGG GAG GCC ACT GCC ser ser thr ala val ile pro giy tyr pro val ala giy gin val trp glu ala thr ala 241/81 271/91 ACG GTC AAT GCG ATT CGC GGC AGC GTC ACG CCC GCG GTC TCG CAG TTC AAT GCC CGC ACC thr val asn ala ile arg gly ser val thr pro ala val ser gin phe asn ala arg thr 301/101 331/111 GCC GAC GGC ATC AAC TAC CGG GTG CTG TGG CAA GCC GCG GGC CCC GAC ACC AH AGC GGA ala asp gly ile asn tyr arg val leu trp gin ala ala giy pro asp thr ile ser giy 361/121 391/131 GCC ACT ATC CCC CAA GGC GAA CAA TCG ACC GGC AAA ATC TAC TTC GAT GTC ACC GGC CCA ala thr ile pro gin gly glu gin ser thr giy lys ile tyr phe asp val thr giy pro 421/141 451/151 TCG CCA ACC ATC GTC GCG ATG AAC AAC GGC ATG GAG GAT CTG CTG An TGG GAG CCG TAG ser pro thr ile val ala met asn asn giy met glu asp leu leu ile trp glu pro AMB (Sequence ID No. 92) 39 58 KD DNA SEQUENCE 1/1 31/11 gtg ACG GAA AAG ACG CCC GAC GAC GTC TTC AAA CTT GCC AAG GAC GAG AAG GTC GAA TAT val thr glu lys thr pro asp asp val phe lys leu ala lys asp glu lys val glu tyr 5 61/21 91/31 GTC GAC GTC CGG TTC TGT GAC CTG CCT GGC ATC ATG CAG CAC TTC ACG ATT CCG GCT TCG val asp val arg phe cys asp leu pro gly ile met gin his phe thr ile pro ala ser 121/41 151/51 GCC TTT GAC AAG AGC GTG TTT GAC GAC GGC TTG GCC TTT GAC GGC TCG TCG ATT CGC GGG 10 ala phe asp lys ser val phe asp asp gly leu ala phe asp gly ser ser ile arg gly 181/61 211/71 TTC CAG TCG ATC CAC GAA TCC GAC ATG TTG CTT CTT CCC GAT CCC GAG ACG GCG CGC ATC phe gin ser ile his glu ser asp met leu leu leu pro asp pro glu thr ala arg ile 241/81 271/91 GAC CCG TTC CGC GCG GCC AAG ACG CTG AAT ATC AAC TTC TTT GTG CAC GAC CCG TTC ACC asp pro phe arg ala ala lys thr leu asn ile asn phe phe val his asp pro phe thr 301/101 331/111 CTG GAG CCG TAC TCC CGC GAC CCG CGC AAC ATC GCC CGC AAG GCC GAG AAC TAC CTG ATC leu glu pro tyr ser arg asp pro arg asn ile ala arg lys ala glu asn tyr leu ile 20 361/121 391/131 AGC ACT GGC ATC GCC GAC ACC GCA TAC TTC GGC GCC GAG GCC GAG TTC TAC ATT TTC GAT ser thr gly ile ala asp thr ala tyr phe gly ala glu ala glu phe tyr ile phe asp 421/141 451/151 TCG GTG AGC TTC GAC TCG CGC GCC AAC GGC TCC TTC TAC GAG GTG GAC GCC ATC TCG GGG 25 ser val ser phe asp ser arg ala asn gly ser phe tyr glu val asp ala ile ser gly 481/161 511/171 TGG TGG AAC ACC GGC GCG GCG ACC GAG GCC GAC GGC AGT CCC AAC CGG GGC TAC AAG GTC trp trp asn thr gly ala ala thr glu ala asp gly ser pro asn arg gly tyr lys val 541/181 571/191 CGC CAC AAG GGC GGG TAT TTC CCA GTG GCC CCC AAC GAC CAA TAC GTC GAC CTG CGC GAC arg his lys gly gly tyr phe pro val ala pro asn asp gin tyr val asp leu arg asp 601/201 631/211 AAG ATG CTG ACC AAC CTG ATC AAC TCC GGC TTC ATC CTG GAG AAG GGC CAC CAC GAG GTG lys met leu thr asn leu ile asn ser gly phe ile leu glu lys gly his his glu val 35 661/221 691/231 GGC AGC GGC GGA CAG GCC GAG ATC AAC TAC CAG TTC AAT TCG CTG CTG CAC GCC GCC GAC gly ser gly gly gin ala glu ile asn tyr gin phe asn ser leu leu his ala ala asp 721/241 751/251 GAC ATG CAG TTG TAC AAG TAC ATC ATC AAG AAC ACC GCC TGG CAG AAC GGC AAA ACG GTC 40 asp met gin leu tyr lys tyr ile ile lys asn thr ala trp gin asn gly lys thr val 781/261 811/271 ACG TTC ATG CCC AAG CCG CTG TTC GGC GAC AAC GGG TCC GGC ATG CAC TGT CAT CAG TCG thr phe met pro lys pro leu phe gly asp asn gly ser gly met his cys his gin ser 841/281 871/291 45 CTG TGG AAG GAC GGG GCC CCG CTG ATG TAC GAC GAG ACG GGT TAT GCC GGT CTG TCG GAC leu trp lys asp gly ala pro leu met tyr asp glu thr gly tyr ala gly leu ser asp 901/301 931/311 ACG GCC CGT CAT TAC ATC GGC GGC CTG TTA CAC CAC GCG CCG TCG CTG CTG GCC TTC ACC thr ala arg his tyr ile gly gly leu leu his his ala pro ser leu leu ala phe thr 50 961/321 991/331 AAC CCG ACG GTG AAC TCC TAC AAG CGG CTG GTT CCC GGT TAC GAG GCC CCG ATC AAC CTG asn pro thr val asn ser tyr lys arg leu val pro gly tyr glu ala pro ile asn leu 1021/341 1051/351 GTC TAT AGC CAG CGC AAC CGG TCG GCA TGC GTG CGC ATC CCG ATC ACC GGC AGC AAC CCG 55 val tyr ser gin arg asn arg ser ala cys val arg ile pro ile thr gly ser asn pro 1081/361 1111/371 AAG GCC AAG CGG CTG GAG TTC CGA AGC CCC GAC TCG TCG GGC AAC CCG TAT CTG GCG TTC lys ala lys arg leu glu phe arg ser pro asp ser ser gly asn pro tyr leu ala phe 1141/381 1171/391 60 TCG GCC ATG CTG ATG GCA GGC CTG GAC GGT ATC AAG AAC AAG ATC GAG CCG CAG GCG CCC ser ala met leu met ala gly leu asp gly ile lys asn lys ile glu pro gin ala pro 1201/401 1231/411 GTC GAC AAG GAT CTC TAC GAG CTG CCG CCG GAA GAG GCC GCG AGT ATC CCG CAG ACT CCG val asp lys asp leu tyr glu leu pro pro glu glu ala ala ser ile pro gin thr pro 65 1261/921 1291/431 40 ACC CAG CTG TCA GAT GTG ATC GAC CGT CTC GAG GCC GAC CAC GAA TAC CTC ACC GAA GGA thr gin leu ser asp val ile asp arg leu glu ala asp his glu tyr leu thr glu giy 1321/441 1351/451 GGG GTG nC ACA AAC GAC CTG ATC GAG ACG TGG ATC AGT TTC AAG CGC GAA AAC GAG ATC gly val phe thr asn asp leu ile glu thr trp ile ser phe lys arg glu asn glu ile 1381/461 1411/471 GAG CCG GTC AAC ATC CGG CCG CAT CCC TAC GAA TTC GCG CTG TAC TAC GAC GTT taa glu pro val asn ile arg pro his pro tyr glu phe ala leu tyr tyr asp val OCH (Sequence ID No. 93) 23.5 KD DNA SEQUENCE 1/1 31/11 gtg CGC ATC AAG ATC TTC ATG CTG GTC ACG GCT GTC Gn nG CTC TGT TGT TCG GST GTG val arg ile lys ile phe met leu val thr ala val val leu leu cys cys ser giy val 61/21 91/31 GCC ACG GCC GCG CCC AAG ACC TAC TGC GAG GAG nG aaa GGC ACC GAT ACC GGC CAG GCG ala thr ala ala pro lys thr tyr cys glu glu leu lys giy thr asp thr giy gin ala 121/41 151/51 TGC CAG AH CAA ATG TCC GAC CCG GCC TAC AAC ATC AAC ATC AGC CTG CCC AGT TAC TAC cys gin ile gin met ser asp pro ala tyr asn ile asn ile ser leu pro ser tyr tyr 181/61 211/71 CCC GAC CAG AAG TCG CTG GAA AAT TAC ATC GCC CAG ACG CGC GAC AAG nc CTC AGC GCG pro asp gin lys ser leu glu asn tyr ile ala gin thr arg asp lys phe leu ser ala 241/81 271/91 GCC ACA TCG TCC ACT CCA CGC GAA GCC CCC TAC GAA nG AAT ATC ACC TCG GCC ACA TAC ala thr ser ser thr pro arg glu ala pro tyr glu leu asn ile thr ser ala thr tyr 301/101 331/111 CAG TCC GCG ATA CCG CCG CGT GGT ACG CAG GCC GTG GTG CTC aag GTC TAC CAG AAC GCC gin ser ala ile pro pro arg gly thr 361/121 gin ala val 391/131 val leu lys val tyr gin asn ala GGC GGC ACG CAC CCA ACG ACC ACG TAC aag gcc nc GAT tgg GAC CAG gcc TAT cgc aag gly gly thr his pro thr thr thr tyr lys ala phe asp trp asp gin ala tyr arg lys 421/141 451/151 CCA ATC ACC TAT GAC ACG CTG TCG CAG GCT GAC ACC GAT CCG CTG CCA GTC GTC nc CCC pro ile thr tyr asp thr leu trp gin ala asp thr asp pro leu pro val val phe pro 481/161 511/171 An GTG CAA GGT GAA CTG AGC AAG CAG ACC GGA CAA CAG GTA TCG ATA gcg ccg AAT gcc ile val gin gly glu leu ser lys gin thr gly gin gin val ser ile ala pro asn ala 40 541/181 571/191 GGC nG GAC CCG GTG AAT TAT CAG AAC nc GCA GTC ACG AAC GAC GGG GTG ATT nc nc gly leu asp pro val asn tyr gin asn phe ala val thr asn asp giy val ile phe phe 601/201 631/211 nC AAC CCG GGG GAG nG CTG CCC GAA GCA GCC GGC CCA ACC CAG GTA nG GTC CCA CGT 45 phe asn pro gly glu leu leu pro glu ala ala gly pro thr gin val leu val pro arg 661/221 TCC GCG ATC GAC TCG ATG CTG GCC tag ser ala ile asp ser met leu ala AMB 50 (Sequence ID No. 94) 41 24 KD DNA SEQUENCE 1/1 31/11 ATG AAG GGT CGG TCG GCG CTG CTG CGG GCG CTC TGG An GCC GCA CTG TCA nc GGG nG Met lys gly arg ser ala leu leu arg ala leu trp ile ala ala leu ser phe giy leu 61/21 91/31 GGC GGT GTC GCG GTA GCC GCG GAA CCC ACC GCC AAG GCC GCC CCA TAC GAG AAC CTG ATG gly gly val ala val ala ala glu pro thr ala lys ala ala pro tyr glu asn leu met 121/41 151/51 GTG CCG TCG CCC TCG ATG GGC CGG GAC ATC CCG GTG GCC nc CTA GCC GGT GGG CCG CAC val pro ser pro ser met giy arg asp ile pro val ala phe leu ala giy giy pro his 181/61 211/71 GCG GTG TAT CTG CTG GAC GCC TTC AAC GCC GGC CCG GAT GTC AGT AAC TGG GTC ACC GCG ala val tyr leu leu asp ala phe asn ala gly pro asp val ser asn trp val thr ala 241/81 271/91 GGT AAC GCG ATG AAC ACG TTG GCG GGC AAG GGG ATT TCG GTG GTG GCA CCG GCC GGT GGT gly asn ala met asn thr leu ala giy lys gly ile ser val val ala pro ala giy giy 301/101 331/111 GCG TAC AGC ATG TAC ACC AAC TGG GAG CAG GAT GGC AGC AAG CAG TGG GAC ACC nc nG ala tyr ser met tyr thr asn trp glu gin asp gly ser lys gin trp asp thr phe leu 361/121 391/131 TCC GCT GAG CTG CCC GAC TGG CTG GCC GCT AAC CGG GGC nG GCC CCC GGT GGC CAT GCG ser ala glu leu pro asp trp leu ala ala asn arg giy leu ala pro giy giy his ala 421/141 451/151 GCC GTT GGC GCC GCT CAG GGC GGT TAC GGG GCG ATG GCG CTG GCG GCC nc CAC CCC GAC ala val gly ala ala gin giy giy tyr giy ala met ala leu ala ala phe his pro asp 481/161 511/171 CGC TTC GGC JJC GCT GGC TCG ATG TCG GGC TTT nG TAC CCG TCG AAC ACC ACC ACC AAC arg phe gly phe ala giy ser met ser giy phe leu tyr pro ser asn thr thr thr asn 541/181 571/191 GGT GCG ATC GCG GCG GGC ATG CAG CAA nc GGC GGT GTG GAC ACC AAC GGA ATG TGG GGA gly ala ile ala ala giy met gin gin phe giy giy val asp thr asn giy met trp gly 601/201 631/211 GCA CCA CAG CTG GGT CGG TGG AAG TGG CAC GAC CCG TGG GTG CAT GCC AGC CTG CTG GCG ala pro gin leu gly arg trp lys trp his asp pro trp val his ala ser leu leu ala 661/221 691/231 CAA AAC AAC ACC CGG GTG TGG GTG TGG AGC CCG ACC AAC CCG GGA GCC AGC GAT CCC GCC gin asn asn thr arg val trp val trp ser pro thr asn pro giy ala ser asp pro ala 721/241 751/251 GCC ATG ATC GGC CAA GCC GCC GAG GCG ATG GGT AAC AGC CGC ATG nc TAC AAC CAG TAT ala mer ile gly gin ala ala glu ala met gly asn ser arg met phe tyr asn gin tyr 781/261 811/271 CGC AGC GTC GGC GGG CAC AAC GGA CAC nc gac nc CCA GCC AGC GGT GAC AAC GGC TGG arg ser val gly gly his asn giy his phe asp phe pro ala ser giy asp asn giy trp 841/281 871/291 GGC TCG TGG GCG CCC CAG CTG GGC GCT ATG TCG GGC GAT ATC GTC GGT GCG ATC CGC TAA gly ser trp ala pro gin leu giy ala met ser gly asp ile val giy ala ile arg OCH (Sequence id No. 95) 40 45 50 This sequence data, combined with the physical properties ascertained using SDS-PAGE, allow these representative majorly abundant extracellular products of the present invention to be characterized and distinguished. The analysis described indicates that these proteins constitute the majority of the extracellular products of M. tuberculosis, with the 71 KD, 30 KD, 32A KD, 23 KD and 16 KD products 55 comprising approximately 60% by weight of the total available extracellular product. It is further estimated that the 30 KD protein may constitute up to 25% by weight of the total products released by M. tuberculosis. Thus, individual exemplary majorly WO 96/37219 PCT/US96/07781 42 abundant extracellular products of M. tuberculosis useful in the practice of the present invention may range anywhere from approximately 0.5% up to approximately 25% of the total weight of the extracellular products.

As previously discussed, following the inability of traditional Western 5 blot analysis to consistently identify the most immunogenically specific extracellular products, the present inventor decided to analyze the immunogenicity of the majorly abundant extracellular products based upon their abundance and consequent ease of identification and isolation. Surprisingly, it was found that these majorly abundant extracellular products induce unexpectedly effective immune responses leading this 10 inventor to conclude that they may function as vaccines. This surprising discovery led to the development of the non-limiting functional theory of this invention discussed above.

To demonstrate the efficacy of the present invention, additional experiments were conducted using individual majorly abundant extracellular products 15 and combinations thereof at various exemplary dosages to induce protective immunity in art accepted laboratory models. More specifically, purified individual majorly abundant extracellular products were used to induce protective immunity in guinea pigs which were then challenged with M. tuberculosis. Upon showing that these proteins were capable of inducing protective immunity, combinations of five purified majorly 20 abundant extracellular products was similarly tested using differing routes of administration. In particular the 30 KD abundant extracellular product was used to induce protective immunity in the accepted animal model as was the purified form of the 71 KD extracellular product. As with the individual exemplary majorly abundant extracellular products the combination vaccines of five majorly abundant extracellular 25 products conferred protection against challenge with lethal doses of M. tuberculosis as well. Results of the various studies of these exemplary vaccines of the present invention follow.

Specific pathogen-free male Hartley strain guinea pigs (Charles River Breeding Laboratories, North Wilmington, Massachusetts) were used in all experiments 30 involving immunogenic or aerosol challenges with M. tuberculosis. The animals were housed two or three to a stainless steel cage and allowed free access to standard guinea pig chow and water. After arrival at the animal facility, the guinea pigs were observed for at least one week prior to the start of each experiment to ensure that they were healthy.

Initial experiments were conducted using individual majorly abundant extracellular products believed to comprise between 3% to 25% of the total extracellular 43 proteins normally present. These experiments demonstrate that majorly abundant extracellular products elicit an effective immune response. More particularly, isolated 30 KD and 71 KD extracellular products were shown to be individually capable of generating a cell-mediated immune response that protected guinea pigs upon exposure 5 to lethal doses of M. tuberculosis as follows.

EXAMPLE 3 Purified 30 KD Protein Skin Testing for Cell-Mediated Immunity of 30 KD Immunized Guinea Pigs To illustrate that a measurable immune response can be induced by purified forms of abundant extracellular products, a cutaneous hypersensitivity assay was performed. Guinea pigs were immunized with the exemplary majorly abundant M. tuberculosis 30 KD secretory product purified according to Example 2 and believed 15 to comprise approximately 25% of the total extracellular product of M. tuberculosis. In three independent experiments, guinea pigs were immunized three times three weeks apart with 100 |ig of substantially purified 30 KD protein in SAF adjuvant. Control animals were similarly injected with buffer in SAF. Three weeks after the last immunization the guinea pigs were challenged with the exemplary 30 KD protein in a 20 cutaneous hypersensitivity assay.

Guinea pigs were shaved over the back and injections of 0.1, 1 and 10 fig of 30 KD protein were administered intradermally with resulting erythema (redness of the skin) and induration measured after 24 hours as shown in Table A below. Data are reported in terms of mean measurement values for the group ± standard error (SE) as 25 determined using traditional methods. ND indicates that this particular aspect of the invention was not done.

TABLE A Erythema (mm) to 71 KD (Mean ± SE') Guinea Pig Status n 0.1 ue 1.0 ue 10 0 ue Expt. 1 Immunised 6 1.2 ±0.5 3.9 + 0.8 6.9 ±1.0 Controls 5 ND ND 3.0 ±0.9 Expt. 2 Immunized 6 0.5 ±0.5 5.4 + 0.7 8.1 ±0.6 Controls 3 0±0 2.5 ± 0 1.7 ±0.8 PCT/U S96/07781 44 Erythema (mm) to 71 KD (Mean ± SE) Guinea Pig Status n 0.1 ^ 1-0 HR .0 ue Exot. 3 Immunized 6 ND 1.7 ± 1.1 6.2 ± 0.3 Controls 3 ND ND 2.0 ±0.0 Induration (mm) to 30 KD (Mean ± SE) Guinea Pig Status n 0.1 |ag 1.0 fig .0 ue ExDt. 1 Immunized 6 0 + 0 3.3 ±0.3 .6 ±0.9 Controls ND ND 1.6 ±1.0 Exot. 2 Immunized 6 0 ± 0 3.8 ±0.7 4.9 ± 1.2 Controls 3 0 ± 0 0.8 ± 0.8 1.7 ±0.8 Expt. 3 Immunized 6 ND 1.1 ± 1.1 4.7 ±0.4 Controls 3 ND 0 ± 0 0±0 As shown in Table A, guinea pigs immunized with the exemplary 30 KD secretory product exhibited a strong cell-mediated immune response as evidenced by marked erythema and induration. In contrast, the control animals exhibited minimal response.

To confirm the immunoreactivity of the 30 KD secretory product and 10 show its applicability to infectious tuberculosis, non-immunized guinea pigs were infected with M. tuberculosis and challenged with this protein as follows.

EXAMPLE 4 Purified 30 KD Protein Testing for Cell-Mediated 15 Immune Responses of Guinea Pigs Infected With M. tuberculosis To obtain bacteria for use in experiments requiring the infection of guinea pigs, M. tuberculosis was first cultured on 7H11 agar and passaged once through 20 a guinea pig lung to insure that they were virulent. For this purpose, guinea pigs were challenged by aerosol with a 10 ml suspension of bacteria in 7H9 broth containing approximately 5 x 104 bacteria/ml. After the guinea pigs became ill, the animals were 45 sacrificed and the lungs, containing prominent M. tuberculosis lesions, were removed. Each lung was ground up and cultured on 7H11 agar for 7 days to 10 days. The bacteria were scraped from the plates, diluted in 7H9 broth containing 10% glycerol, sonicated in a water bath to obtain a single cell suspension, and frozen slowly at -70°C at a 5 concentration of approximately 2 x 107 viable bacteria/ml. Viability of the frozen cells was measured by thawing the bacterial suspension and culturing serial dilutions of the suspension on 7H11 agar. Just before a challenge, a vial of bacterial cells was thawed and diluted to the desired concentration in 7H9 broth.

The guinea pigs were exposed to aerosols of the viable M. tuberculosis 10 in a specially designed lucite aerosol chamber. The aerosol chamber measured 14 by 13 by 24 in. and contained two 6 inch diameter portals on opposite sides for introducing or removing guinea pigs. The aerosol inlet was located at the center of the chamber ceiling. A vacuum pump (Gast Mfg. Co., Benton Harbor, Michigan) delivered air at 30 lb/in2 to a nebulizer-venturi unit (Mes Inc., Burbank, California), and an aerosol was 15 generated from a 10-ml suspension of bacilli. A 0.2 jam breathing circuit filter unit (Pall Biomedical Inc., Fajardo, Puerto Rico) was located at one end of the chamber to equilibrate the pressure inside and outside of the assembly. Due to safety considerations, the aerosol challenges were conducted with the chamber placed completely within a laminar flow hood.

The animals were exposed to pathogenic aerosol for 30 minutes during which time the suspension of bacilli in the nebulizer was completely exhausted. Each aerosol was generated from the 10 ml suspension containing approximately 5.0 x 104 bacterial particles per ml. Previous studies have shown that guinea pig exposure to this concentration of bacteria consistently produces infections in non-protected animals. 25 Following aerosol infection, the guinea pigs were housed in stainless steel cages contained within a laminar flow biohazard safety enclosure (Airo Clean Engineering Inc., Edgemont, Pennsylvania) and observed for signs of illness. The animals were allowed free access to standard guinea pig chow and water throughout the experiment.

In this experiment, the infected guinea pigs were sacrificed and splenic 30 lymphocyte proliferation was measured in response to various concentrations of the 30 KD protein. More specifically, splenic lymphocytes were obtained and purified as described by Brieman and Horwitz {J. Exp. Med 7(54:799-811) which is incorporated herein by reference. The lymphocytes were adjusted to a final concentration of 107/ml in RPMI 1640 (GIBCO Laboratories, Grand Island, New York) containing penicillin 35 (lOOU/ml), streptomycin (100 fag/ml), and 10% fetal calf serum (GIBCO) and incubated with various concentrations of purified 30 KD secretory product in a total 46 volume of 100 jal in microtest wells (96-well round-bottom tissue culture plate; Falcon Labware, Oxnard, California) for 2 days at 37°C in 5% C02-95% air and 100% humidity. Noninfected animals were used as negative controls. At the end of the incubation period, 0.25 fiCi of [3H]thymidine (New England Nuclear, Boston, 5 Massachusetts) was added to each well and the cells were further incubated for 2 hours at 37°C in 5% C02-95% air at 100% humidity. A multisample automated cell harvester (Skatron Inc., Sterling, Virginia) was used to wash each well, and the effluent was passed through a filtermat (Skatron). Filtermat sections representing separate microtest wells were placed in scintillation vials, and 2 ml of Ecoscint H liquid scintillation 10 cocktail (National Diagnostics, Manville, New Jersey) was added. Beta particle emission was measured in a beta scintillation counter (Beckman Instruments Inc., Fullerton, California).

Tissue samples from the infected and noninfected guinea pigs were assayed against 1 and 10 pg/ml of isolated 30 KD secretory protein. Samples were then 15 monitored for their ability to incorporate [3H]thymidine. The results of these assays were tabulated and presented in Table B below.

Data are reported as a stimulation index which, for the purposes of this disclosure, is defined as: mean [3H]thymidine incorporation of lymphocytes incubated with 20 antigen / mean [3H]thymidine incorporation of lymphocytes incubated without antigen.

-TABLE B Stimulation Indices to 30KD (Mean ± SE) Guinea Pig Status n 1.0 qg/ml 10.0 ug/ml Infected 6 2.2 ± 0.2 9.7 ± 4.6 Controls 6 1.5 + 0.3 2.0 + 0.8 As shown in Table B, the cells of the infected animals exhibited a strong 25 response to the exemplary 30 KD protein as manifested by dose dependent splenic lymphocyte proliferation in response to exposure to this majorly abundant secretory product. Conversely, the uninfected control animals showed little lymphocyte proliferation. Accordingly, the 30 KD secretory product clearly induces a cell-mediated immune response in mammals infected with M. tuberculosis. 47 To illustrate the protective aspects of the vaccines of the present invention, guinea pigs were immunized with purified 30 KD protein and exposed to M. tuberculosis as follows.

EXAMPLE 5 Challenge of 30 KD Immunized Guinea Pig With Aerosolized M. tuberculosis As before, the animals were immunized three times at three week 10 intervals with 100 |ig of the exemplary 30 KD secretory protein in SAF. Control guinea pigs were immunized with 120 (ig of bulk EP in SAF or sham-immunized with buffer in the same adjuvant. Three weeks after the last immunization, the animals were challenged with aerosolized M. tuberculosis as described in Example 4. The survival rates for the three groups of animals were monitored and are graphically presented in 15 Figure 4. Absolute mortality was determined 14 weeks after challenge as presented in Table C below.

TABLE C Status of Survivors/ Percent Guinea Pies Challenged Survival KD Immunized 4/6 67% EP Immunized 3/6 50% Sham Immunized 1/6 17% As shown in Figure 4 guinea pigs immunized three times with the exemplary 30 KD protein were protected against death. Approximately 67% of the guinea pigs immunized with the 30 KD protein survived whereas only 17% of the control sham-immunized guinea pigs survived.

Weight retention of the immunized animals was also monitored (data not shown) and further illustrates the prophylactic capacity of vaccines incorporating majorly abundant extracellular products produced by pathogenic bacteria as taught by the present invention. While the immunized animals appeared to maintain their weight, the high mortality rate of the sham-immunized animals precluded the graphical 30 comparison between the immunized animals and the control animals. 48 Following conclusion of the weight monitoring study, the surviving animals were sacrificed and the right lung and spleen of each animal was assayed for viable M. tuberculosis. The animals were soaked in 2% amphyl solution (National Laboratories, Montvale, New Jersey), and the lungs and spleen were removed 5 aseptically. The number of macroscopic primary surface lesions in the lungs were enumerated by visual inspection. Colony forming units (CFU) of M. tuberculosis in the right lung and spleen were determined by homogenizing each organ in 10 ml of 7H9 with a mortar and pestle and 90-mesh Norton Alundum (Fisher), serially diluting the tissue homogenate in 7H9, and culturing the dilutions on duplicate plates of 7H11 agar 10 by using drops of 0.1 ml/drop. All plates were kept in modular incubator chambers and incubated 12 to 14 days at 37°C in 5% C02, 95% air at 100% humidity. The assay was conducted using this protocol and the results of the counts are presented in Table D below in terms of mean colony forming units (CFU) ± standard error (SE).

TABLE D Mean CFU + SE Guinea Pig Status n Right Lung Spleen KD Immunized 4 3.4±1.7xl07 7.7 ±3.9xl06 Sham-immunized 1 1.8 xlO8 8.5 xlO7 Log-Difference 0.73 1.04 As shown in Table D, immunization with the exemplary 30 KD 20 secretory protein limited the growth of M. tuberculosis in the lung and the spleen. Although only data from the one surviving sham-immunized animal was available for comparative purposes, the four surviving 30 KD immunized animals had 0.7 log fewer CFU in their lungs and 1 log fewer CFU in their spleen than the surviving sham-immunized animal. Based on previous demonstrations of a high correlation between 25 CFU counts and mortality, the surviving animal likely had fewer CFU in the lungs and spleen than the animals who died before a CFU analysis could be performed. Again this reduction of CFU in the lungs and spleens of the immunized animals conclusively demonstrates the scope and operability of the present invention. 49 The immunoprotective potential of another majorly abundant extracellular product from M. tuberculosis, the 71 KD extracellular product, was tested in its isolated form to demonstrate its immunoprotective capacity.

EXAMPLE 6 Purified 71 KD Protein Skin Test of Guinea Pigs Immunized with a Bulk Preparation of EP To demonstrate the potential of 71 KD protein to provoke an effective 10 immune response in animals, this isolated majorly abundant extracellular product was used to skin test guinea pigs immunized with a bulk preparation of M. tuberculosis extracellular proteins (EP) in a cutaneous hypersensitivity assay. As discussed above, bulk EP will impart acquired immunity against infection by M. tuberculosis but to a lesser extent than the vaccines of the present invention.

Guinea pigs were immunized on two occasions spaced three weeks apart, with 120 fig of a bulk preparation of EP prepared as detailed in Example 1. The vaccination was prepared in incomplete Freund's adjuvant with sham-immunized animals receiving buffer in place of EP. Three weeks after the last vaccination the guinea pigs from each group were shaved over the back and skin tested with an 20 intradermal injection of 0.1, 1.0 and 10 |ig of 71 KD protein. 10.0 (ig of buffer was used as a control and all injections were performed using a total volume of 0.1 ml. The diameters of erythema and induration were measured after 24 hours with the results as shown in Table E below. Data are reported in terms of mean measurement values for the group ± standard error (SE) as determined using traditional methods. 50 TABLEE Guinea Pig Status n Immunized 4 Controls 3 Erythema ("mm) to 71 KD (Mean ± SE) 0-1 ue 1.0 ue 10.0 ug 6.510.7 11.9 ±1.4 18.9 ±2.2 2.5 ±1.4 5.0 ±2.9 11.8 ±2.1 Guinea Pig Status Immunized Controls n 4 3 Induration (mm) to 71 KD (Mean + SE) 0.1 ug 1.0 ug 10.0 ug 3.6 ±1.1 6.8 ± 1.1 11.6 ± 0.8 0.7 ±0.7 3.7 ±0.9 7.8 ±1.0 The responses of the immunized animals were almost twice the response of the guinea pigs challenged with buffer alone and were comparable to those 5 challenged with bulk EP identical to that used to immunize the animals (data not shown).

To further confirm that the purified exemplary 71 KD majorly abundant extracellular product elicits cell-mediated immune responses, the bulk EP immunized guinea pigs were sacrificed and splenic lymphocyte proliferation was measured in 10 response to various concentrations of the 71 KD protein. Nonimmunized animals were used as controls. Following the protocol of Example 4, the lymphocytes were incubated with and without 71 KD protein for 2 days and then assayed for their capacity to incorporate [3H]thymidine.

Data is reported in terms of stimulation indices calculated as in Example 15 4. The results of this 71 KD challenge are shown in Table F below.

PCT/U S96/07781 51 TABLE F Stimulation Indices to 71 KD ("Mean ± SE) Guinea Pig Status n 0.01 ug/ml 0.1 ug/ml 1.0 ug/ml Immunized 4 1.5 ±0.1 2.3 ±0.5 8.1 ±2.2 Controls 2 1.7 ±0.6 1.610.4 2.5 ±0.6 Stimulation Indices to EP (Mean + SE) Guinea Pig Status n 0.01 ue/ml 0.1 ug/ml 1.0 ug/ml Immunized 4 1.5 ±0.1 2.2 ±0.3 5.3 ±1.4 Controls 2 1.4 ±0.2 1.510.2 1.2 ±0.1 As shown in Table F, stimulation indices for the lymphocyte proliferation assay were comparable to the results obtained in the cutaneous 5 hypersensitivity assay. Both the 71 KD and bulk EP tested samples showed responses between two and three times higher than those obtained with the controls indicating that isolated exemplary 71 KD majorly abundant extracellular product is capable of provoking a cell-mediated immune response in animals immunized with M. tuberculosis extracts. However, it should again be emphasized that the purified 10 majorly abundant or principal extracellular product is free of the problems associated with prior art or bulk compositions and is more readily adaptable to synthetic and commercial production making the vaccines of the present invention superior to the prior art.

More particularly the bulk preparation cannot be manufactured easily on 15 a large scale through modern biomolecular techniques. Any commercial production of these unrefined bulk preparations containing all extracellular products would involve culturing vast amounts of the target pathogen or a closely related species and harvesting the resultant supernatant fluid. Such production methodology is highly susceptible to contamination by the target pathogen, toxic byproducts or other parasitic agents. 20 Further, the large number of immunogenic determinants in such a preparation is far more likely to provoke a toxic immune reaction in a susceptible segment of the immunized population. Using these unrefined bulk preparations also negates the use of the most popular skin tests currently used for tuberculosis screening and control. 52 In direct contrast, the vaccines of the present invention can be mass-produced in relative safety using high yield transformed hosts. Similarly, the vaccines of the present invention can be produced in identical, easy to standardize batches as opposed to the wider variable production of bulk extracellular products. Moreover, as 5 the number of immunogenic determinants presented to the host immune system is relatively small, toxic reactions and the chance of invalidating popular screening tests are greatly reduced.

EXAMPLE 7 Purified 71 KD Protein Skin Test of 71 KD Immunized Guinea Pigs Following demonstration that the isolated exemplary 71 KD majorly abundant extracellular product generates a cell-mediated immune response in bulk EP 15 immunized animals, it was shown that the purified form of this majorly abundant product was able to induce a cell-mediated immune response in animals immunized with 71 KD.

Guinea pigs were twice vaccinated with 100 fig of purified 71 KD protein in SAF three weeks apart. Control animals were sham-immunized with buffer 20 in SAF on the same schedule. Three weeks after the last immunization both sets of animals were intradermally challenged with 1 and 10 (ig of isolated 71 KD protein. The resulting erythema and indurations were measured after 24 hours with the results shown in Table G below. 53 Guinea Pig Status Immunized Controls n 3 3 TABLE G Erythema (mm) to 71 KD (Mean ± SE) 0 ue 1.0 ug 10.0 ug 0 ± 0 6.5 + 1.5 15.0 ±1.5 0 ± 0 2.7 ±1.3 6.7 ±1.3 Guinea Pig Status Immunized Controls n 3 3 Induration (mm) to 71 KD (Mean + SE) 0_U£ 10 ue lMj±g 0 ± 0 3.0 ±1.0 9.3 ±0.3 0±0 0±0 1.3 ±1.3 The extent of induration and erythema was much greater in the immunized animals than in the non-immunized control animals demonstrating that a 5 strong cell-mediated immune response to 71 KD protein had been initiated by the vaccination protocol of the present invention.

To further confirm the capacity of this abundant extracellular product to induce an effective immune response on its own in accordance with the teachings of the present invention, lymphocyte proliferation assays were performed. Animals 10 immunized as in Table G were sacrificed and splenic lymphocyte proliferative assays were run using the protocol established in Example 4. The tissue samples from the 71 KD immunized guinea pigs and those from the control guinea pigs were challenged with 0.1, 1 and 10 jag/ml of isolated 71 KD protein and monitored for their ability to incorporate [3H]thymidine. Stimulation indices were calculated as previously 15 described. The results of these assays are presented in Table H below.

Guinea Pig Status Immunized Controls TABLE H Stimulation Indices to 71 KD (Mean + SE) n 0.1 ug/ml 1.0 ug/ml 10.0 ug/ml 3 4.0 ±1.3 5.6 ±2.5 12.2 ±5.1 3 1.3 ±0.3 1.3 ±0.3 3.2 ±1.5 54 As with the cutaneous hypersensitivity assay, the 71 KD immunized animals showed a much higher response to purified 71 KD than did the sham-immunized controls. Though expected of a foreign protein, such results clearly show that a majorly abundant extracellular product has the capacity to induce an cell-5 mediated immune response.

After establishing that an isolated majorly abundant extracellular protein will induce an effective cell-mediated immune response, further experiments were conducted to confirm that any such response is cross-reactive against tubercle bacilli as follows.

EXAMPLE 8 Purified 71 KD Protein Challenge of Guinea Pigs Infected With M. tuberculosis Non-immunized guinea pigs were infected with aerosolized M. tuberculosis as reported in Example 4. Purified protein derivative (PPD-CT68; Connaught Laboratories Ltd.) was employed as the positive control to ensure that the infected animals were demonstrating a cell-mediated immune response indicative of M. tuberculosis. Widely used in the Mantoux test for tuberculosis exposure, PPD is generally prepared by ammonium sulfate fractionation and comprises a mixture of small proteins having an average molecular weight of approximately 10 KD. Immune responses to PPD are substantially analogous to those provoked by the bulk EP fractions isolated in Example 1.

Three weeks after infection the guinea pigs were challenged intradermally with 0.1,1 and 10 jag of the exemplary purified majorly abundant 71 KD extracellular protein. Uninfected animals used as controls were similarly challenged with the isolated protein. The extent of erythema and induration were measured 24 hours later with the results reported in Table I below.

TABLE I Erythema (mm) to 71 KD (Mean i SE) Guinea Pig Status n 0.1 ue 1-0 ue 10 0 ug Infected 7 9.5 ±1.7 13.4 ±1.3 19.7 ±1.3 Controls 6 2.3 ±2.3 3.5 ±2.2 7.8 ±1.9 55 Induration (mm) to 71 KD (Mean + SE) Guinea Pig Status n 0.1 ue 1.0 ue 10.0 ue Infected 7 5.3 ±1.8 8.7 ±1.6 13.4 ±1.1 Controls 6 0 ± 0 0.8 ± 0.8 0 ± 0 As shown in Table I, strong immune responses are present in the infected animals challenged with the exemplary purified majorly abundant extracellular protein of the present invention. These responses are on the order of three to four times greater 5 for erythema and more than 10 times greater for induration than those of the uninfected animals, confirming that the prominent 71 KD extracellular protein induces a strong cell-mediated immune response in M. tuberculosis-infected animals.

To further corroborate these results the infected animals and uninfected animals were sacrificed and subjected to a lymphocyte proliferative assay according to the 10 protocol of Example 4. The tissue samples from both sets of guinea pigs were assayed against 0.1,1 and 10 (ig/ml of isolated 71 KD protein and PPD. The samples were then monitored for their ability to incorporate [3H]thymidine as previously described with the results of these assays presented in Table J below.

TABLE J Stimulation Indices to 71 KD (Mean ± SE) Guinea Pig Status n 0.1 ue/ml 1.0 ue/ml 10.0 ue/ml Infected 3 2.4 ±0.5 6.21 1.8 29.1 1 16.2 Controls 3 1.110.1 2.610.8 18.216.1 Stimulation Indices to PPD (Mean 1 SE) Guinea Pig Status n 0.1 ue/ml 1.0 ue/ml 10.0 ue/ml Infected 3 1.010.1 4.011.5 11.413.4 Controls 3 0.910.2 0.910.03 1.5 10.3 As with the results of the cutaneous sensitivity assay, Table J shows that the stimulation indices were much higher for the infected tissue than for the uninfected samples. More specifically, the mean peak stimulation index of infected animals was 2- 56 fold higher to the exemplary 71 KD protein and 3-fold higher to PPD than it was to uninfected controls confirming that a strong cell-mediated immune response is induced in animals infected with M. tuberculosis by the exemplary majorly abundant extracellular protein vaccines of the present invention.

Following this demonstration of cross-reactivity between the exemplary purified 71 KD majorly abundant protein and M. tuberculosis, additional experiments were performed to demonstrate that an effective immune response could be stimulated by these exemplary purified samples of the majorly abundant extracellular products as disclosed by the present invention.

EXAMPLE 9 Challenge of 71 KD Immunized Guinea Pigs With Aerosolized M. tuberculosis To demonstrate the immunoprotective capacity of exemplary majorly abundant or principal extracellular protein vaccines, guinea pigs were immunized twice, 3 weeks apart, with 100 fig of the exemplary majorly abundant 71 KD protein purified according to Example 2. Control animals were immunized with 120 fig bulk EP from Example 1 or buffer. All animals were immunized using the adjuvant SAF. Three weeks after the last immunization, guinea pigs immunized with the exemplary 71 KD protein were skin-tested with 10 fig of the material to evaluate whether a cell-mediated immune response had developed. The control animals and 71 KD immunized guinea pigs were then infected with aerosolized M. tuberculosis as detailed in Example 4. Following infection the animals were monitored and weighed for six months.

The graph of Figure 5 contrasts the weight loss experienced by the sham- immunized group to the relatively normal weight gain shown by the 71 KD and bulk EP immunized animals. Data are the mean weights ± SE for each group. Mortality curves for the same animals are shown in the graph of Figure 6. The absolute mortality rates for the study are reported in Table K below. 57 TABLE K Status of Survivors/ Percent Guinea Pies Challeneed Survival 71 KD Immunized 3/6 50% EP Immunized /8 62.5% Sham Immunized 0/6 0% Both the weight loss curves and the mortality rates clearly show that the 5 majorly abundant extracellular proteins of the present invention confer a prophylactic immune response. This is emphasized by the fact that 100% of the non-immunized animals died before the end of the monitoring period.

EXAMPLE 10 Challenge of 71 KD Immunized Guinea Pigs With Aerosolized M. tuberculosis A similar experiment was conducted to verify the results of the previous Example and show that the administration of an exemplary principal extracellular 15 protein can confer a protective immune response in animals. In this experiment, guinea pigs were again immunized three times, 3 weeks apart, with 100 fig of the 71 KD extracellular protein in SAF. Control guinea pigs were sham-immunized with buffer in SAF. Three weeks after the last immunization, the animals were challenged with aerosolized M. tuberculosis and weighed weekly for 13 weeks. Mean weights ± SE for 20 each group of 6 guinea pigs were calculated and are graphically represented in Figure 7. This curve shows that the sham-immunized animals lost a considerable amount of weight over the monitoring period while the immunized animals maintained a fairly consistent body weight. As loss of body mass or "consumption" is one of the classical side effects of tuberculosis, these results indicate that the growth and proliferation of 25 tubercle bacilli in the immunized animals was inhibited by the exemplary vaccine of the present invention.

Protective immunity having been developed in guinea pigs through vaccination with an abundant extracellular product in an isolated form, experiments were run to demonstrate the inter-species immunoreactivity of the vaccines of the PCT/U S96/07781 58 present invention and to further confirm the validity and applicability of the guinea pig model.

EXAMPLE 11 Testing Cell-Mediated Immunity of PPD Positive Humans With Purified 71 KD Protein To assess the cell-mediated component of a human immune response to the exemplary 71 KD majorly abundant protein, the proliferation of peripheral blood 10 lymphocytes from PPD-positive and PPD-negative individuals to the protein were studied in the standard lymphocyte proliferation assay as reported in Example 4 above. A positive PPD, or tuberculin, response is well known in the art as being indicative of previous exposure to M. tuberculosis. The proliferative response and corresponding incorporation of [3H]thymidine were measured at two and four days. Data for these 15 studies is shown in Figures 8A and 8B. Figure 8A shows the response to various levels of 71 KD after two days while Figure 8B shows the same responses at four days.

As illustrated in Figures 8A and 8B, the mean peak stimulation index of PPD-positive individuals was twofold higher to the 71 KD protein and threefold higher to PPD than that of PPD negative individuals. Among PPD-positive individuals, there 20 was a linear correlation between the peak stimulation indices to the exemplary 71 KD protein and to PPD demonstrating that a strong cell-mediated response is stimulated by the most prominent or majorly abundant extracellular products of M. tuberculosis in humans previously exposed to M. tuberculosis. This data corresponds to the reactivity profile seen in guinea pigs and confirms the applicability of the guinea pig model to 25 other mammals subject to infection.

Thus, as with the previously discussed 30 KD exemplary protein, the development of a strong immune response to the majorly abundant 71 KD extracellular product demonstrates the broad scope of the present invention as evidenced by the fact that the 71 KD product is also effective at stimulating cell-mediated immunity in 30 humans.

Again, it should be emphasized that the present invention is not limited to the extracellular products of M. tuberculosis or to the use of the exemplary 71 KD protein. Rather the teachings of the present invention are applicable to any majorly abundant extracellular product as demonstrated in the examples. 35 Additional studies were performed in order to ascertain whether combinations of majorly abundant extracellular products of M. tuberculosis would 59 provide protective immunity as well. In general, these studies utilized guinea pigs which were immunized either intradermally or subcutaneously with various dosages of vaccines comprising combinations of 5 purified extracellular proteins of M. tuberculosis in SAF three times, 3 or 4 weeks apart.

The first protein combination used for the immunization procedure, labeled Combination I, was comprised of 71 KD, 32A KD, 30 KD, 23 KD, and 16 KD proteins purified according to the protocols described in Example 2. This combination is believed to comprise up to 60% of the total extracellular protein normally present in M. tuberculosis culture supernatants. These proteins selected for use in Combination I, 10 are identified with an asterisk in Figure 2. Combination I vaccine containing 100 (ig, 20 jag, or 2 (ig of each protein was administered intradermally with the adjuvant SAF. Combination I vaccine containing 20 jig of each protein was also administered subcutaneously in similar experiments. Negative control guinea pigs were sham-immunized with equivalent volumes of SAF and buffer on the same schedule while 15 positive controls were immunized using 120 fig of the bulk extracellular protein preparation from Example 1 in SAF. All injection volumes were standardized using buffer.

EXAMPLE 12 Response of Combination I Immunized Guinea Pigs to a Challenge With Combination I Vaccine To determine if the animals had developed a measurable immune response following vaccination with the Combination I mixture of principal 25 extracellular products, a cutaneous hypersensitivity assay was performed. Guinea pigs were shaved over the back and injected intradermally with 1.0 p.g and 10.0 (j.g of the same combination of the five purified extracellular proteins. 10.0 fig of buffer was used as a control and all injections were performed using a total volume of 0.1 ml. The diameters of erythema and induration at skin tests sites were measured at 24 hours after 30 injection.

The results of the measurements are presented in Table L below. Data are again reported in terms of mean measurement values for the group ± standard error (SE) as determined using traditional methods. ND indicates that this particular aspect of the experiment was not done. 60 Guinea Pig Status Immunized Controls Immunized Controls n 6 6 n 6 6 TABLE L Erythema (mm) (Mean + SE) PD 1.0 ue 10.0 ue 0 11.4 ±4.6 17.4 ±2.6 0 ND 6.0 ± 0.5 Induration (mm) (Mean + SE) PD 1.0 ug 10.0 fig 0 7.3±0.8 11.6 ±1.2 0 ND 4.2 ± 0.3 The data clearly demonstrate that a strong cell-mediated immune response to the Combination I extracellular proteins was generated by the vaccinated 5 animals. The immunized guinea pigs show erythema and induration measurements almost three times greater than the control animals.

EXAMPLE 13 Immunoprotective Analysis of Combination I Vaccine 10 Against Aerosolized M. tuberculosis Three weeks after the last immunization, the guinea pigs used for the preceding hypersensitivity assay were challenged with aerosolized M. tuberculosis, Erdman strain and weighed weekly for 10 weeks. This aerosol challenge was 15 performed using the protocol of Example 4. Six animals immunized with 100 jag of the principal extracellular products of Combination I, along with equal sized groups of positive and negative controls, were challenged simultaneously with aerosolized M. tuberculosis. Positive controls were immunized three times with 120 |ig EP in SAF.

Guinea pigs that died before the end of the observation period were 20 autopsied and examined for evidence of gross tuberculosis lesions. Such lesions were found in all animals which expired during the study.

Differences between immunized and control animals in mean weight profiles after aerosol challenge were analyzed by repeated measures analysis of variance (ANOVA). Differences between immunized and control guinea pigs in survival after 25 challenge were analyzed by the two-tailed Fisher exact test. Data are the mean weights ± standard error (SE) for each group of six guinea pigs. 61 Results of the weekly weight determinations following challenge are shown in Figure 9. Compared with guinea pigs immunized with the combination of extracellular products, sham-immunized animals lost 15.9% of their total body weight. Weights of the positive controls were similar to those of animals immunized with the 5 combination of five purified extracellular proteins. Body weights were normalized immediately before challenge. The difference between animals immunized with Combination I and sham-immunized controls was highly significant with p <.0000001 by repeated measures ANOVA.

Mortality was determined ten and one-half weeks after challenge. All 10 three of the sham-immunized animals died within three days of each other between ten and ten and one-half weeks after challenge. The mortality results of the experiment are provided in Table M below.

TABLE M Status of Survivors/ Percent Guinea Pigs Challenged Survival Combination 6/6 100% Immunized EP-Immunized 5/6 83% Sham-Immunized 3/6 50% Following the conclusion of the weight monitoring study, the surviving animals were sacrificed by hypercarbia and the right lung and spleen of each animal was assayed for viable M. tuberculosis using the protocol of Example 5. The results of 20 the counts, including the 3 animals that died the last week of the experiment, are presented in Table N below in terms of mean colony forming units (CFU) ± standard error (SE). 62 TABLEN Mean CFU + SE Guinea Pig n Status Right Lung Spleen Sham-immunized 6 8.9±5.4xl07 1.3±0.7xl07 Immunized 6 3.4±1.7xl06 1.8±0.6xl06 EP-immunized 6 1.7±0.7xl07 5.0 ±2.8xl06 The log difference between the concentration of bacilli in the lung of the 5 animals immunized with the combination of purified proteins and that of the sham-immunized animals was 1.4 while the log difference of bacilli in the spleen was 0.9. Paralleling this, on gross inspection at autopsy immunized animals had markedly decreased lung involvement with tuberculosis compared with sham-immunized controls. Positive control animals immunized with the bulk extracellular preparation 10 (EP) of Example 1 showed 0.7 log more bacilli in the lung and .5 log more bacilli in the spleen than animals immunized with the Combination I mixture of purified extracellular proteins.

EXAMPLE 14 immunoprotection analysis of combination i vaccine at low doses through Intradermal and Subcutaneous Delivery While Example 13 confirmed that Combination I proteins demonstrated immunoprotection in animals immunized intradermally with 100 |ig of each protein (30 20 + 32A + 16 + 23 + 71)3 times, 4 weeks apart, an alternative study was conducted to demonstrate the immunoprotective capacity of lower doses of Combination I proteins, specifically 20 \ig or 2 |ig of each protein. As in Example 13, guinea pigs (6 animals per group) were immunized with Combination I proteins (30 + 32A +16 + 23 + 71) intradermally in SAF 4 times, 3 weeks apart. Animals received either 20 |ig or each 25 protein per immunization or 2 jag of each protein per immunization. Control animals were sham-immunized utilizing the previous protocol. Three weeks later, the animals were challenged with aerosolized M. tuberculosis and weights were measured weekly for 9 weeks. All immunized animals survived to the end of the experiment while one sham-immunized animal died before the end of the experiment. As the following 30 results illustrate, doses 5 fold and even 50 fold lower than those of Example 13 63 protected immunized animals from aerosolized M. tuberculosis and that delivery by both the intradermal and subcutaneous route was effective.

Compared with guinea pigs immunized with 20 |_ig of each protein of Combination I, sham-immunized animals lost 12 % of their total body weight during 5 the 9 weeks of the experiment (weights were normalized to just before challenge). Compared with guinea pigs immunized with 2 fig of each protein of Combination I, sham-immunized animals lost 11% of their normalized total body weight. Thus, guinea pigs immunized intradermally with low doses of Combination I proteins were protected against weight loss after aerosol challenge with M. tuberculosis. 10 Similarly, guinea pigs immunized intradermally with low doses of Combination I proteins also were protected against splenomegaly associated with dissemination of M. tuberculosis to the spleen. As shown in Table O, whereas animals immunized with 20 |ig or 2 jag of each protein of Combination I had spleens weighing an average of 4.6 ± 1.2g and 4.0 ± 0.8g (Mean ± SE), respectively, sham-immunized 15 animals had spleens weighing an average of 9.6 ± 1.8g (Table 1), or more than twice as much.

TABLEO Spleen Weight (g) Status of Guinea Pies n Mean ± SE Sham-Immunized 5 9.6 ±1.8 Immunized (20 jig) 6 4.6 ± 1.2 Immunized (2 |ig) 6 4.0 ± 0.8 Guinea pigs immunized intradermally with low doses of Combination I proteins also had fewer CFU of M. tuberculosis in their spleens. As shown in Table P, when compared with sham-immunized animals, guinea pigs immunized with 20 |ig or 2 fig of each protein of Combination I had an average of 0.6 and 0.4 log fewer CFU, 25 respectively, in their spleens. 64 TABLE P Guinea Pig Status Sham-Immunized Immunized (20 fig) Immunized (2 fig) 6 6 CFU in Spleen Mean ± SE 3.1 ± 2.3 x 106 8.1 ±2.4x 105 1.2 ± 0.6 x 106 Log Difference -0.6 -0.4 Moreover, guinea pigs immunized subcutaneously with Combination I proteins were also protected against weight loss, splenomegaly, and growth of M. tuberculosis in the spleen. In the same experiment described in Example 14, guinea pigs were also immunized subcutaneously rather than intradermally with 20 fig of Combination I proteins, 4 times, 3 weeks apart. These animals were protected from challenge almost as much as the animals immunized intradermally with 20 fig of Combination I proteins.

EXAMPLE 15 Response of Combination I and Combination II Immunized Guinea Pigs to Challenge with Combination I and Combination II Additional studies were performed to ascertain whether other combinations of majorly abundant extracellular products of M. tuberculosis would provide protective immunity as well. One study utilized guinea pigs which were immunized with a vaccine comprising two combinations - Combination I (71, 32A, 30, 20 23, and 16) and Combination II (32A, 30, 24, 23, and 16). Combination II is believed to comprise up to 62% of the total extracellular protein normally present in M. tuberculosis supernatants. Animals (6 per group) were immunized four times with 100 fig of each protein in Combination I or II in SAF, 3 weeks apart. Negative control animals were sham-immunized with equivalent volumes of SAF and buffer on the same 25 schedule.

As in Example 12, the animals were tested for cutaneous delayed-type hypersensitivity to determine if the animals developed a measurable immune response following vaccination. Animals immunized with Combination II had 16.8 ±1.3 mm (Mean ± SE) erythema and 12.8 ± 1.2 mm induration in response to skin-testing with 30 Combination II whereas sham-immunized animals had only 1.3 ± 0.8 mm erythema and 0.3 ± 3 mm induration in response to Combination II. Thus, animals immunized with 65 Combination II had greater than 12 fold more erythema and greater than 40 fold more induration than controls. By way of comparison, animals immunized with Combination I had 21.3 ± 2.0 mm erythema and 15.8 ± 0.1 mm induration in response to skin-testing with Combination I, whereas sham-immunized animals had only 6.4 ± 0.8 mm erythema and 2.6 ± 0.7 mm induration in response to Combination I. Thus, animals immunized with Combination I had greater than 3 fold more erythema and greater than 6 fold more induration than controls. The difference from controls for Combination II proteins was even greater than that for Combination I proteins.

In the same experiment, animals immunized with a lower dose of 10 Combination II proteins (20 jig of each protein vs. 100 ug) also developed strong cutaneous hypersensitivity to Combination II. They had 21.0 + 2.0 mm erythema and 15.3 ± 0.9 mm induration in response to Combination II, whereas the sham-immunized animals had only 1.3 ± 0.8 mm erythema and 0.3 ± 0.3 mm induration, as noted above. Thus, animals immunized with a lower dose of Combination II proteins had greater than 15 16 fold erythema and greater than 50 fold more induration than controls, a difference that was even greater than for animals immunized with the higher dose of Combination II proteins.

EXAMPLE 16 Immunoprotective Analysis of Combination I and II Vaccine Against Aerosolized M. tuberculosis Three weeks after the last immunization, the guinea pigs used for the preceding hypersensitivity assay were challenged with aerosolized M. tuberculosis, 25 Erdman strain as in Example 13 and weighed weekly for 7 weeks. As in Example 13, 6 animals were in each group. During the first 7 weeks after challenge, sham-immunized animals lost an average of 19.5g. In contrast, animals immunized with Combination II (100 ug of each protein) gained 52.4 g and animals immunized with Combination II at a lower dose (20 ug of each protein) gained an average of 67.2g. By way of contrast, 30 animals immunized with Combination I gained 68g. Thus, compared with guinea pigs immunized with Combination II (100 jig), sham-immunized animals lost 11% of their total body weight. Compared with guinea pigs immunized with Combination II at a lower dose (20 ^g), sham-immunized animals lost 14% of their total body weight. Compared with animals immunized with Combination I, sham-immunized animals also 35 lost 14% of their total body weight. 66 EXAMPLE 17 Response of Guinea Pigs Immunized with Combinations III through XII to a Challenge with the Same Vaccine or Its Components Additional experiments were performed to demonstrate the effectiveness of various combinations of M. tuberculosis majorly abundant extracellular products. In these studies, Hartley type guinea pigs were immunized intradermally with vaccines comprising combinations of 2 or more majorly abundant extracellular products purified as in Example 2. The purified extracellular products are identified using their apparent molecular weight as determined by SDS-PAGE. The guinea pigs were immunized with the following combinations of majorly abundant extracellular products.

Combination Protein Constituents III + 32A + 32B + 16 + 23 IV + 32A V + 32B VI +16 VII + 23 VIII + 71 IX + 23.5 X +12 XI + 24 XII + 58 Each combination vaccine included 100 [ig of each listed protein. The combination vaccines were volumetrically adjusted and injected intradermally in the adjuvant SAF. As before the guinea pigs were immunized four times, three weeks apart.

A cutaneous hypersensitivity assay was performed to determine if the animals had developed a measurable immune response following vaccination with the Combinations III to XII. Groups of six guinea pigs were shaved over the back and injected intradermally with the same combination of purified extracellular products to which they were immunized. For this challenge 10 |o.g of each of the proteins in the combination were injected. All injections were performed using a total volume of 0.1 67 ml. Sham-immunized controls, which had been immunized with SAF only were also skin-tested with Combinations III to XII, again using 10 |ig of each protein in the respective combination. The diameters of erythema and induration at skin tests sites were measured 24 hours after injection as described in Example 3.

The results of these measurements are presented in Table Q below. Data are again reported in terms of mean measurement values for the group ± standard error (SE) as determined using traditional methods.

TABLE O Diameter of Skin Reaction (mm) Vaccine Skin Test Combination Combination Erythema Induration III III 12.2 ±2.0 6.8 ±0.8 IV IV 9.9 ±0.5 6.3 ±0.2 V V 13.0 ±1.1 8.1 ±0.7 VI VI 19.2 ±1.2 12.4 ±0.5 VII VII 14.3 ±1.0 8.7 ±0.4 VIII VIII 18.9 ±1.1 12.6 ±0.8 IX IX 17.0 ±0.9 12.1 ±0.9 X X 19.3 ±1.4 13.6 ±1.2 XI XI 18.3 ±1.2 12.4 ±0.8 XII XII 17.7 ±0.9 14.0 ±1.2 Sham III 4.8 ± 0.9 2.0 ±0.0 Sham IV 4.3 ±1.1 2.0 ± 0.0 Sham V .0 ±0.5 2.0 ± 0.0 Sham VI 4.5 ± 0.3 2.0 ±0.0 Sham VII 4.5 ± 0.3 2.0 ±0.0 Sham VIII 3.3 ±0.3 2.3 ± 0.3 Sham IX 3.7 ±0.3 2.0 ± 0.0 Sham X 3.7 ±0.4 2.0 ±0.0 Sham XI 3.7 ± 0.2 2.0 ±0.0 Sham XII 3.8 ±0.2 2.0 ± 0.0 The results clearly demonstrate that a strong cell-mediated immune response was generated to each of the combinations of purified extracellular proteins. The immunized guinea pigs showed erythema at least twice and usually 3 fold or more that of controls for all combinations. Further, the immunized guinea pigs showed 15 induration at least 3 fold that of controls for all combinations. 68 EXAMPLE 18 Immunoprotective Analysis of Combinations III-XII Against Aerosolized M. tuberculosis To demonstrate the prophylactic efficacy of these exemplary combinations of purified extracellular products, guinea pigs immunized with Combinations III through XII were challenged with M. tuberculosis three weeks after the last immunization using the protocol of Example 4.

Consistent with earlier results guinea pigs immunized with Combinations III through XII were all protected against death after challenge. At 4 weeks after challenge, 2 of 6 sham-immunized animals (33%) died compared with 0 animals in groups immunized with Combinations IV-XII and 1 of 6 animals (17%) in the group immunized with Combination III. At 10 weeks after challenge, 50% of the 15 sham-immunized animals had died compared with 0 deaths in the animals in groups immunized with Combinations IX and XII (0%), 1 of 6 deaths (17%) in the animals in the groups immunized with Combination III, IV, V, VI, X, and XI, 1 of 5 deaths (20%) in the animals immunized with Combination VIII, and 2 of 6 deaths (33%) in the animals immunized with Combination VII.

Guinea pigs that died before the end of the observation period were autopsied and examined for evidence of gross tuberculosis lesions. Lesions were found in all animals which expired during the study.

Following the conclusion of the mortality study, the surviving animals were sacrificed by hypercarbia and the spleen of each animal was assayed for viable 25 M. tuberculosis using the protocol of Example 5. The results are presented in Table R below in terms of mean colony forming units (CFU) along with the log decrease from the sham immunized animals. An asterisk next to the CFU value indicates that spleen counts were zero on one animal in each group. For purposes of calculation, zero counts were treated as 103 CFU per spleen or 3 logs. 69 TABLE R Vaccine CFU in Spleen Log Decrease Group (Mean Log) from Sham III 5.99 .5 IV 5.41 1.1 V 6.27 .3 VI <5.80* >.7 VII <5.61* >.9 VIII 6.47 .1 IX <5.85* >.7 X <5.74* >.8 XI 5.93 .6 XII 6.03 .5 Sham 6.53 Animals immunized with Combinations III, IV, VI, VII, IX, X, XI, and XII had at least 0.5 log fewer colony forming units of M. tuberculosis in their spleens 5 on the average than the sham-immunized controls. In particular, combinations IV and VII proved to be especially effective, reducing the average number of colony forming units by roughly a factor of ten. Animals immunized with Combinations V and VIII had 0.3 and 0.1 log fewer colony forming units (CFU), respectively, in their spleens on average, than sham-immunized controls. This dramatic reduction in colony forming 10 units in the animals immunized in accordance with the teachings of the present invention once again illustrates the immunoprotective operability of the present invention.

EXAMPLE 19 Response of Guinea Pigs Immunized with 3 Different Dosages of Combination XIII to a Challenge with Combination XIII To further define the operability and scope of the present invention as well as to demonstrate the efficacy of additional combinations of purified extracellular 20 products, guinea pigs were immunized as before using alternative vaccination dosages. Specifically, 50 |j.g, 100 fig and 200 |j.g of an alternative combination of 3 majorly abundant extracellular products identified as Combination XIII and comprising the 30 KD, 32(A) KD, and 16 KD proteins. As with the preceding examples, groups of animals were immunized intradermally 4 times, 3 weeks apart with the alternative 25 dosages of Combination XIII in SAF. 70 A cutaneous hypersensitivity assay was performed to determine if the animals had developed a measurable immune response following vaccination. The animals were shaved over the back and injected intradermally with Combination XIII containing 10.0 |ig of each of the purified extracellular products. All injections were 5 performed using a total volume of 0.1 ml. Sham-immunized controls were also skin-tested with the same dosage of Combination XIII. The diameters of erythema and induration at skin- test sites were measured 24 hours after injection.

The results are presented in Table S below in terms of mean measurement values for the group ± standard error (SE) as determined using traditional 10 methods Vaccine Combination XIII XIII XIII Sham Vaccine Dose (ug) 50 100 200 0 TABLE S Diameter of Skin Reaction (mm) Erythema 17.8 ±1.3 11.2 ±0.9 10.0 ±0.7 .7 ±0.5 Induration 13.2 ± 1.0 7.3 ± 0.4 7.0 ± 0.4 0.2 ± 0.2 Once again, these results clearly demonstrate that a strong cell-mediated immune response to Combination XIII was generated in animals immunized with each of the three dosages of Combination XIII. The immunized animals exhibited erythema about two to three times that of controls. Even more strikingly, the immunized animals exhibited induration at least 35 fold that of control animals which exhibited a minimal response in all cases.

EXAMPLE 20 Immunoprotective Analysis of Combination XIII in Three Different Dosages Against Aerosolized M. tuberculosis To further demonstrate the protective immunity aspects of the vaccines of the present invention at various dosages, the immunized guinea pigs (6 per group) used for the preceding cutaneous hypersensitivity assay were challenged with aerosolized M. tuberculosis three weeks after the last immunization. The aerosol 71 challenge was performed using the protocol detailed in Example 4. A control group of 12 sham-immunized animals was challenged simultaneously.

Results of the weekly weight determinations following challenge are graphically represented in Figure 10 and distinctly show guinea pigs immunized with 5 each of the three dosages of Combination XIII were protected from weight loss. Animals immunized with the higher dosages of Combination XIII (100 and 200 jig) actually showed a net gain in weight and animals immunized with the lower dosage (50 Ug) showed a relatively small loss in weight. In contrast, the sham immunized animals lost approximately 22% of their total body weight in the weeks immediately after 10 challenge and averaged a loss of 182 g over the 10 week observation period.

Table U below illustrates the percent weight change for immunized and control animals as determined by taking the mean weight at the end of the challenge, subtracting the mean weight at the start of the challenge and dividing the result by the mean weight at the start of the challenge. Similarly, the percent protection was 15 determined by subtracting the mean percent weight loss of the controls from the mean percent weight gain or loss of the immunized animals.

TABLE U Immunoeen Dosaee % Weight % Protection from Chanee Weight Loss Combination XIII 50 -4% 18% Combination XIII 100 +7% 29% Combination XIII 200 +5% 27% Sham Sham -22% Table U shows that the sham-immunized animals lost a considerable amount of weight (18% - 29%) over the monitoring period compared with the immunized animals. Figure 10 provides a more graphic illustration of the net weight loss for each group of immunized animals versus sham-control animals plotted at weekly intervals over the ten week monitoring period. As loss of body mass or "consumption" is one of the classical side effects of tuberculosis, these results indicate that the growth and proliferation of tubercle bacilli in the immunized animals was inhibited by the three different dosages of the exemplary combination vaccine of the present invention. 72 EXAMPLE 21 Immunoprotective Analysis of Combinations XIV-XVIII against Challenge with Combinations XIV-XVIII To further demonstrate the scope of the present invention and the broad range of effective vaccines which may be formulated in accordance with the teachings thereof, five additional combination vaccines, Combinations XIV through XVIII, were tested in guinea pigs. Identified by the apparent molecular weight of the purified extracellular products determined using SDS-PAGE, the composition of each of the 10 combination vaccines is given below.

Combination Protein Constituents XIV 30, 32A, 16, 32B, 24,23,45 XV 30, 32A, 16,32B, 24,23,45, 23.5,12 XVI 30, 32A, 16, 32B, 24,23 XVII 30, 32A, 16, 32B, 24, 71 XVIII I 30, 32A, 16,23,71 In addition to the new combination vaccines and appropriate controls, Combination I was also used in this series of experiments. Guinea pigs were 15 immunized intradermally with 50 (j.g of each protein of Combination XIV or XV and with 100 fig of each protein of Combinations I, XVI, XVII, and XVIII all in SAF adjuvant. The animals were immunized a total of four times, with each injection three weeks apart.

A cutaneous hypersensitivity assay was performed to determine if the 20 animals had developed a measurable immune response following vaccination using the previously discussed protocol. Guinea pigs were shaved over the back and injected intradermally with the same combination of purified extracellular proteins to which they were immunized. For each challenge the appropriate combination vaccine containing 10 |ig of each protein was injected. All injections were performed using a total volume 25 of 0.1 ml. Sham-immunized controls were also skin-tested with the same dosage of each combination. The diameters of erythema and induration at skin test sites were measured at 24 hours after injection as described in Example 3.

^ WO 96/37219 73 The results of these measurements are presented in Table V below, reported in terms of mean measurement values for the group ± standard error (SE) as determined using traditional methods.

Vaccine Combination Skin Test Combination TABLE V Diameter of Skin Reaction (mm) Erythema Induration XIV XV XVI XVII XVIII I XIV XV XVI XVII XVIII I 13.3 ±0.7 .4 ±0.4 8.0 ± 1.8 9.4 ± 0.9 13.6 ±1.2 10.0 ±0.3 9.1 ±0.4 6.5 ±0.4 5.1 ± 1.0 6.1 ± 1.1 8.7 ±0.7 6.7 ± 0.2 Sham Sham Sham Sham Sham Sham XIV XV XVI XVII XVIII I .5 ± 1.6 6.1 ±0.5 4.6 ± 1.4 .7 ± 1.2 2.1 ± 1.1 6.0 ±1.2 0.4 ± 0.2 0.4 ± 0.2 0.4 ± 0.2 0.2 ± 0.2 0 ± 0 0.6 ± 0.2 These results clearly demonstrate that a strong cell-mediated immune response was generated to Combinations XIV through XVIII, and, as before, to Combination I. Immunized animals exhibited erythema about twice that of controls. Even more strikingly, the immunized animals exhibited induration at least 10 fold greater than the sham-immunized controls which exhibited a minimal response in all cases.

EXAMPLE 22 Immunoprotective Analysis of Combinations XIV-XVIII and Combination I Against Aerosolized M. tuberculosis To confirm the immunoreactivity of the combination vaccines of Example 21 and to demonstrate their applicability to infectious tuberculosis, the 20 immunized guinea pigs used for the preceding cutaneous hypersensitivity assay were challenged with aerosolized M. tuberculosis three weeks after the last immunization and 74 monitored using the protocol of Example 4. A control group of 12 sham-immunized animals, the same as used in Example 20, was similarly challenged. The results of these challenge are graphically represented in Figure 11 and shown in Table W directly below.

Percent weight change was determined by taking the mean weight at the end of the challenge, subtracting the mean weight at the start of the challenge and dividing the result by the mean weight at the start of the challenge. Similarly, the percent protection was determined by subtracting the mean percent weight loss of the controls from the mean percent weight gain or loss of the immunized animals.

TABLE W Immunogen % Weight % Protection from Chanee Weight Loss Combination XIV 3% % Combination XV -4% 18% Combination XVI -15% 7% Combination XVII -11% 11% Combination XVIII -12% % Combination I -11% 11% Sham -22% As shown in Table W, guinea pigs immunized with each of the combination vaccines were protected from weight loss. Sham-immunized animals lost 15 approximately 22% of their total combined body weight. In contrast the prophylactic effect of the combination vaccines resulted in actual weight gain for one of the test groups and a reduced amount of weight loss in the others. Specifically, animals immunized with Combination XIV evidenced a 3% weight gain while those animals immunized with the other combinations lost only 4% to 15% of their total combined 20 weight.

These results are shown graphically in Figure 11 which plots weekly weight determinations in terms of net weight gain or loss for each group of animals following aerosolized challenge. This statistically significant difference between the net weight loss for the immunized animals and the sham-immunized controls shown in 25 Figure 11 provides further evidence for the immunoprophylactic response generated by the combination vaccines of the present invention. 75 EXAMPLE 23 Cell-Mediated Immunity in Guinea Pigs Immunized with Three Different Adjuvants In order to further demonstrate the broad applicability and versatility of the vaccine formulations of the present invention, immunogenic studies were conducted using different adjuvants. Specifically three different immunogens, purified 30 KD protein, Combination I (30, 32A, 16, 23, 71) and Combination XIII (30, 32A, 16) were each formulated using three different adjuvants, Syntex Adjuvant Formulation I (SAF), 10 incomplete Freund's adjuvant (IFA) and Monophosphoryl Lipid A containing adjuvant (MPL). Such adjuvants are generally known to enhance the immune response of an organism when administered with an immunogen.

Guinea pigs were immunized intradermally with 100 jig of each protein comprising Combinations I and XIII and approximately 100 fig of purified 30 KD 15 protein in each of the three different adjuvant formulations. The guinea pigs were immunized with each formulation a total of three times with injections three weeks apart.

Following immunization, a cutaneous hypersensitivity assay was performed to determine if the guinea pigs had developed a measurable immune 20 response. Guinea pigs were shaved over the back and injected intradermally with the same immunogen to which they had been immunized. For the challenge, 10 fig of each protein in Combinations I and XIII or 10 jig of purified 30 KD protein was injected in a total volume of 100 jj.1. Sham-immunized guinea pigs, vaccinated with one of the three adjuvants, were skin-tested with each of the immunogen formulations containing the 25 same adjuvant. The diameters of erythema and induration at skin test sites were measured 24 hours after challenge as described in Example 3.

The results of these measurements are presented in Table X below. As previously discussed data are reported in terms of mean measurement values for the group ± standard error as determined using accepted statistical techniques.

PCT/U S96/07781 76 TABLE X Diameter of Skin Reaction (mm) Skin Test Vaccine Adiuvant Reaeent Ervthema Induratior SAF .7 ± 1.6 .8 ± 1.5 IFA 8.8 ±0.7 4.6 ±0.7 MPL .2 ±1.7 .3 ±1.5 XIII SAF XIII 7.3 ± 0.5 4.1 ±0.5 XIII IFA XIII 6.8 ±0.9 3.5 ±0.5 XIII MPL XIII 6.3 ± 0.4 3.4 ±0.3 I SAF I 6.9 ± 0.6 4.0 ± 0.3 I IFA I 6.8 ±0.2 3.6 ±0.3 I MPL I 7.4 ± 0.4 3.9 ±0.5 Sham SAF 0.7 ± 0.7 1.0±0 Sham IFA 0 ± 0 0 ± 0 Sham MPL 0 ± 0 0±0 Sham SAF XIII 1.0 ± 1.0 1.0 ± 0 Sham IFA XIII 0 ± 0 0.3 ± 0.3 Sham MPL XIII 0 ± 0 0 ± 0 Sham SAF I 4.7 ±0.3 1.0 ±0 Sham IFA I 2.0 ± 1.0 0.7 ±0.3 Sham MPL I 1.0 ± 1.0 0.7 ± 0.3 As shown in the data presented in Table X, the combination vaccines and purified extracellular products of the present invention provide a strong cell-mediated 5 immunogenic response when formulated with different adjuvants. Moreover, each one of the three adjuvants provided about the same immunogenic response for each respective immunogen. In general, the immunized guinea pigs exhibited erythema diameters approximately seven to ten times that of the sham-immunized guinea pigs while indurations were approximately four to six times greater than measured in the 10 control animals.

The ability of the present invention to provoke a strong immunogenic response in combination with different adjuvants facilitates vaccine optimization. That is, adjuvants used to produce effective vaccine formulations in accordance with the teachings herein may be selected based largely on consideration of secondary criteria 15 such as stability, lack of side effects, cost and ease of storage. These and other criteria, not directly related to the stimulation of an immune response, are particularly important 77 when developing vaccine formulations for widespread use under relatively primitive conditions.

EXAMPLE 24 Immunoprotective Analysis of Combinations XIX-XXVIII against Challenge with Combinations XIX-XXVIII The broad scope of the present invention was further demonstrated through the generation of an immune response using ten additional combination 10 vaccines, Combinations XIX through XXVIII. In addition to the new combination vaccines and appropriate controls, Combinations IV and XIII were also used as positive controls to provoke an immune response in guinea pigs. Identified by the apparent molecular weight of the purified extracellular products determined using SDS-PAGE, the composition of each of the combination vaccines is given below.

Combination Protein Constituents XIX , 32A, 23 XX , 32A, 23.5 XXI ,32A, 24 XXII , 32A, 71 XXIII , 32A, 16,23 XXIV , 32A, 16, 23.5 XXV , 32A, 16, 24 XXVI , 32A, 16, 71 XXVII , 32A, 16,32B XXVIII , 32A, 16,45 IV , 32A XIII , 32A, 16 The guinea pigs were immunized a total of four times, with each injection three weeks apart. Each combination vaccine used to immunize the animals consisted of 100 fig of each protein in SAF adjuvant to provide a total volume of 20 0.1 ml.

Using the protocol discussed in Example 3, a cutaneous hypersensitive assay was performed to determine if the animals had developed a measurable immune 78 PCT/U S96/07781 response following vaccination with the selected combination vaccine. The guinea pigs were shaved over the back and injected intradermally with the same combination of purified extracellular proteins with which they were immunized. The protein combinations used to challenge the animals consisted of 10 p.g of each protein. Sham 5 immunized controls were also skin-tested with the same dosage of each combination. As in Example 3, the diameters of erythema and induration at the skin test sites were measured at 24 hours after injection.

The results of these measurements are presented in Table Y below, reported in terms of mean measurement values for the group of animals + standard 10 error. 79 TABLE Y Diameter of Skin Reaction ("mm) Vaccine Skin Test Combination Combination Erythema Induration XIX XIX 8.510.6 3.910.3 XX XX 8.2 ± 0.3 3.710.3 XXI XXI 11.1 ± 1.1 4.5 10.4 XXII XXII 9.410.8 4.310.4 XXIII XXIII 8.311.1 3.010.3 XXIV XXIV 8.510.9 3.410.5 XXV XXV 7.910.5 3.210.4 XXVI XXVI 8.910.7 3.310.5 XXVII XXVII 7.211.0 2.8 1 0.5 XXVIII XXVIII 8.510.5 2.810.3 IV IV 9.010.9 4.1 10.3 XIII XIII 9.410.9 4.3 10.3 Sham XIX 4.012.6 1.01 0 Sham XX 1.311.3 © +1 p Sham XXI 3.511.0 1.311.3 Sham XXII 1.311.3 1.011.0 Sham XXIII 0 10 o +1 p Sham XXIV 0 10 o +1 p Sham XXV 0 10 1.01 0 Sham XXVI 2.312.3 2.011.0 Sham XXVII 0 10 o +1 p Sham XXVIII 2.011.2 o +1 p Sham IV 2.811.6 1.01 0 Sham XIII 1.511.5 1.01 0 The results presented in Table Y explicitly show that a strong cell-mediated immune response was generated to Combinations XIX through XXVIII when 5 challenged with the same immunogens. As before, a strong cell-mediated immune response was also provoked by Combinations IV and XIII. The erythema exhibited by the immunized guinea pigs was at least twice, and generally proved to be and more then four fold greater than, the reaction provoked in the corresponding sham immunized control animals. Similarly, the induration exhibited by the immunized animals was at 10 least twice, and generally three to four times greater than, that of the non-immunized controls. The substantially stronger immune response generated among the animals 80 immunized in accordance with the teachings of the present invention once again illustrates the immunoprotective operability of the combination vaccines of the present invention.

Those skilled in the art will also appreciate additional benefits of the 5 vaccines and methods of the present invention. For example, because individual compounds or selected combinations of highly purified molecular species are used for the subject vaccines rather than whole bacteria or components thereof, the vaccines of the present invention are considerably less likely to provoke a toxic response when compared with prior art attenuated or killed bacterial vaccines. Moreover, the 10 molecular vaccines of the present invention are not life threatening to immunocompromised individuals. In fact, the compositions of the present invention may be used therapeutically to stimulate a directed immune response to a pathogenic agent in an infected individual.

Selective use of majorly abundant extracellular products or their 15 immunogenic analogs also prevents the development of an opsonizing humoral response which can increase the pathogenesis of intracellular bacteria. As the protective immunity generated by this invention is directed against unbound proteins, any opsonic response will simply result in the phagocytosis and destruction of the majorly abundant extracellular product rather than the expedited inclusion of the parasitic bacteria. 20 Moreover, the selective use of purified extracellular products reduces the potential for generating a response which precludes the use of widely used screening and control techniques based on host recognition of immunogenic agents. Unlike prior art vaccines, the screening tests could still be performed using an immunoreactive molecule that is expressed by the pathogen but not included in the vaccines made according to the 25 present invention. The use of such an immunogenic determinant would only provoke a response in those individuals which had been exposed to the target pathogen allowing appropriate measures to be taken.

Another advantage of the present invention is that purified extracellular products are easily obtained in large quantities and readily isolated using techniques 30 well known in the art as opposed to the attenuated bacteria and bacterial components of prior art vaccines. Since the immunoreactive products of the present invention are naturally released extracellularly into the surrounding media for most organisms of interest, removal of intracellular contaminants and cellular debris is simplified. Further, as the most prominent or majorly abundant extracellular products or immunogenic 35 analogs thereof are used to stimulate the desired immune response, expression levels and culture concentrations of harvestable product is generally elevated in most 81 production systems. Accordingly, whatever form of production is employed, large scale isolation of the desired products is easily accomplished through routine biochemical procedures such as chromatography or ultrafiltration. These inherent attributes and molecular characteristics of the immunogenic determinants used in the present 5 invention greatly facilitate the production of a consistent, standardized, high quality composition for use on a large scale.

Alternatively, the use of purified molecular compounds based on the immunogenic properties of the most prominent or majorly abundant extracellular products of target pathogens also makes the large scale synthetic generation of the 10 immunoactive vaccine components of the present invention relatively easy. For instance, the extracellular products of interest or their immunogenic analogs may be cloned into a non-pathogenic host bacteria using recombinant DNA technology and harvested in safety. Molecular cloning techniques well known in the art may be used for isolating and expressing DNA corresponding to the extracellular products of 15 interest, their homologs or any segments thereof in selected high expression vectors for insertion in host bacteria such as Escherichia coli. Exemplary techniques may be found in II R. Anon, Synthetic Vaccines 31-77, 1987, Tam et al., "Incorporation of T and B Epitopes of the Circumsporozoite Protein in a Chemically Defined Synthetic Vaccine Against Malaria,: J. Exp. Med. 777:299-306, 1990, and Stover et al., "Protective 20 Immunity Elicited by Recombinant Bacille Calmette-Guerin (BCG) Expressing Outer Surface Protein A (OspA) Lipoprotein: A Candidate Lyme Disease Vaccine," J. Exp. Med 775:197-209 (1993).

Similarly, the extracellular proteins, their analogs, homologs or immunoreactive protein subunits may be chemically synthesized on a large scale in a 25 relatively pure form using common laboratory techniques and automated sequencer technology. This mode of production is particularly attractive for constructing peptide subunits or lower molecular weight analogs corresponding to antigenic determinants of the extracellular products. Exemplary techniques for the production of smaller protein subunits are well known in the art and may be found in II R. Anon, Synthetic Vaccines 30 15-30, 1987, and in A. Streitwieser, Jr., Introduction to Organic Chemistry 953-55, 1985 (3d ed.). Alternative techniques may be found in Gross et al., "Nonenzymatic Cleavage of Peptide Bonds: The Methionine Residues in Bovine Pancreatic Ribonuclease," The Journal of Biological Chemistry 237(6), 1962, Mahoney, "High-Yield Cleavage of Tryptophanyl Peptide Bonds by o-Iodosobenzoic Acid," 35 Biochemistry 75(17), 1979, and Shoolnik et al., "Gonococcal Pili," Journal of Experimental Medicine 159, 1984. Other immunogenic techniques such as anti- 82 PCT/U S96/07781 idiotyping or directed molecular evolution using peptides, nucleotides or other molecules such as mimetics can also be employed to generate effective, immunoreactive compounds capable of producing the desired prophylactic response.

Nucleic acid molecules useful for the practice of the present invention 5 may be expressed from a variety of vectors, including, for example, viral vectors such as herpes viral vectors (e.g., U.S. Patent No. 5,288,641), retroviruses (e.g., EP 0,415,731; WO 90/07936, WO 91/0285, WO 94/03622; WO 93/25698; WO 93/25234; U.S. Patent No. 5,219,740; WO 89/09271; WO 86/00922; WO 90/02797; WO 90/02806; U.S. Patent No. 4,650,764; U.S. Patent No. 5,124,263; 10 U.S. Patent No. 4,861,719; WO 93/11230; WO 93/10218; Vile and Hart, Cancer Res. 53:3860-3864, 1993; Vile and Hart, Cancer Res. 53:962-967, 1993; Ram et al., Cancer Res. 53:83-88, 1993; Takamiya et al., J. Neurosci. Res. 33:493-503, 1992; Baba et al., J. Neurosurg. 79:729-735, 1993), pseudotyped viruses, adenoviral vectors (e.g., WO 94/26914, WO 93/9191; Kolls et al., PNAS 97(1):215-219, 1994; Kass-Eisler et 15 al., PNAS 90(24): 11498-502, 1993; Guzman et al., Circulation SS(6):2838-48, 1993; Guzman et al., Cir. Res. 73(6): 1202-1207, 1993; Zabner et al., Cell 75(2):207-216, 1993; Li et al., Hum. Gene Ther. 4(4):403-409, 1993; Caillaud et al., Eur. J. Neurosci. 5(10): 1287-1291, 1993; Vincent et al., Nat. Genet. 5(2):130-134, 1993; Jaffe et al., Nat. Genet. /(5):372-378, 1992; and Levrero et al., Gene 101(2): 195-202, 1991), 20 adenovirus-associated viral vectors (Flotte etal., PNAS 90(22): 10613-10617, 1993), parvovirus vectors (Koering et al., Hum. Gene Therap. 5:457-463, 1994), and pox virus vectors (Panicali and Paoletti, PNAS 79:4927-4931,1982).

The nucleic acid molecules (or vectors, i.e., an assembly capable of directing the expression of a sequence of interest) may be introduced into host cells by a 25 wide variety of mechanisms, including, for example, transfection, including, for example, DNA linked to killed adenovirus (Michael et al., J.Biol. Chem. 268( 10):6866-6869, 1993; and Curiel et al., Hum. Gene Ther. 3(2):147-154, 1992), cytofectin-mediated introduction (DMRIE-DOPE, Vical, Calif.), direct DNA injection (Acsadi et al., Nature 352:815-818, 1991); DNA ligand (Wu et al., J. Biol. Chem. 30 264:16985-16987, 1989); lipofection (Feigner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417,1989); liposomes (Pickering et al., Circ. #9(1):13-21, 1994; and Wang et al., PNAS 84:7851-7855, 1987); microprojectile bombardment (Williams et al., PNAS 88:2726-2730, 1991); and direct delivery of nucleic acids which encode the enzyme itself, either alone (Vile and hart, Cancer Res. 53:3860-3864, 1993), or utilizing PEG-35 nucleic acid complexes (see also WO 93/18759; WO 93/04701; WO 93/07283 and WO 93/07282). 83 As an additional alternative, DNA or other genetic material encoding one or more genes capable of inducing the expression of one or more of the extracellular products, homologs, analogs, or subunits of the present invention can be directly injected into a mammalian host utilizing so called "naked DNA" techniques. Following 5 the in vivo introduction and the resultant uptake of the genetic construct by the host's cells the host will begin the endogenous production of the one or more encoded immunoreactive products engendering an effective immune response to subsequent challenge. As those skilled in the art will appreciate, coupling the genetic construct to eucaryotic promoter sequences and/or secretion signals may facilitate the endogenous 10 expression and subsequent secretion of the encoded immunoreactive product or products. Exemplary techniques for the utilization of naked DNA as a vaccine can be found in International Patent No. WO 9421797 A (Merck & Co. Inc. and ViCal Inc.), International Patent Application No. WO 9011092 (ViCal Inc.), and Robinson, "Protection Against a Lethal Influenza Virus Challenge by Immunization with a 15 Hemagglutinin-Expressing Plasmid DNA," Vaccine 11:9, 1993, and in Ulmer et al., "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein," Science 259, 1993, incorporated by reference herein.

Alternatively, techniques for the fusion of a strongly immunogenic protein tail have been disclosed in Tao et al., "Idiotype/Granulocyte-Macrophage 20 Colony-Stimulating Factor Fusion Protein as a Vaccine for B-Ceo Lymphoma," Nature 362, 1993, and for T-cell epitope mapping in Good et al., "Human T-Cell Recognition of the Circumsporozoite Protein of Plasmodium falciparum: Immunodominant T-Cell Domains Map to the Polymorphic Regions of the Molecule," Proc. Natl. Acad. Sci. USA 85, 1988, and Gao et al., "Identification and Characterization of T Helper Epitopes 25 in the Nucleoprotein of Influenza A Virus," J. 1mm. 143(9), 1989.

As many bacterial genera exhibit homology, the foregoing examples are provided for the purposes of illustration and are not intended to limit the scope and content of the present invention or to restrict the invention to the genus Mycobacterium or to particular species or serogroups therein or to vaccines against tuberculosis alone. 30 It should also be reemphasized that the prevalence of interspecies homology in the DNA and corresponding proteins of microorganisms enables the vaccines of the present invention to induce cross-reactive immunity. Because the immunodominant epitopes of the majorly abundant extracellular products may provide cross-protective immunity against challenge with other serogroups and species of the selected genera, those skilled 35 in the art will appreciate that vaccines directed against one species may be developed using the extracellular products or immunogenic analogs of another species.

WO 96/37219 PCT/US96/07781 84 For example, M. bovis is between 90% and 100% homologous with M. tuberculosis and is highly cross-reactive in terms of provoking an immune response. Accordingly, vaccines based on abundant extracellular products of M. bovis or other Mycobacterium can offer various degrees of protection against infection by 5 M. tuberculosis and vice versa. Thus, it is contemplated as being within the scope of the present invention to provide an immunoprophylactic response against several bacterial species of the same genera using an highly homologous immunogenic determinant of an appropriate majorly abundant extracellular product.

It should also be emphasized that the immunogenic determinant selected 10 to practice the present invention may be used in many different forms to elicit an effective protective or immunodiagnostic immune response. Thus the mode of presentation of the one or more immunogenic determinants of selected majorly abundant extracellular products to the host immune system is not critical and may be altered to facilitate production or administration. For example, the vaccines of the 15 present invention may be formulated using whole extracellular products or any immunostimulating fraction thereof including peptides, protein subunits, immunogenic analogs and homologs as noted above. In accordance with the teachings of the present invention, effective protein subunits of the majorly abundant extracellular products of M. tuberculosis can be identified in a genetically diverse population of a species of 20 mammal. The resultant immunodominant T-cell epitopes identified should be recognized by other mammals including humans and cattle. These immunodominant T-cell epitopes are therefore useful for vaccines as well as for immunodiagnostic reagents. An exemplary study identifying the immunodominant T-cell epitopes of the 30 KD major secretory protein of M. tuberculosis was conducted as follows.

EXAMPLE 25 Immunodominant Epitope Mapping of the 30 KD Protein Fifty-five synthetic peptides (15-mers) covering the entire native 30 KD 30 protein and overlapping by 10 amino acids were used for splenic lymphocyte proliferation assays to identify the immunodominant T-cell epitopes of the 30 KD major secretory protein of M. tuberculosis 55. The sequence of each 15-mer synthetic peptide utilized is given below in conjunction with an identification number (1-55) corresponding to the antigen peptide sequence numbers in Figures 12a and b as well as 35 an identification of the amino acid residues and relative position of each sequence. 1 2 3 4 6 7 8 9 11 12 13 14 16 17 18 19 21 22 23 24 26 27 28 29 31 32 33 34 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 85 Residues PeDtide Seauence Sea ID No. 1 - F S R P G L P V E Y L Q V P S 37 6 - L P V E Y L Q V P S P SMGR 38 11 - L Q V P S P S M G R D I K V Q 39 16 - P S M G R D I K V Q F Q S G G 40 21 - D I K V Q F Q S G G N N S P A 41 26 - 40 F Q S G G N N S P A V Y L L D 42 31 - 45 N N S P A V Y L L D G L R A Q 43 36 - 50 V Y L L D G L R A Q D D Y N G 44 41 - 55 G L R A Q D D Y N G W DINT 45 46 - 60 D D Y N G W D I N T P A F E W 46 51 - 65 W D I N T P A F E W Y Y Q S G 47 56 - 70 P A F E W Y Y Q S G L S I V M 48 61 - 75 Y Y Q S G L S I V M P V G G Q 49 66 - 80 L S I V M P V G G Q S S F Y S 50 71 - 85 P V G G Q S S F Y S D W Y S P 51 76 - 90 S S F Y S D W Y S P A C G K A 52 81 - 95 DW Y S P A C G K A G C Q T Y 53 86 - 100 A C G K A G C Q T Y K W E T F 54 91 - 105 G C Q T Y K W E T F L TS'EL 55 96 - 110 K W E T F L T S E L P Q W L S 56 101 - 115 L T S E L P Q W L S A N R A V 57 106 - 120 P Q W L S A N R A V K P T G S 58 111 - 125 A N R A V K P T G S A A I G L 59 116 - 130 K P T G S A A I G L S MAGS 60 121 - 135 A A I G L S M A G S S AM I L 61 126 - 140 S M A G S S A M I L A A Y H P 62 131 - 145 SAM I L A A Y H P Q Q F I Y 63 136 - 150 A A Y H P Q Q F I Y A G S L S 64 141 - 155 Q Q F I Y A G S L S A L L D P 65 146 - 160 A G S L S A L L D P S Q G M G 66 151 - 165 A L L D P S Q G M G P S L I G 67 156 - 170 SQGM G P S L I G L A M G D 68 161 - 175 P S L I G L A M G D A G G Y K 69 166 - 180 LA M G D A G G Y K A A D M W 70 171 - 185 A G G Y K A A D M W G P S S D 71 176 - 190 A A D M W G P S S D P A W E R 72 181 - 195 G P S S D P A W E R N D P T Q 73 186 - 200 P A W E R N D P T Q Q I P K L 74 191 - 205 N D P T Q Q I P K L V A N N T 75 196 - 210 Q I P K L V A N N T R LWVY 76 201 - 215 V A N N T R L W V Y C G N G T 77 206 - 220 R L W V Y C G N G T P N E L G 78 211 - 225 C G N G T P N E L G G A N I P 79 216 - 230 P N E L G G A N I P A E F L E 80 221 - 235 G A N I P A E F L E N F V R S 81 226 - 240 A E F L E N F V R S S N L K F 82 231 - 245 N F V R S S N L K F Q D A Y N 83 236 - 250 S N L K F Q D A Y N A A G G H 84 241 - 255 Q D A Y N A A G G H N A V F N 85 246 - 260 A A G G H N A V F N F P P N G 86 251 - 265 N A V F N F P P N G T HSWE 87 256 - 270 F P P N G T H S W E Y W G A Q 88 86 53 261 - 275 T H S W E Y W G A Q L N A M K 89 54 266 - 280 Y W G A Q L N A M K G D L Q S 90 55 271 - 285 L N A M K G D L Q S S L G A G 91 Splenic lymphocytes were obtained from outbred male Hartley strain guinea pigs (Charles River Breeding Laboratories) that had been immunized intradermally 3-4 times with 100 jj.g of purified 30 KD protein emulsified in SAF 5 (Allison and Byars, 1986). Control animals received phosphate buffered saline in SAF. Cell mediated immune responses were evaluated by skin testing as described above. Lymphocytes were seeded in 96-well tissue culture plates (Falcon Labware) and incubated in triplicate with the synthetic 15-mer peptides at 20 jig ml"1, purified 30 KD protein at 20 fag ml"1, purified protein derivative [(PPD); Connaught Laboratories LTD] 10 at 20 |ig ml"1, or concanavalin A at 10 jag ml'1 for 2 days in the presence of 10 U polymyxin B. Subsequently, cells were labeled for 16 h with 1 jaCi [3H] thymidine (New England Nuclear) and then harvested (Breiman and Horwitz, 1987). A positive proliferative response was defined as follows: (dpm of antigen) - (dpm of medium) > 1 500 and (dpm of antigen)/(dpm of medium) > 1.2. Immunodominant epitopes 15 recognized by greater than 25% of the guinea pigs immunized with purified M. tuberculosis 30 KD protein are presented in Table Z below and graphically illustrated in Figures 12a and 12b. 87 TABLE Z Inclusive Amino Acids for Peptide No.

Mature Protein Sea ID No. 1 1 - 15 37 2 6- 20 38 3 11-25 39 21 - 35 41 6 26- 40 42 13 61 - 75 49 21 101 -115 57 26 126-140 62 27 131 -145 63 31 151 -165 67 33 161 -175 69 36 176-190 72 37 181 -195 73 41 201 -215 77 45 221 -235 81 49 241 -255 85 53 261 - 275 89 The results presented in Table Z identify the immunodominant T-cell epitopes of the 30 KD major secretory protein of M. tuberculosis. Those skilled in the 5 art will appreciate that earlier investigators have studied the 30 KD protein of M. bovis which is highly related to M. tuberculosis protein. However, these earlier studies of the M. bovis protein differ markedly from the foregoing study in that the prior art studied actual patients, BCG vaccinees, patients with tuberculosis, or PPD-positive individuals. Because the response to this protein in such individuals is often weak, the prior art 10 epitope mapping studies were difficult and of questionable accuracy. In contrast, the study of Example 25 utilized outbred guinea pigs immunized with purified protein, thereby focusing the immune system on this single protein and producing a very strong cell-mediated immune response. Moreover, these guinea pigs were studied within a few weeks of immunization, at the peak of T-cell responsiveness. 15 In accordance with the teachings of the present invention one or more of the immunodominant epitopes identified above can be incorporated into a vaccine against tuberculosis. For example, individual immunodominant epitopes can be synthesized and used individually or in combination in a multiple antigen peptide system. Alternatively, two or more immunodominant epitopes can be linked together 20 chemically. The peptides, either linked together or separately, can be combined with an appropriate adjuvant and used in subunit vaccines for humans or other mammals. In 88 addition, the immunodominant epitopes can be used in new immunodiagnostic reagents such as new skin tests.

Those skilled in the art will also appreciate that DNA encoding the peptides can be synthesized and used to express the peptides, individually or 5 collectively, or can be combined in a DNA vaccine injected directly into humans or other mammals. A construct consisting of only the immunogenic epitopes (or the DNA coding therefor) would focus the immune response on the protective portions of the molecule. By avoiding irrelevant or even immunosuppressive epitopes such a construct may induce a stronger and more protective immune response. 10 Smaller protein subunits of the majorly abundant extracellular products, molecular analogs thereof, genes encoding therefore, and respective combinations thereof are within the scope of the present invention as long as they provoke effective immunoprophylaxis or function as an immunodiagnostic reagent. Moreover, recombinant protein products such as fusion proteins or extracellular products modified 15 through known molecular recombinant techniques are entirely compatible with the teachings of the present invention. In addition, immunogenically generated analogs of the selected immunoactive determinants or peptides and nucleotides derived using directed evolution are also within the scope of the invention. Moreover, the selected immunoactive determinants can be modified so as to bind more tightly to specific MHC 20 molecules of humans or other species or be presented more efficiently by antigen presenting cells. Further, the selected immunoactive determinants can be modified so as to resist degradation in the vaccinated host.

Similarly, the formulation and presentation of the immunogenic agent to the host immune system is not limited to solutions of proteins or their analogs in 25 adjuvant. For example, the immunogenic determinant derived from the appropriate extracellular proteins may be expressed by M. tuberculosis, different species of Mycobacteria, different species of bacteria, phage, mycoplasma or virus that is nonpathogenic and modified using recombinant technology. In such cases the whole live organism may be formulated and used to stimulate the desired response. Conversely, 30 large scale vaccination programs in hostile environments may require very stable formulations without complicating adjuvants or additives. Further, the vaccine formulation could be directed to facilitate the stability or immunoreactivity of the active component when subjected to harsh conditions such as lyophilization or oral administration or encapsulation. Accordingly, the present invention encompasses vastly 35 different formulations of the immunogenic determinants comprising the subject vaccines depending upon the intended use of the product.

PCT/U S96/07781 89 Those skilled in the art will appreciate that vaccine dosages should be determined for each pathogen and host utilizing routine experimentation. At present, it is believed that the lowest practical dosage will be on the order of 0.1 p.g though dosages of 2.0 fig, 20.0 (ig, 100 jig and even 1 mg may be optimum for the appropriate 5 system. The proper dosage can be administered using any conventional immunization technique and sequence known in the art.

EXAMPLE 26 Expression Of Recombinant 30 kDa Protein For the expression of the mature 30 kDa protein, the gene encoding the 30 kDa protein was engineered such that the initiator phenylalanine of the mature protein was fused to a glycine residue artificially inserted at the Ncol site or carboxyl terminus of the pelB leader sequence in pET22b (Novagen, Madison, WI) (see Figure 15 13). This strategy provided a fusion molecule from which the mature 30 kDa protein could be easily released and led to the expression of relatively large quantities of recombinant 30 kDa protein over a period of 4 hours. Thereafter, expression of recombinant protein reached a plateau. Expression of the recombinant molecules continued for up to 8 hours without exerting serious detrimental effects on the bacterial 20 culture. A typical yield from 1 liter of E. coli culture was approximately 50 mg, amounting to nearly 25% of the total cell protein.

To achieve expression of recombinant 30 kDa protein in its full-length or truncated version, constructs in pET22b were expressed in E. coli BL21(DE3)pLysS upon induction with 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG). Samples of 25 induced cultures were taken at hourly intervals for up to 8 hours and aliquots of the culture supernatants and cell pellets were run on 12.5% denaturing polyacrylamide gels and stained with Coomassie brilliant blue R. Recombinant protein was purified as described by Horwitz et al. ("Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis,'''' Proc. 30 Natl. Acad. Sci. USA 92:1530-1534, 1995), with the exception that all chromatography steps included the addition of 8 M urea to the buffers. The purified recombinant protein was dialyzed against phosphate buffered saline and remained soluble.

The mature 30 kDa protein was expressed in the pET22b vector either with its own or the plasmid encoded pelB leader peptide. The results of the 35 electrophoresis of the cell pellets are shown in Figure 14. Lanes A and B show WO 96/37219 PCT/US96/07781 90 Coomassie stained protein extracts upon IPTG induction of bacteria carrying the pET22b vector with the mature 30 kDa protein gene fused to the pelB leader DNA sequence (A) and the pET22b vector with the full-length 30 kDa protein gene (B). Lane C shows mature 30 kDa protein isolated from M. tuberculosis culture filtrates as a 5 reference. Lanes D, E, and F show a Western blot analysis of the same proteins as in A, B, and C probed with anti-30/32A-B kDa complex specific antibodies. Lane G, protein extract from E. coli cultures carrying the pET22b vector alone, probed with the same antibodies. Positions of full-length and mature 30 kDa proteins are marked 30W and 30M, respectively, and these recombinant proteins are further identified by their first 5 10 or 7 N-terminal amino acids. Numbers on the left refer to molecular mass standards in kDa.

EXAMPLE 27 Expression Of Soluble, Processed, Extracellular, M. tuberculosis 30 kda major secretory protein using the Plasmid PSMT3 in Mycobacterium smegmatis and Mycobacterium vaccae This example is directed to demonstrating the expression and secretion of the M. tuberculosis 30 kDa major secretory protein in a mycobacterium. We used 20 the pSMT3 plasmid (Dr. Douglas B. Young, Dept. Medical Microbiology, St. Mary's Hospital Medical School, Norfolk Place, London, W2 IPG, United Kingdom, a 5.7 kb (kilo base pairs) plasmid with both E. coli (column El ori) and mycobacterium (Mycobacterium fortuitum plasmid pAL5000 ori) origins of replication, a hygromycin resistance marker, a hsp60 promoter (Mycobacterium bovis BCG heat shock protein 25 promoter sequence), and a multicloning site downstream of the hsp60 promoter. The expression system is shown diagrammatically in Figure 15.

The insert consisted of a 4.7 kb HinDIII - BamHI genomic DNA fragment from M. tuberculosis Erdman strain containing the sequence for the 30 kDa protein. The insert was cloned into pSMT3 in E. coli DH5a and recombinant plasmid 30 DNA was transformed into M. smegmatis l-2c and M. vaccae R877R (National Collection of Type Cultures (NCTC) 11659) by electroporation at a setting of 6250 V/cm and 25 mFarad. M. smegmatis l-2c is a cured isolate of strain M. smegmatis mc26, which is a single cell isolate of ATCC 607 (American Type Culture Collection) which was prepared from M. smegmatis mc26 by the procedure described in Zhang 35 etal., Molecular Microbiology 5(2):381-391, 1991. M. smegmatis mc26 was isolated from ATCC 607 by the procedure described in Jacobs et al., Nature 327:532-535, 1987. 91 Using 1 mg of recombinant plasmid DNA and approximately 4 x 109 CFU of Mycobacteria, this method yielded 100-200 hygromycin-resistant transformants. The transformants were stable in broth culture and constitutively expressed the M. tuberculosis 30 kDa protein, yielding approximately 10 mg processed protein/L of 5 culture. Most importantly, the protein was soluble and approximately 90% of the expressed protein was secreted in the culture supernatant (see Figure 16).

The electrophoresis results shown in Figure 16 were obtained as follows. Supernatant fluid from each of 5 recombinant M. smegmatis clones containing the pSMT3 construct with the M. tuberculosis 30 kDa gene was subjected to SDS-PAGE 10 (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) analysis (5 rightmost lanes). The major protein (arrow in Figure 16) is the recombinant mature M. tuberculosis 30 kDa major secretory protein. The left most lane depicts molecular mass standards (66, 45, 36, 29, 24, 20, 14 kDa). The recombinant protein migrates just above the 29 kDa marker.

Western blot analysis was used to confirm that the major extracellular protein in the culture supernatant was the recombinant mature M. tuberculosis 30 kDa major secretory protein. The results are shown in Figure 17. In Figure 17, the proteins depicted in the four rightmost lanes of Figure 16 were subjected to SDS-PAGE and blotted onto nitrocellulose (4 rightmost lanes). The blot was probed with rabbit 20 polyclonal antibody specific to the M. tuberculosis 30/32 kDa protein complex. Only the recombinant M. tuberculosis 30 kDa protein is stained (arrow). The lane to the left contains prestained molecular mass markers (106, 80, 49.5, 32.5, 27.5, and 18.5 kDa). The recombinant protein migrates between the 32.5 and 27.5 kDa mass standards.

In addition, N-terminal sequence analysis of the first 6 N-terminal amino 25 acids yielded FSRPGL, confirming that the N-terminal sequence was identical to that of the mature M. tuberculosis 30 kDa protein.

Two constructs in pET20 (Novagen, Madison, WI), one for the mature 30 kDa protein and the other for the 32A kDa protein, failed to yield expression of either protein in E. coli. The isolation of pKK233 is described by Amann and Brosius, 30 Gene 40:183-190, 1985. pTrc99A (Pharmacia Biotech, Sweden) may be used in place of the pKK233 vector. Three different constructs in pKK233 - one for the full-length 30 kDa protein, one for the full-length 32 kDa protein, and one for the mature 30 kDa protein - failed to yield expression of any of the proteins in E. coli.

One construct in pRSET-A for the mature 30 kDa protein yielded a 35 fusion protein in E. coli, but the 30 kDa protein could not be cleaved free of this fusion protein with enterokinase. Similarly, two constructs in pTrx-Fus, one for the mature 30 92 kDa protein and one for the mature 32 kDa protein, yielded fusion proteins in E. coli from which the M. tuberculosis proteins could not be efficiently cleaved with enterokinase. A summary of the suitability of various expression systems is set forth in Table AA. All of the inserts are for the 32A kDa protein. 93 3 H -J CQ < H g?£ x 3 a. c -? -S CO © s g> 8 •i 2 4> £ u ~ £ .£ 3 % I o M 2 Z f M *-> + CD + 00 P 11 £ H a. s V.O CO o E VO +• CQ 2 a. vO O**-© o 8P &> 00 (0 > > ea o ra Cu e J1 "O f £ >> 3 ^ Q. -* © i c o C. ,52 'C M , O a. .2 "3* > J a.

ID Q w 3 CQ o. a> *§ LU 2 S — 3 PS J CQ w -£ 2 CQ *1 Q. O e 0d r- on 00 v> S £ t) — >» -J m LU ' D -J CQ © oe $ s 5 5 *i .5 ^ D si o ^ o 5 4 c s 5 -1 © " 2 o > < o -J u.

S* e < © < *7 u. rs rn £ < I > I [/) u 5 ■o £ o £ CB c« g I o > I on U 2 > 2 CQ 4 < P o m I £ UJ e H > S3 CQ 1 z © 2 c Cu U 2 Ui e H U o m f, U rs r*> f, P UJ a.

P UJ P UJ p UJ t o f, s c/3 H UJ u. e H u. e 93 3 W J m < H Comments 40% Processing F-L/mature/mature+2aa 90% Processing F-L/mature+2aa 50% Processing pelB+/mature/mature+2aa 60% Processing pelB+/mature/mature+2aa 90% Processing i 1 90% processing No EK cleavage mature+2aa % EK cleavage mature+2aa % EK cleavage mature+2aa Solubility/Yield insoluble (pellet) I mg/L; purified insoluble (pellet) 1 mg/L; purified i insoluble (pellet) 1 mg/L; purified insoluble (pellet) 1 mg/L; purified soluble (supernatant) soluble (supernatant) insoluble (pellet) not purified soluble (cytoplasm) not purified soluble (cytoplasm) not purified Expression Yes, no Fusion 100 mg/L | Yes, no Fusion 100 mg/L Yes, pelB-Fusion 120 mg/L Yes, pelB-Fusion 150mg/L No No No No Yes, no Fusion 10 mg/L Yes, no Fusion 10 mg/L Yes, Fusion 100 mg/L Yes, Trx-Fusion 50 mg/L It E E H o .. tr. io u >- £ c/5 h- CO o X BL21(DE3)/pLyS unstable J BL21 (DE3)/pLysS unstable BL21 (DE3)/pLysS unstable BL2 l(DE3)/pLysS unstable BL21 (DE3)/pLysS BL21 (DE3)/pLysS BL21(DE3)/pLyS BL21(DE3)/pLysS M. smegmatis I-2c M. vaccae R877R NCTC 11659 BL2I(DE3)/pLysS stable GI724 & GI698 stable in GI698 G1724 & GI698 stable in GI698 Junctions '-NdeI-ATG-30K(F-L)-TGA—N—EcoRI-Vector-3' -NdeI-ATG-32K(F-L)-TAG—N—EcoRI-Vector-3' rn ha Q U 4> > 2 0 u uj z < £ 1 o T U £ 8 jz; ca 1.

"C ■o Cn rn b* Q L) 0> > s o o u Z o < >7 s 2 > 2 0 O uj 1 1 U o 7 u ? Cn U. o 0 > 1 2 o o uj J o < 2 o 0 uj 1 < 0 *7 2" O m 1 o> 73 iz •h rn ha © T> 4> > 8 UJ 1 ? Si f-j- s u

Claims (6)

1. What is claimed is: 1. A DNA molecule containing a coding sequence comprising the amino acid sequence of M. tuberculosis 58 KD protein and fragments and derivatives thereof, wherein said coding sequence includes the sequence: 1 31 gtg ACG GAA AAG ACG CCC GAC GAC GTC TTC AAA CTT GCC AAG GAC GAG AAG GTC GAA TAT 61 91 GTC GAC GTC CGG TTC TGT GAC CTG CCT GGC ATC ATG CAG CAC TTC ACG ATT CCG GCT TCG 121 .151 GCC TTT GAC AAG AGC GTG TTT GAC GAC GGC TTG GCC TTT GAC GGC TCG TCG ATT CGC GGG 181 211 TTC CAG TCG ATC CAC GAA TCC GAC ATG TTG CTT CTT CCC GAT CCC GAG ACG GCG CGC ATC 241 271 GAC CCG TTC CGC GCG GCC AAG ACG CTG AAT ATC AAC TTC TTT GTG CAC GAC CCG TTC ACC 301 331 CTG GAG CCG TAC TCC CGC GAC CCG CGC AAC ATC GCC CGC AAG GCC GAG AAC TAC CTG ATC 361 391 AGC ACT GGC ATC GCC GAC ACC GCA TAC TTC GGC GCC GAG GCC GAG TTC TAC An TTC GAT 421 451 TCG GTG AGC TTC GAC TCG CGC GCC AAC GGC TCC TTC TAC GAG GTG GAC GCC ATC TCG GGG 481 511 TGG TGG AAC ACC GGC GCG GCG ACC GAG GCC GAC GGC AGT CCC AAC CGG GGC TAC AAG GTC 541 571 CGC CAC AAG GGC GGG TAT i i C CCA GTG GCC CCC AA.C GAC CAA TAC GTC GAC CTG CGC GAC 601 631 AAG ATG CTG ACC AAC CTG ATC AAC TCC GGC TTC ATC CTG GAG AAG GGC CAC CAC GAG GTG 661 691 GGC AGC GGC GGA CAG GCC GAG ATC AAC TAC CAG TTC AAT TCG CTG CTG CAC GCC GCC GAC 721 751 GAC ATG CAG i iG TAC AAG TAC ATC ATC AAG AAC ACC GCC TGG CAG AAC GGC AAA ACG GTC 781 • 811 ACG I iC ATG CCC AAG CCG CiG i iC GGC GAC AAC GGG TCC GGC ATG CAC TGT CAT CAG TCG 841 871 CiG iGG AAG GAC GGG GCC CCG CiG AiG TAC GAC GAG ACG GGT TAT GCC GGT C:G TCG GAC 901 931 ACG GCC CGT CAT TAC ATC GGC GGC CTG TTA CAC CAC GCG CCG TCG CTG CTG GCC TTC ACC 961 . 991 AAC CCG ACG GTG AAC TCC TAC AAG CGG CTG GTT CCC GGT TAC GAG GCC CCG ATC AAC CTG 1021 1051 GiC TAi AGu CAG CG<~ AAC Ccu iCu Gv^A iGC GiG CGC AiC CCG ATC ACC GGC AGC AA.C CCG 1081 1111 AAG GCl AAG CGG C i b GAG i i C CGA AGC CCC GAC i CG TCG GGC AAC CCG TAT CTG GCG i i C 1141 1171 TCG GCC ATG CTG ATG GCA GGC CTG GAC GGT ATC AAG AAC AAG ATC GAG CCG CAG GCG CCC intellectual property office of n.z. ' 1 MAR 2001 RECEIVED 150 //? U hf, 1201 1231 GTC GAC AAG GAT CTC TAC GAG CTG CCG CCG GAA GAG GCC GCG AGT ATC CCG CAG ACT CCG 1251 1291 ACC CAG CTG TCA GAT GTG ATC GAC CGT CTC GAG GCC GAC CAC GAA TAC CTC ACC GAA GGA 1321 1351 GGG GTG TTC ACA AAC GAC CTG ATC GAG ACG TGG ATC AGT TTC AAG CGC GAA AAC GAG ATC 1381 1411 GAG CCG GTC AAC ATC CGG CCG CAT CCC TAC GAA TTC GCG CTG TAC TAC GAC GTT taa, and respective analogs, homologs and subunits thereof wherein said fragments, derivatives, analogs, homologs and subunits thereof comprise at least 70% homology to said DNA molecule.
2. 2. An amino acid sequence encoded by the DNA molecule of claim 1.
3. 3. A vaccinating agent suitable for use in promoting an effective immune response, in a mammalian host, against an infectious pathogen from the genus Mycobacterium, said vaccinating agent comprising: a DNA construct including a DNA sequence of the formula: 1 31 gtg ACG GAA AAG ACG CCC GAC GAC GTC TTC AAA CTT GCC AAG GAC GAG AAG GTC GAA TAT 61 91 GiC GAC GTC CGG TTC iGi GAC C i G CCT GGC ATC ATG CAG CAC TTC ACG ATT CCG GCi TCG 121 151 GCC TTT GAC AAG AGC GiG TTT GAC GAC GGC i iG GCC TTT GAC GuC TCG TCG ATT CGC GGG 181 211 TTC CAG TCG ATC CAC GAA TCC GAC ATG TTG CTT CCC GAT rrr GAG ACG GCG CGC ATC 241 271 GAC CCG TTC CGC GCG GCC AA.G ACG CTG AAT ATC AAC TTC TTT GTG CAC GAC CCG i i u AC1- 301 T71 ww * CTG GAG CCG TAC TCC CGC GAC CCG CGC AAC ATC GCC CGC AAG GCC GAG AAC TAC CTG ATC 361 3S1 AGC ACi GGC AiC GCC GAC ACC GCA TAC TTC GGC GCC GAG GCC GAG TTC TAC ATT TTC GAT 421 451 TCG GiG AGC TTC GAC TCG CGC GCC AAC GGC TCC TTC TAC GAG GTG GAC GCC A i o iCG GGG 481 511 TGG TGG AAC ACC GGC GCG GCG ACC GAG GCC GAC GGC AGT CCC AAC CGG GGC TAC AAG GTC 541 571 CGC CAC AAG GGC GGG 1Ai TTC CCA GTG GCC CCC AAC GAC CAA TAC GTC GAC CTG 601 631 AAG ATG CTG ACC AAC CTG ATC AAC TCC GGC i iC ATC C i G GAG AAG GGC CAC CAC GAG GTG 661 691 GGC AGC GGC GGA CAG GCC GAG ATC AAC TAC CAG TTC AAT TCG CTG CTG CAC GCC GCC GAC intellectual property office of n.z. ~ 1 MAR 2001 RECEIVED 151 721 751 GAC ATG CAG nG TAC AAG TAC ATC ATC AAG AAC ACC GCC TGG CAG AAC GGC AAA ACG GTC 781 811 ACG TTC ATG CCC AAG CCG CTG TTC GGC GAC AAC GGG TCC GGC ATG CAC TGT CAT CAG TCG 841 871 CTG TGG AAG GAC GGG GCC CCG CTG ATG TAC GAC GAG ACG GGT TAT GCC GGT CTG TCG GAC 901 931 ACG GCC CGT CAT TAC ATC GGC GGC CTG TTA CAC CAC GCG CCG TCG CTG CTG GCC TTC ACC 961 991 AAC CCG ACG GTG AAC TCC TAC AAG CGG CTG GTT CCC GGT TAC GAG GCC CCG ATC AAC CTG 1021 1051 GTC TAT AGC CAG CGC AAC CGG TCG GCA TGC GTG CGC ATC CCG ATC ACC GGC AGC AAC CCG 1081 1111 AAG GlC AAG CGG CiG GAG TTC CGA AGC CCC GA.C TCG TCG GGC AAC CCG sAT CTG GCG i iC 1141 1171 TCG GCC ATG CTG ATG GCA GGC CTG GAC GGT ATC AAG AAC AAG ATC GAG CCG CAG GCG CCC 1201 1231 GTC GAC AAG GAT CTC TAC GAG CTG CCG CCG GAA GAG GCC GCG AGT ATC CCG CAG ACT CCG 1261 1291 ACC CAG CTG TCA GAT GTG ATC GAC CGT CTC GAG GCC GAC CAC GAA TAC CTC ACC GAA GGA 1321 1351 GGG GTG TTC ACA AAC GAC CTG ATC GAG ACG TGG ATC AGT TTC AAG CGC GAA AAC GAG ATC 1381 1411 GAG CCG GTC AAC ATC CGG CCG CAT CCC TAC GAA TTC GCG CTG TAC TAC GAC GTT taa,. and respective analogs, homologs and subunits thereof having at least 70% homology to said DNA sequence, and capable of of inducing the expression of said extracellular product upon in vivo introduction into and resultant uptake by cells of said mammalian host.
4. 4. A use of a nucleic acid construct including a nucleic acid encoding a 58 KD protein of M. tuberculosis which includes a DNA sequence of the formula: 1 31 gtg ACG GAA AAG ACG CCC GAC GA.C GTC TTC AAA CTT GCC AAG GAC GAG AAG GTC GAA TAT 61 91 GTC GAC GTC CGG TTC TGT GAC CTG CCT GGC ATC ATG CAG CAC TTC ACG ATT CCG GC i TCG 121 151 GCC TTT GAC AAG AGC GTu 11 i GAC GAC Guv- i iG GLL TTT GAC Gut Tllj IC'j AI I C^I~ Guu 181 211 TTC CAG TCG ATC CAC G.M TCC GAC ATG TTG CTT CTT CCC GAT CCC GAG ACG GCG CGC AiC 241 271 GAC CCG TTC CGC GCG GCC AAG ACG CTG AAT ATC AAC TTC TTT GTG CAC GAC CCG i i C ACC 301 331 CTG GAG CCG TAC TCC CGC GAC CCG CGC AA.C ATC GCC CGC AAG GCC GAG AAC TAC CTG ATC 361 391 _ AGC ACT GGC ATC GCC GAC ACC GCA TAC TTC GGC GCC GAG GCC GAG TTC TAC An TTC GAi 421 451 TCG GTG AGC TTC GAC TCG CGC GCC AAC GGC TCC TTC TAC GAG GTG GAC GCC ATC TCG GGG 481 511 TGG TGG AAC ACC GGC GCG GCG ACC GAG GCC GA.C GGC AGT CCC AAC CGG GGC TAC AAG GTC intellectual property office of n.z. ~ 1 mar 2001 n c p c i \( c n 152 30 541 571 CGC CAC AAG GGC GGG TAT TTC CCA GTG GCC CCC AAC GAC CAA TAC GTC GAC CTG CGC GAC 601 631 AAG ATG CTG ACC AAC CTG ATC AAC TCC GGC TTC ATC CTG GAG AAG GGC CAC CAC GAG GTG 661 691 GGC AGC GGC GGA CAG GCC GAG ATC AAC TAC CAG ~C AAT TCG CTG CTG CAC GCC GCC uAC 721 751 GAC ATG CAG TTG TAC AAG TAC ATC ATC AAG AAC ACC GCC TGG CAG AAC GGC AAA ACG GTC 781 811 ACG TTC ATG CCC AAG CCG CTG TTC GGC GAC AAC GGG TCC GGC ATG CAC TGT CAT CAG TCG 841 871 CTG TGG AAG GAC GGG GCC CCG CTG ATG TAC GAC GAG ACG GGT TAT GCC GGT CTG TCG GAC 901 931 ACG GCC CGT CAT TAC ATC GGC GGC CTG TTA CAC CAC GCG CCG TCG CTG CTG GCC TTC ACC 961 991 AAC CCG ACG GTG AAC TCC TAC AAG CGG CTG GTT CCC GGT TAC GAG GCC CCG ATC AAC CTG 1021 1051 GTC TAT AGC CAG CGC AAC CGG TCG GCA TGC GTG CGC ATC CCG ATC ACC GGC AGC AAC CCG 1081 1111 AAG GCC AAG CGG CTG GAG TTC CGA AGC CCC GAC TCG TCG GGC AAC CCG TAT CTG GCG TTC 1141 1171 TCG GCC ATG CTG ATG GCA GGC CTG GAC GGT ATC AAG AAC AAG ATC GAG CCG CAG GCG CCC 1201 1231 GTC GAC AAG GAT CTC TAC GAG CTG CCG CCG GAA GAG GCC GCG AGT ATC CCG CAG ACT CCG 1261 1291 ACC CAG CTG TCA GAT GTG ATC GAC CGT CTC GAG GCC GAC CAC GAA TAC CTC ACC GAA GGA, 1321 1351 GGG GTG TTC ACA AAC GAC CTG ATC GAG ACG TGG ATC AGT TTC AAG CGC GAA AAC GAG ATC 1381 1411 GAG CCG GTC AAC ATC CGG CCG CAT CCC TAC GAA TTC GCG CTG TAC TAC GAC GTT taa, and respective analogs, homologs, and subunits thereof having at least 70% homology to said DNA sequence, and capable of inducing the expression of said extracellular product upon in vivo introduction and resultant uptake by mammalian host cells, in the manufacture of a medicament for immunizing a mammalian host against infectious pathogen of the genus Mycobacterium. acid sequence ofM tuberculosis 23.
5. 5 KD protein, wherein said coding sequence includes the sequence: 5. A DNA molecule containing a coding sequence comprising the amino intellectual property office of n.z. " 1 MAR 2001 RECEIVED 153 3 1 31 gtg CGC ATC AAG ATC TTC ATG CTG GTC ACG GCT GTC GTT TTG CTC TGT TGT TCG GST GTG 61 91 GCC ACG GCC GCG CCC AAG ACC TAC TGC GAG GAG TTG AAA GGC ACC GAT ACC GGC CAG GCG 121 151 TGC CAG ATT CAA ATG TCC GAC CCG GCC TAC AAC ATC AAC ATC AGC CTG CCC AGT TAC TAC lai 211 CCC GAC CAG AAG TCG CTG GAA AAT TAC ATC GCC CAG ACG CGC GAC AAG TTC CTC AGC GCG 241 271 GCC ACA TCG TCC ACT CCA CGC GAA GCC CCC TAC GAA TTG AAT ATC ACC TCG GCC ACA TAC 301 331 CAG TCC GCG ATA CCG CCG CGT GGT ACG CAG GCC GTG GTG CTC AAG GTC TAC CAG AAC GCC 361 391 GGC GGC ACG CAC CCA ACG ACC ACG TAC AAG GCC TTC GAT TGG GAC CAG GCC TAT CGC AAG 421 451 CCA ATC ACC TAT GAC ACG CTG TCG CAG GCT GAC ACC GAT CCG CTG CCA GTC GTC TTC CCC 481 511 ATT GTG CAA GGT GAA CTG AGC AAG CAG ACC GGA CAA CAG GTA TCG ATA GCG CCG AAT GCC 541 571 GGC TTG GAC CCG GTG AAT TAT CAG AAC TTC GCA GTC ACG AAC GAC GGG GTG ATT TTC TTC 601 631 TTC C AAC CCG GGG GAG nG CTG CCC GAA GCA GCC GGC CCA ACC CAG GTA TTG GTC CCA CGT 001 TCC GCG ATC GAC TCG ATG CTG GCC tag, r and fragments and derivatives thereof having at least 70% homology to said DNA sequence.
6. 6. The vaccinating agent of claim 3 wherein said DNA construct includes at least a portion of a DNA sequence of the formula: 1 31 gtg CGC ATC AAG ATC nc ATG CTG GTC ACG GCT GTC Gn nG CTC TGT TGT TCG GST G i G 61 91 GCC ACG GCC GCG CCC AAG ACC TAC TGC GAG GAG nc AAA. GGC ACC GAT ACC GGC CAG GCG 121 151 TGC CAG An CAA ATG TCC GAC CCG GCC TAC AAC ATC AA.C ATC AGC CTG CCC AGT TAC TAC 181 211 CCC GAC CAG AAG TCG C i G GAA AAT TAC ATC GCC CAG ACG CGC GAC AAG nc C i c AGC GCG 241 271 GCC ACA TCG TCC ACT CCA CGC GAA GCC CCC TAC GAA nc AAT ATC ACC i CG GC- ACA TAC 301 331 CAG TCC GCG ATA CCG CCG CG i GGT ACG CAG GCC GTG GTG CTC AAG GTC TAC CAG AAC GCC 361 391 GGC GGC ACG CAC CCA ACG ACC ACG TAC AAG GCC nc GAT TGG GAC CAG nr^r-UL'w TAT CGC AAG 421 451 CCA ATC ACC TAT GAC ACG CTG TCG CAG GCT GA.C ACC GAT CCG CTG CCA G i C GTC nc CCC 481 511 An GTG CAA •GGT GAA CTG AGC AAG CAG ACC GGA CAA CAG GTA TCG ATA GCG CCG AAT GCC 541 571 GGC nG GAC CCG GTG AAT TAT CAG aac nc GCA GTC ACu AAC GAC ggg GTG An nc nc 601 631 nc AAC CCG UUU GAG nG CTG CCC GAA GCA GCC GGC CCA ACC CAG GTA nG GTC CCA CGT 661 TCC GCG ATC GAC TCG ATG CTG GCC tag. INTELLECTUAL PROPERTY office of n.z. ~ 1 MAD onni 154 3 7. The use of claim 4 wherein said nucleic acid construct includes a DNA sequence of the formula: ~l 31 gtg CGC ATC MG ATC TTC ATG CTG GTC ACG GCT GTC GTT TTG CTC TGT TGT TCG GST GTG 61 ■ 91 GCC ACG GCC GCG CCC AAG ACC TAC TGC GAG GAG TTG AAA GGC ACC GAT ACC GGC CAG GCG 121 151 TGC CAG ATT CAA ATG TCC GAC CCG GCC TAC AAC-ATC AAC ATC AGC CTG CCC AGT TAC TAC 181 211 CCC GAC CAG AAG TCG CTG GAA AAT TAC ATC GCC CAG ACG CGC GAC AAG TTC CTC AGC GCG 241 271 GCC ACA TCG TCC ACT CCA CGC GAA GCC CCC TAC GAA TTG AAT ATC ACC TCG GCC ACA TAC 301 331 ■CAG TCC GCG ATA CCG CCG CGT GGT ACG CAG GCC GTG GTG CTC AAG GTC TAC CAG AAC GCC 361 391 GGC GGC ACG CAC CCA ACG ACC ACG TAC AAG GCC TTC GAT TGG GAC CAG GCC TAT CGC AAG 421 451 CCA ATC ACC TAT GAC ACG CTG TCG CAG GCT GAC ACC GAT CCG CTG CCA GTC GTC TTC CCC 431 511 ATT GTG CAA GGT GAA CTG AGC AAG CAG ACC GGA CAA CAG GTA TCG ATA GCG CCG AAT GCC 541 571 GGC TTG GAC CCG GTG AAT TAT CAG AAC TTC GCA GTC ACG AAC GAC GGG GTG ATT TTC TTC 601 631 TTC AAC CCG GGG GAG TTG CTG CCC GAA GCA GCC GGC CCA ACC CAG GTA TTG GTC CCA CGT 661 TCC GCG ATC GAC TCG ATG CTG GCC tag. 8. A DNA molecule containing a coding sequence comprising the amino acid sequence of M. tuberculosis 24 KD protein, wherein said coding sequence includes the sequence: 1 31 ATG AAG GGT CGG TCG GCG CTG CTG CGG GCG CTC TGG ATT GCC GCA CTG TCA TTC GGG'* i i G 61 91 GGC GGT GTC GCG GTA GCC GCG GAA CCC ACC. GCC AAG GCC GCC CCA TAC GA.G AAC CiG AiG 121 151 GTG CCG TCG CCC TCG ATG GGC CGG GAC ATC CCG GTG GCC nc CTA GCC GGT GGG CCb CAC 181 211 GCG GTG TAT CTG CTG GAC GCC TTC AAC GCC GGC CCG GAT GTC AGT AAC TGG GTC ACC GCG 241 271 GGT AAC GCG ATG AAC ACG TTG GCG.GGC AAG GGG ATT TCG GTG GTG GCA CCG GCC GGT GGT 301 331 GCG TAC AGC ATG TAC ACC AAC TGG GAG CAG GAT nnn AGC AAG CAG TGG GAC ACC TTC TTG 361 391 TCC GCT GAG CTG CCC GAC TGG CTG GCC GCT AAC CGG GGC TTG GCC CCC GG i GGC CAi GCG 421 451 GCC Gii GGC GCC GCT CAG GGC GGT TAC GGG GCG ATG GCG CTG GCG GCC TTC CAC CCC GAC 481 511 CGC TTC GGC TTC GCT GGC TCG AiG TCG GGC TTT TTG TAC CCG TCG AAC ACC ACC ACC AAC 541 571 GGT GCG ATC GCG GCG GGC ATG CAG CAA TTC GGC GGT GTG GAC ACC AAC GGA ATG TGG GGA INTELLECTUAL PROPERTY OFFICE OF N.Z. - 1 MAR 2001 155 601 - 631 30 9 9 4 GCA CCA CAG CTG GGT CGG TGG AAG TGG CAC GAC CCG TGG GTG CAT GCC AGC CTG CTG GCG 661 691 CAA AAC AAC ACC CGG GTG TGG GTG TGG AGC CCG ACC AAC CCG GGA GCC AGC GAT CCC GCC 721 751 GCC ATG ATC GGC CAA GCC GCC GAG GCG ATG GGT AAC AGC CGC ATG TTC TAC AAC CAG TAT 781 811 CGC AGC GTC GGC GGG CAC AAC GGA CAC TTC GAC TTC CCA GCC AGC GGT GAC AAC GGC TGG 841 871 GGC TCG TGG GCG CCC CAG CTG GGC GCT ATG TCG GGC GAT ATC GTC GGT GCG ATC CGC taa, and fragments and derivatives thereof having at least 70% homology to said DNA sequence. 9. An amino acid sequence encoded by the DNA molecule of claim 8. 10. The vaccinating agent of claim 3 wherein said DNA construct includes a DNA sequence of the formula: 1 31 ATG AAG GGT CGG TCG GCG CiG CiG CGG GCG CTC TGG Ai i GCC GCA CTG TCA TTC GGG i iG 61 91 GGC GGT GTC GCG GTA GCC GCG GAA. CCC ACC GCC AAG GCC GCC CCA TAC GAG AA.C CTG ATG 121 151 GTG CCG TCG CCC TCG ATG GGC CGG GAC ATC CCG GTG GCC iiC CiA GCC GGi GGG CCG CAC 181 211 GCG GTG TAT CTG CTG GAC GCC TTC AAC GCC GGC CCG GAT GTC AGT AAC TGG GTC ACC GCG 241 271 GGT AAC GCG ATG AAC ACG TTG GCG GGC AAG GGG Ai i TCG GTG GTG GCA CCG GCC GGT GGT 301 331 GCG TAC AGC ATG TAC ACC AAC TGG GAG CAG GAT GGC AGC AAG CAG TGG GAC ACC TTC TTG 361 391 TCC GCT GAG CTG CCC GAC TGG CTG GCC GCT AAC CGG GGC TTG GCC CCC GGT GGC CAT GCG 421 451 GCC GTT GGC GCC GCT CAG GGC GGT TAC GGG GCG ATG GCG CTG GCG GCC TTC CAC CCC GAC 481 511 CGC TTC GGC TTC GCT GGC TCG ATG TCG GGC TTT TTG TAC CCG TCG AAC ACC ACC ACC AAC 541 571 GGT GCG A i C GCG GCG GGC ATG CAG CAA 11C GGC GG I GTG GAC ACC AAC GGA A i G TGG GGA 601 631 GCA CCA CAG CTG GGT CGG TGG AAG TGG CAC GAC CCG TGG GTG CAT GCC AGC CTG CTG GCG 661 691 CAA AAC AAC ACC CGG GTG TGG GTG TGG AGC CCG ACC AAC CCG GGA GCC AGC GAT CCC GCC . 721 751 GCC ATG ATC GGC CAA GCC GCC GAG GCG ATG GGT AAC AGC CGC ATG TTC TAC AAC CAG TAT 781 811 CGC AGC GTC GGC GGG CAC AAC GGA CAC TTC GAC TTC CCA GCC AGC GGT GAC AAC GGC TGG 841 871 GGC TCG TGG GCG CCC CAG CTG GGC GCT ATG TCG GGC GAT ATC GTC GGT GCG ATC CGC taa. intellectual property office of n.z. ~ 1 MAR 2001 RECEIVED WO 96/37219 PCT/US96/07781 156 11. The use of claim 4 wherein said nucleic acid construct includes a DNA sequence of the formula: ATG AAG GGT CGG TCG GCG CTG CTG CGG GCG CTC TGG ATT GCC GCA CTG TCA TTC GGG TTG 61 91 GGC GGT GTC GCG GTA GCC GCG GAA CCC ACC GCC AAG GCC GCC CCA TAC GAG AAC CTG ATG 121 151 GTG CCG TCG CCC TCG ATG GGC CGG GAC ATC CCG GTG GCC TTC CTA GCC GGT GGG CCG CAC 181 211 GCG GTG TAT CTG CTG GAC GCC TTC AAC GCC GGC CCG GAT GTC AGT AAC TGG GTC ACC GCG 241 271 GGT AAC GCG ATG AAC ACG TTG GCG GGC AAG GGG ATT TCG GTG GTG GCA CCG GCC GGT GGT 301 331 GCG TAC AGC ATG TAC ACC AAC TGG GAG CAG GAT GGC AGC AAG CAG TGG GAC ACC TTC TTG 361 391 TCC GCT GAG CTG CCC GAC TGG CTG GCC GCT AAC CGG GGC TTG GCC CCC GGT GGC CAT GCG 421 451 GCC GTT GGC GCC GCT CAG GGC GGT TAC GGG GCG ATG GCG CTG GCG GCC TTC CAC CCC GAC .481 511 CGC TTC GGC TTC GCT GGC TCG ATG TCG GGC TTT TTG TAC CCG TCG AAC ACC ACC ACC AAC 541 571 GGT GCG ATC GCG GCG GGC ATG CAG CAA TTC GGC GGT GTG GAC ACC AAC GGA ATG TGG GGA 601 631 GCA CCA CAG CTG GGT CGG TGG AAG TGG CAC GAC CCG TGG GTG CAT GCC AGC CTG CTG GCG 661 691 CAA AAC AAC ACC CGG GTG TGG GTG TGG AGC CCG ACC AAC CCG GGA GCC AGC GAT CCC GCC 721 751 GCC ATG ATC GGC CAA GCC GCC GAG GCG ATG GGT AAC AGC CGC ATG TTC TAC AAC CAG TAT 781 811 CGC AGC GTC GGC GGG CAC AAC GGA CAC TTC GAC TTC CCA GCC AGC GGT GAC AAC GGC TGG 841 871 GGC TCG TGG GCG CCC CAG CTG GGC GCT ATG TCG GGC GAT ATC GTC GGT GCG ATC CGC taa. 12. A DNA molecule containing a coding sequence comprising the amino acid sequence of M. tuberculosis 16 KD protein and fragments and derivatives thereof having at least 70% homology to said amino acid sequence, comprising 1 31 intellectual property office of n.z. ■ 1 MAR 2001 RECEIVED WO 96/37219 PCT/US96/07781 said coding sequence includes the sequence: 1/1 31/11 ATG GCG GCC ATC GCG ACC TTT GCG GCA CCG GTC GCG TTG GCT Met ala ala ile ala thr phe ala ala pro val ala leu ala 61/21 GCC TAT CCC ATC ACC GGA AAA CTT GGC AGT GAG CTA ACG ATG ala tyr pro ile thr gly lys leu gly ser glu leu thr met 91/31 121/41 ACC GAC ACC GTT GGC CAA GTC GTG CTC GGC TGG AAG GTC AGT thr asp thr val gly gin val val leu gly trp lys val ser 151/51 GAT CTC AAA TCC AGC ACG GCA GTC ATC CCC GGC TAT CCG GTG asp leu lys ser ser thr ala val ile pro gly tyr pro val 181/61 GCC GGC CAG GTC TGG"GAG GCC ACT GCC ACG GTC AAT GCG ATT ala gly gin val trp glu ala thr ala thr val asn ala ile 211/71 241/81 CGC GGC AGC GTC ACG CCC GCG GTC TCG CAG TTC AAT GCC CGC arg gly ser val thr pro ala val ser gin phe asn ala arg 271/91 ACC GCC GAC GGC ATC AAC TAC CGG GTG CTG TGG CAA GCC GCG thr ala asp gly ile asn tyr arg val leu trp gin ala ala 301/101 331/111 GGC CCC GAC ACC ATT AGC GGA GCA CTA TCC CCC AAG GCG AAC gly pro asp thr ile ser gly ala leu ser pro lys ala asn 361/121 AAT CGA CCG GAA AAT CTA CTT CGA TGT CAC CGG CCC ATC GCC asn arg pro glu asn leu 391/131 leu arg cys his arg pro ile ala AAC CAT CGT CGC GAT GAA CAA CGG ATG GAG GAT CTG CTG ATT asn his arg arg asp glu gin arg met glu asp leu leu ile 421/141 TGG GAG CCG TAG trp glu pro amb. 13. An amino acid sequence encoded by the DNA molecule of claim 12. 14. The vaccinating agent of claim 3 wherein said DNA construct includes a DNA sequence of the formula: 1/1 31/11 ATG GCG GCC ATC GCG ACC TTT GCG GCA CCG G i C GCG nG GCT Met ala ala ile ala thr phe ala ala pro val ala leu ala 61/21 GCC TAT CCC ATC ACC GGA AAA CTT GGC AG i GAG CTA ACG ATG ala tyr pro ile thr gly lys leu gly ser glu leu thr met 91/31 121/41 ACC GAC ACC GTT GGC CAA GTC GTG CTC GGC TGG AAG GTC AGT thr asp thr val gly gin val val leu gly trp lys val ser 151/51 GAT CTC AAA TCC AGC ACG GCA GTC ATC CCC GGC TAT CCG GTG asp leu lys ser ser thr ala val ile pro giy tyr pro val intellectual property office of n.z. ~ 1 MAR 2001 RECEIVED WO 96/37219 PCT/US96/07781 158 181/61 GCC GGC CAG GTC TGG GAG GCC ACT GCC ACG GTC MT GCG ATT ala gly gin val trp glu ala thr ala thr val asn ala ile 211/71 241/81 CGC GGC AGC GTC ACG CCC GCG GTC TCG CAG TTC MT GCC CGC arg gly ser val thr pro ala val ser gin phe asn ala arg 271/91 ACC GCC GAC GGC ATC MC TAC CGG GTG CTG TGG CM GCC GCG thr ala asp gly ile asn tyr arg val leu trp gin ala ala 301/101 331/111 GGC CCC GAC ACC ATT AGC GGA GCA CTA TCC CCC MG GCG MC gly pro asp thr ile ser gly ala leu ser pro lys ala asn 361/121 MT CGA CCG GM MT CTA CTT CGA TGT CAC CGG CCC ATC GCC asn arg pro glu asn leu leu arg cys his arg pro ile ala 391/131 MC CAT CGT CGC GAT GM CM CGG ATG GAG GAT CTG CTG ATT asn his arg arg asp glu gin arg met glu asp leu leu ile 421/141 TGG GAG CCG TAG trp glu pro AMB 15. The use of claim 4 wherein said nucleic acid construct includes a DNA sequence of the formula: 1/1 ATG GCG GCC ATC GCG Met ala ala ile ala GCC TAT CCC ATC ACC ala tyr pro ile thr 91/31 ACC GAC ACC GTT GGC thr asp thr val gly ACC TTT GCG thr phe ala 61/21 GGA AM CTT gly lys leu CM GTC GTG gin val val GAT CTC asp leu GCC GGC ala gly 211/71 CGC GGC arg gly ACC GCC thr ala GGC CCC gly pro AM TCC AGC ACG GCA GTC lys ser ser thr ala val 181/61 CAG GTC TGG GAG GCC ACT gin val trp glu ala thr AGC GTC ACG ser val thr GAC GGC ATC asp gly ile 301/101 GAC ACC ATT asp thr ile CCC GCG GTC pro ala val 271/91 MC TAC CGG asn tyr arg AGC GGA GCA ser gly ala MT CGA CCG GM MT CTA CTT CGA asn arg pro glu asn leu leu-arg 31/11 GCA CCG GTC GCG ala pro val ala GGC AGT GAG CTA gly ser glu leu CTC GGC TGG MG leu gly trp lys 151/51 ATC CCC GGC TAT ile pro gly tyr GCC ACG GTC AAT ala thr val asn 241/81 TCG CAG TTC MT ser gin phe asn GTG CTG TGG CM val leu trp gin CTA TCC CCC MG leu ser pro lys 361/121 TGT CAC CGG CCC cys his arg pro TTG GCT leu ala ACG ATG thr met 121/41 GTC AGT val ser CCG GTG pro val GCG ATT ala ile GCC CGC ala arg GCC GCG ala ala 331/111 GCG MC ala asn ATC GCC ile ala intellectual property office of n.z" 1 MAR 2001 RECEIVED WO 96/37219 PCT/TJS96/07781 ^ 159 391Z131 AAC CAT CGT CGC GAT GAA CAA CGG ATG GAG GAT CTG CTG ATT asn his arg arg asp glu gin arg met glu asp leu leu ile 421/141 TGG GAG CCG TAG trp glu pro amb. 16. A vaccinating agent suitable for use in promoting an effective immune response, in a mammalian host, against an infectious pathogen from the genus Mycobacterium, said vaccinating agent comprising: at least one immunodominant epitope of at least one majorly abundant extracellular product selected from the group consisting of Mtuberculosis 30 KD protein subunits having the amino acid sequences FSRPGLPVEYLQVPS (Seq ID No:37), LPVEYLQVPSPSMGR (Seq ID No:38), LQVPSPSMGRDIKVQ (Seq ID No:39), DIKVQFQSGGNNSPA (Seq ID No:41), FQSGG NNSPAV Y L L D (Seq ID No:42), YYQSGLSIVMPVGGQ (Seq ID No:49), L T S E L P Q WLSANRAV (Seq ID No:57), SMAGSSAMILAAYHP (Seq ID No:62), S A M ILAAYHPQQFIY (Seq ID No:63), ALLDPSQGMGPSLIG (Seq ID No:67), PSLIGLAMGDAGGYK (Seq ID No:69), AADMWGPSSDPAWER (Seq ID No:72), GPSSDPAWERNDPTQ (Seq ID No:73), VANNTRL WV YCGN G T (Seq ID No:77), GANIPAEFLENFVRS (Seq ID No:81), QDAYNAAGG H N A V F N (Seq ID No:85), THS WE Y WGAQLN AMK (Seq ID No:89), and respective analogs, homologs, and subunits thereof including single or multiple amino acid substitutions, deletions, insertions, and inversions wherein said analogs, homologs and subunits have at least 70% homology to said amino acid sequence. 17. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence FSRPGLPVEYLQV PS (Seq ID No:37), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequenceintellectual property office of n.z" 1 mar 2001 received WO 96/37219 PCT/US96/07781 160 18. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence LPVEYLQVPSPSMGR (Seq ID No:38), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 19. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence LQVPSPSMGRDIKVQ (Seq ID No:39), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 20. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence DIKVQFQSGGNNSPA (Seq ID No:41), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 21. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence FQSGGNNSPAVYLLD (Seq ID No:42), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 22. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence YYQSGLSIVMPV GGQ (Seq ID No:49), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 23. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence LTSELPQWLSANRAV (Seq ID No:57), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 24. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence SMAGSSAMILAAYHP (Seq ID No:62), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequenceintellectual property office of n.z* 1 mar 2001 O r n r i u r n WO 96/37219 PCT/US96/07781 25. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence SAMILAAYHPQQFIY (Seq ID No:63), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 26. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence ALLDPSQGMGPSLIG (Seq ID No:67), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 27. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence PSLIGLAMGDAGGYK (Seq ID No:69), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 28. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence AADMWGPSSDPAWER (Seq ID No:72), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 29. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence GPSSDPAWERNDPTQ (Seq ID No:73), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 30. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence V ANNTRL WV Y CGNGT (Seq ID No:77), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 31. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the ammo acid sequence GANIPAEFLENFVRS (Seq ID No:81), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequenceINTELLECTUAL PROPERTY OFFICE OF n.z" 1 MAR 2001 P FP Fivcn PCT/US96/07781 32. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence QDAYNAAGGHNAVFN (Seq ID No:85), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 33. The vaccinating agent of claim 16 wherein said at least one immunodominant epitope has the amino acid sequence THSWEYWGAQLNAMK (Seq ID No:89), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 34. An immunodiagnostic agent for use in promoting a detectable immune response in a mammalian host identifying an infectious pathogen from the genus Mycobacterium, said immunodiagnostic agent comprising: at least one immunodominant epitope selected from the group consisting of Mtuberculosis 30 KD protein subunits having the amino acid sequences FSRPGLPVEYLQVPS (Seq ID No:37), LPVEYLQVPSPSMGR (Seq ID No:38), LQVPSPSMGRDIKVQ (Seq ID No:39), DIKVQFQSGGNNSPA (Seq ID No:41), FQSGGNNSPAV Y L L D (Seq ID No:42), YYQSGLSIVMPVGGQ (Seq ID No:49), L T S E L P Q WLSANRAV (Seq ID No:57)S M A G S S A M I L A A Y H P (Seq ID No:62)S A M ILAAYHPQQFIY (Seq ID No:63), ALLDPSQGMGPSLIG (Seq ID No:67), PSLIGLAMGDAGGYK (Seq ID No:69), AADMWGPSSDPAWER (Seq ID No:72), GPSSDPAWERNDPTQ (Seq ID No:73), VANNTRL WVYCGN G T (Seq ID No:77), G ANIP AEFLENFVRS (Seq ID No:81), QDAYNAAGG H N A V F N (Seq ID No:85), THSWEYWGAQLNAMK (Seq ID No:89), and WO 96/37219 INTELLECTUAL property OFFICE OF n.z- 1 MAR 2001 RECEIVED WO 96/37219 PCT 17781 163 respective analogs, homologs, and subunits thereof including single or multiple amino acid inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 35. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence FSRPGLPVEYLQVPS (Seq ID No:37), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 36. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence LPVEYLQVPSPSMGR (Seq ID No:38), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 37. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence LQVPSPSMGRDIKVQ (Seq ID No:39), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 38. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence DIKVQFQSGGNNSPA (Seq ID No:41), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 39. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence FQSGGNNSPAVYLLD (Seq ID No:42), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 40. The. immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence YYQSGLSIVMPVGGQ (Seq ID No:49), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 41. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence LTSELPQWLSANRAV INTELLECTUAL PROPERTY OFFICE OF N.Z" 1 mar 7001 D r p c i u r n WO 96/37219 PCT/US96/07781 164 £ (Seq ID No:57), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 42. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence SMAGSSAMILAAYHP (Seq ID No:62), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 43. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence SAMILAAYHPQQF'IY (Seq ID No:63), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 44. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence ALLDPSQGMGPSLIG (Seq ID No:67), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequenceimmunodominant epitope has the amino acid sequence PSLIGLAMGDAGGYK (Seq ID No:69), including single or multiple aniino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 46. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence AADMWGPSSDPAWER (Seq ID No:72), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 47. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence GPSSDPAWERNDPTQ (Seq ID No:73), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 48. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence VANNTRLWVYCGNGT 45. The immunodiagnostic agent of claim 34 wherein said at least one INTELLECTUAL PROPERTY OFFICE OF N.Z" 1 mar 2001 n p a r i \f r i% WO 96/37219 PCT/US96/07781 165 \*?g \ n (Seq ID No:77), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 49. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence GANIPAEFLENFVRS (Seq ID No:81), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 50. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence QDAYNAAGGHNAVFN (Seq ID No:85), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 51. The immunodiagnostic agent of claim 34 wherein said at least one immunodominant epitope has the amino acid sequence THSWEYWGAQLNAMK (Seq ID No:89), including single or multiple amino acid substitutions, deletions, insertions, inversions, analogs, homologs, and subunits thereof, having at least 70% homology to said amino acid sequence. 52. The use in the manufacture of a medicament for immunizing a mammalian host against an infectious pathogen of the genus Mycobacterium of at least one immunodominant i epitope is selected from the group consisting of Mtuberculosis 30 KD protein subunits having the amino acid sequences FSRPGLPVEYLQVPS (Seq ID No:37), LPVEY LQVPSPSMGR (Seq ID No:38), LQVPSPSMGRDIKVQ (Seq ID No:39), D I INTELLECTUAL PROPERTY OFFICE OF N.Z" 1 MAR 7001 RECEIVED WO 96/37219 PCT/US96/07781 166 j 9 y 4 KVQFQSGGNNSPA (Seq ID No:41), FQSGGNNSPAV YLLD (Seq ID No:42), YYQSGLS.IVMPVGGQ (Seq ID No:49), LTSELPQWLS ANRAV (Seq ID No: 5 7), SMAGSS AMILAAYHP (Seq ID No:62), SAMILAAYHPQ Q F I Y (Seq ID No:63), ALLDPSQGMGPSLIG (Seq ID No:67), P S L I G L A M G D A G G Y K (Seq ID No:69), AADMWGPSSDPAWER (Seq ID No:72), GPS SDPAWERNDPTQ (Seq ID No:73), VANNTRLWVYCGNGT (Seq ID No: 77), GANIPAEFLENFVRS (Seq ID No:81), QDAYNAAGGHNAVFN (Seq ID No:85), THSWEYWGAQLNAMK (Seq ID No:89), and respective analogs, homologs, and subunits thereof including single or multiple amino acid substitutions, deletions, insertions and inversions having at least 70% homology to said amino acid sequence. 53. A method for detecting the presence of an immune response in a mammal against a pathogen of the genus Mycobacterium, said method comprising the steps of: providing at least one immunodominant epitope selected from the group consisting of Mtuberculosis 30 KD protein subunits having the amino acid sequences FSRPGLPVEYLQVPS (Seq ID No:37), LPVEY LQVPSPSMGR (Seq ID No:38), LQVPSPSMGRDIKVQ (Seq ID No:39), D I KVQFQSGGNNSPA (Seq ID No:41), FQSGGNNSPAVYLLD (Seq ID No:42), YYQSGLSIVMPVGGQ (Seq ID No:49), LTSELPQWLS ANRAV (Seq ID No:57), SMAGSS AMILAAYHP (Seq ID No:62), SAMILAAYHPQ Q F I Y (Seq ID No:63), ALLDPSQGMGPSLIG (Seq ID No:67), P S L I G L A M G D A G G Y K (Seq ID No:69), AADMWGPSSDPAWER (Seq ID No:72), GPS SDPAWERNDPTQ (Seq ID No:73), VANNTRLWVY CGNGT (Seq ID INTELLECTUAL PROPERTY OFFICE OF N.Z~ 1 MAR 2001 RECEIVED PCTAJS96/07781 _ n ]U£T- r ^3 l% r| N°: 77), GANIPAEFLENFVRS (Seq ID No:81), QDAYNAAG G H N A V F N (Seq ID No.85), THSWEYWGAQLNAMK (Seq ID No:89), and respective analogs, homologs, and subunits thereof mcluding single or multiple amino acid substitutions, deletions, insertions and inversions having at least 70% homology to said amino acid sequence; administering said at least one immunodominant epitope to said mammal; and measuring the resultant immune response. 54. A vaccinating agent as claimed in claim 3 or 16 substantially as herein described with reference to any example thereof and/or the accompanying drawings. 55. A DNA molecule as claimed in any one of claims 1, 5, 8 and 12 substantially as herein described with reference to any example thereof and/or the accompanying drawings. 56. An amino acid sequence as claimed in any one of claims 2, 9 and 13 substantially as herein described with reference to any example thereof and/or the accompanying drawings. 57. A use as claimed in claim 4 or 52 substantially as herein described with reference to any example thereof and/or the accompanying drawings. 58. An immunodiagnostic agent as claimed in claim 34 substantially as herein described with reference to any example thereof and/or the accompanying drawings. 59. A method fordetecting the presence of an immune response in an mammal against a pathogen of the genus Mycobacterium as claimed in claim 53 substantially as herein described with reference to any example thereof and/or the accompanying drawingsWO 96/37219 167 INTELLECTUAL PROPERTY OFFICE OF N.Z" 1 mar 7001 received